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ABSTRACT 
Convincing evidence that activated macrophages play a critical role in control of 
mycobacterial diseases has been clearly established from animal and in-vitro studies. 
Macrophages produce a variety of molecules upon appropriate stimulation, which act in 
concert towards eventual killing of bacteria. People with SUb-optimal macrophage 
activation are more susceptible to infection with intracellular pathogens. My project 
aims to answer two questions relating to genetic regulation of macrophage activation in 
tuberculosis: do macrophage genes regulate microbial-induced responses and do 
macrophage genes influence susceptibility to tuberculosis? A whole blood assay was 
used to investigate IFN-y responsiveness in healthy individuals and those who develop 
tuberculosis in The Gambia. Cytokine responses to lipopolysaccaride (LPS), 
Lipoarabinomanan (LAM) and the enhancing effect of IFN-y on these stimulants were 
measured. LPS induced IL-l 0 levels was higher in recovered TB cases than in controls 
(p=0.02). LPS and LAM induced cytokines were highly correlated (p<0.0001) 
similarly, levels of IL-IB and TNF were highly correlated (P<O.OOOl). Ten new 
polymorphisms were detected by sequencing specific regions within the promoter of 
IFNG and IFNGRI genes. One, a double deletion of TT in the promoter of IFNGR1, 
abolishes a GAS binding site at position -470 and another, a CIT transition, is close to 
a putative NF-kappa B binding site at position -56 in the IFNGRI gene (positions are 
relative to the transcription start site). These along with published polymorphisms at 
some macrophage candidate gene loci were genotyped. Comparisons were made to 
determine whether different alleles at candidate gene loci influence macrophage 
cytokine responses. TNFA-863 , LTA NeaL lL1RN and NRAMPl (469+14) 
polymorphisms were shown to influence macrophage cytokine levels significantly. 
TNFA-863 was associated with LPS induced TNF (P < 0.05), LTA was associated with 
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LAM and LPS induced TNF and 1L-~ levels (p < 0.01). NRAMPI (469+14) was 
associated with LAM induced 1L-I0 (P<O.OI) and fL1RN was associated with LAM 
and LPS induced 1L-l 0 (P<0.05). 
Alleles 1 (G) of TNFA-308, 2 (A) of TNFA-238, 1 (T) of fL1B-511 and 2 (ddeVT) of 
fFNGR1 were significantly associated with TB in the panel of samples studied. For the 
microsatellite markers, allele 5 of fL9 (TG)n repeat in intron 4 and allele 3 of the Z 
DNA promoter polymorphism NRAMP 1, were significantly associated with TB. 
NRAMP 1 !NT 4 variant was significantly associated with both TB and LAM induced 
1L-I0 secretion. 
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CHAPTER! 
INTRODUCTION 
1.1 Tuberculosis 
1.1.1 Tuberculosis: an overview 
Tuberculosis (TB) is currently the world's single leading infectious cause of adult deaths. 
In 1990, it was estimated that about 1,700 million people, a third of the world's 
population, were infected with Mycobacterium tuberculosis (Raviglione et aI., 1997). In 
1993 the World Health Organization (WHO) declared TB to be a global emergency 
(Reichman, 1996). A recent WHO report estimated that in 1998 there were 8 million new 
cases of clinical tuberculosis and 1.9 million deaths from the disease. It is expected to kill 
a hundred million more over the next thirty years. Although BCG vaccine constitutes an 
integral part of the TB control and Expanded Programme of Immunisation (EPI) in most 
developing countries, its efficacy varies between populations from 0-80% (Fine, 1989). 
Current treatment relies on a combination of drugs acting against the micro-organism, but 
unfortunately about 30% of organisms are now resistant to first-line drugs (Jacobs, 1994). 
Also, treatment must continue for 6-9 months which is often not practical, especially in 
developing countries, and results in poor compliance. In fact, because of extensive 
poverty most control programmes have been below the required standard, resulting in 
many clear failures of treatment. Although the overall proportion of infected people is 
similar in industrialised and developing countries, the age of infection differs: 80% of 
infected individuals in industrialised countries are aged 50 years or more while 750/0 of 
those in developing countries are less than 50 years old (Harris, 1997). The epidemic is 
increasing in both industrialised and developing countries but still has not reached its 
peak in most countries of Africa. Sub-Saharan Africa has the greatest burden of morbidity 
and mortality from TB (Dolin, 1994), a large proportion of which is now associated with 
co-infection with the human immunodeficiency virus (HIV; Hawken et aI., 1993). The 
increase has mainly occurred in childbearing and economically active groups. An increase 
in HIV related childhood TB has been documented from most African countries such as 
Zambia and Cote d'Ivoire (Harris., 1997). Social factors such as population growth, 
smoking, alcoholism, over-crowding, war and natural disasters such as drought and 
famine create conditions that predispose to the spread of TB (Daniel et aI., 1994). 
Economic priorities and government policies in the worst affected areas preclude health-
related expenditure. General lack of first line drugs for tuberculosis has resulted in drug 
misuse and therefore resistant organisms. The most cost effective control tool, prevention, 
would be aided by the development of a more effective vaccine. F or this, an 
understanding of the host determinants of protective immunity is paramount. 
Human pulmonary infection with M tuberculosis results in parasitisation and activation 
of alveolar macrophages (Hirsch et aI., 1994). At the initial stage of infection, the only 
evidence of infection in most cases is the development of a positive tuberculin skin test 
(Hopewell, 1994). Within the first 2 years after infection only about 10% develop disease 
(Bloom and Small, 1998). For those who do, there are two main clinical syndromes. 
Miliary TB is the most serious form of the disease and occurs in children, 
immunosupressed individuals and patients with advanced pulmonary TB who have an 
ineffective immune response. It is characterised by hematogenous dissemination of large 
numbers of organisms throughout the body and severe disease that is almost invariably 
fatal if untreated. This form of the disease is characterised by a high frequency of 
negative tuberculin skin test and failure of T lymphocytes to respond to M tuberculosis 
antigens (Uberoi et aI., 1975). At the other end of the disease spectrum is tuberculosis 
pleuritis where patients mount a strong immune response to infection reflected by 
resolution of pleuritis often without therapy. Between these extremes lie a number of 
other clinical phenotypes including bronchopulmonary TB, TB meningitis, pericarditis 
and osteomyelitis (Harris, 1997). 
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1.1.2 An historical perspective 
In 1882 Robert Koch identified M tuberculosis as the causative agent ofTB (Grange and 
Bishop 1982). Tuberculosis is an ancient disease and the aetiologic agent probably 
preceded the development of man on earth. It is speculated that cattle were the source of 
human TB infection and that M tuberculosis evolved from M bovis, which has a broad 
host range, capable of infecting man and several other species. M tuberculosis is 
pathogenic only to man (a point relevant to the use of animal models in TB research 
generally). The first human infections presumably were isolated events resulting from 
eating infected meat or drinking contaminated milk. As man started settling in villages 
and began cultivation in 7000 BC, and domestication of cattle swine and sheep occurred, 
TB probably occurred more frequently in man. Records dating back to the time of 
Hippocrates suggest that TB existed, and was referred to as phthisis, the Greek word for 
wasting. (Castiglioni, 1933). Signs of spinal tuberculosis were found in Neolithic 
skeletons and early Egyptian remains and clearly depicted in figurines and paintings 
throughout the era (Morse et al., 1964). Examinations of prehistoric human skeletons in 
South America between 100 BC and 1300 AD revealed skeletal deformities compatible 
with TB. 
TB became a major problem in the western world when the industrial revolution created 
crowded urban living conditions, favouring the spread of the bacillus. Oliver Wandall 
Holme's "white plague" (Dubos and Dubos, 1952) arose in the 1600's and peaked at the 
beginning of the nineteenth century when TB was the commonest cause of death in 
Europeans. The epidemic spread later to United States and then world-wide as infected 
Europeans migrated to more distant sites (Budd, 1867). In the 1880's when native 
Americans were forced to live in small fixed huts, an epidemic began. Contact with 
surrounding white settlers became frequent and people started living in crowded 
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communities. These conditions favoured the rapid spread of TB and death rates from TB 
increased rapidly: by 1886, the TB death rate was 10 times higher in the indigenous 
population than the Europeans. 
As this was happening in America, TB was still practically unknown in most of North and 
sub-Saharan Africa. Notable scholars resident in different parts of Africa for decades did 
not record any TB in their communities. Black people taken to America were free of TB 
upon arrival but between 1822 and 1861 TB death rates gradually increased. Early reports 
of TB in Africans occurred following close contact with Europeans or Egyptians 
(Cummins, 1908). Healthy young Senegalese men recruited into the French Army during 
World War I died in great numbers as a result of first time exposure to the bacillus. TB 
was first reported in South Africa in 1908 in black men working in mines (Cummins, 
1929). By 1967, Paviot reported endemicity of TB in several African countries including 
The Gambia (Paviot, 1967). The British Medical Research Council and East African 
Research Centres carried out large surveys in Kenya and Tanzania between 1964 and 
1984. All together 8741 TB patients were studied; 90% had pulmonary disease, others 
had lymphadenopathy, bone or joint disease, pleural effusion and pericardial or peritoneal 
disease. The TB epidemic had not reached its peak in Africa before it was exacerbated by 
the advent of HIV infection (Hawken et aI., 1993, Harris, 1997). 
1.1.3 The epidemiology of TB in The Gambia 
The Gambia is a small coastal country in West Africa surrounded by Senegal. The 
Gambia lies between latitude 16° 34W and longitude 13 °28 N of the equator. Five ethnic 
groups predominate: Mandinka (42%), Wolof (16%), Fula (18%), lola (100/0), and 
Serahuleh (9%). Manjago, Serere, Bambara and Aku form the remaining 50/0. Significant 
proportions (400/0) of the population live in the West in or around the major towns of 
Serrekunda, Banjul and Brikama. There is intermarriage between these ethnic groups and 
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marriages are often transient. It is common place to find single parent families making 
family studies more difficult. The people are also highly mobile and it is a big endeavour 
to track down family members because they may be at opposite ends of the country. 
The joint Leprosy and Tuberculosis Control Programme has been in place since 1986 and 
is run under a j oint agreement between The Gambian Government and the Dutch agency 
Nederlandse Stichlting voor Lepraobeshtrijding. Prior to 1994, 94% of tuberculosis had 
not been treated (Lienhardt, et al., 1998) and BCG was administered in sporadic 
vaccination campaigns of school children and among children and adults in the 
community. There are chest c1inie-s- incl-iffefent-J3arts--0f~the-oountry. Eighty-€ight p~rGent 
of treated cases were smear positive. Culture using specimens by both commercial 
Lowenstein Jensen slopes and BACTEC (Becton Dickinson) became available at the 
Medical Research Council Laboratories in Fajara in 1997. A retrospective review of 
patient notes indicated that 6.20/0 of tuberculosis patients were positive for HIV 
(Lienhardt et aI., 1998). Records for 1994 and 1995 show that 78% of smear positive 
patients were either cured or had completed treatment, 4.3% were treatment failures, and 
4.6% had died, with mortality significantly higher among HIV patients (Lienhardt et a/., 
1998). 
The prevalence of drug resistance among M tuberculosis strains in The Gambia is 
presumed to be minimal although this is currently under investigation. Statistics for The 
Gambia shows that there are one thousand new cases per year; for a country with a 
population of a little over a million the incidence is 1 case per thousand per year. TB is 
therefore a serious public health problem in The Gambia (WHO bulletin 2000). 
1.1.4 The pathogenesis of TB 
There are two types of pulmonary TB: primary and secondary TB. Following infection 
with M tuberculosis, primary TB results from parasitisation and activation of alveolar 
macrophages and M cells in mice (Hirsch et aI., 1994, Teitelbaum et aI., 1999). Upon 
inhalation of bacilli contaminated droplets, most of these particles settle in the upper 
respiratory epithelium and are expelled by the mucocilliary escalator. Only a few droplets 
reach the respiratory bronchioles and alveoli in the peripheral lung tissue. The bacilli 
contained within these droplets are then engulfed by alveolar macrophages, which are 
transformed into epithelioid cells (Schlesinger, 1996). Chemotactic factors attract 
circulating monocytes, lymphocytes and neutrophils leading to the formation of 
granulomatous focal lesions. This non-specific defence develops within a few days, limits 
the spread of infection and may achieve complete resolution. After about 3 weeks, 
antigen specific defences develop which contribute to the resolution of infection. After 4-
5 weeks of progressive infection microscopic granuloma enlarge as individual foci 
expand and coalesce. This results in relatively large areas of necrotic tissue. M 
tuberculosis bacilli are unable to multiply within this caseous tissue, due to its acid pH, 
low availability of oxygen and the presence of toxic fatty acid (Dannenberg and Rook, 
1994). With intact cell mediated immunity (CMI) the infection may be arrested 
permanently at this point. However, M tuberculosis is well adapted to its host and can 
survive for many years within an infected individual. The granuloma subsequently heals, 
leaving small fibrous and calcified lesions. If CMI is insufficient, haematogenous and 
lymphatic dissemination may occur. Enlarged hilar lymph nodes can rupture into adjacent 
airways, releasing necrotic material and causing tuberculous bronchopneumonia, while 
more distal spread results in miliary TB (Dannenberg and Rook, 1994). 
Secondary (postprimary) TB occurs in two ways, either by reinfection or by reactivation 
of a dormant primary lesion. Until recently, it was generally believed that most post 
primary TB in developing nations was reactivation. However, DNA fingerprinting of the 
organisms involved, has shown that reinfection accounted for 75% of recurrent TB in a 
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South African study (van Rie et al., 1999). In either case, a localised hypersensitivity 
reaction is the characteristic response, accompanied by tissue necrosis and caseation. 
Lymphocytes and other cells converge upon the site forming a wall of fibrous tissue to 
seal the necrotic site. There may be extensive tissue destruction resulting in the formation 
of cavities, and healing occurs by fibrosis rather than calcification (Dannenberg and 
Rook, 1994). An open cavitating lesion can leak infectious material directly into the 
bronchus, resulting in continuous discharge of bacilli into the sputum. In this instance, the 
individual is most infectious to others. Leaked bacilli can also be inhaled into other 
portions of the host lungs, resulting in tuberculous bronchopneumonia. If the growing 
granulomatous lesion erodes the wall of a vein, organisms can spread in via the 
circulation resulting in disseminated disease (Dannenberg and Rook, 1994). 
The mechanisms that govern dormancy and reactivation, within either the organism or the 
host are not yet understood. Any condition that compromises cellular immunity makes 
reactivation more likely. However, the majority of individuals who develop tuberculosis 
have no obvious immunocompromise, suggesting host factors play an important role. It 
would appear that such individuals do not develop a truly protective immune response. 
1.2 Imm one responses to M. tuberculosis infection 
M tuberculosis is a facultative intracellular parasite that grows within mononuclear 
phagocytes. For this reason, the immune response to M tuberculosis is predominantly 
cellular, requiring the co-ordinated activity of a wide range of T cell and macrophage 
functions. Much of our current understanding of mycobacterial immunity is derived from 
murine studies: the use of genetically engineered mice which lack specific components of 
the immune response has been particularly enlightening. However, M tuberculosis is not 
a natural pathogen in mice and extrapolation of murine data to humans requires caution. 
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The immune system comprises two arms - innate immunity, which consists of non-
specific mechanisms present prior to an encounter with a particular organism, and 
acquired immunity which, is specifically induced by foreign antigens. The two arms are 
bridged by antigen presenting cells such as dendritic cells, and CD 1 cells and yoT cells. 
Figure 1.1 summarises the inter-relationship between the various pathways involved in 
the immune response to mycobacteria. 
FIG. 1.1 Pathways of mycobacterial immunity. 
Figure 1.1 overleaf shows the interaction between the innate and acquired immune system 
and the cells thought to bridge the gap. All abbreviations are listed in pages xiv and xv. 
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1.2.1 Innate immunity 
The macrophage is central to the innate immune response to mycobacterial infection. The 
initial interaction with the alveolar macrophage is likely to playa key role in determining 
the outcome of infection and understanding the early events could provide new 
intervention strategies. 
1.2.li Macrophages 
The macrophage under normal physiological conditions is the natural host and eventual 
killer of M tuberculosis. Uptake of invading organisms by the macrophage requires the 
binding of pathogen associated molecular patterns (PAMPs) molecules on bacteria, such 
as cell-wall components of bacteria (e.g. lipopolysaccahride, LPS) and mycobacteria (e.g. 
lipoarabinomannan, LAM) to receptors referred to as pattern recognition receptors 
(PRRs) on macrophages (reviewed by Schlesinger, 1996). For example, bacterial LPS can 
bind to the CD14 molecule and the Toll-like receptors (TLR) -2 and -4. ManLAM from 
M tuberculosis can also bind CD14, TLR-2 and the macrophage mannose receptor. Other 
macrophage receptors utilised by mycobacteria include the complement receptors, 
surfactant protein A (Sp-A) and Sp-A receptors, scavenger receptors and the Fcy 
receptors. The state of differentiation or activation of macrophages may affect receptor 
usage (Ernst, 1998). 
In response to invasion, macrophages become activated to produce several potent 
molecules, which make the macrophage milieu hostile and therefore are important for 
protection against intracellular pathogens (reviewed by Murray, 1999). These include 
reactive oxygen (ROI) and nitrogen intermediates (RNI), toxic hydrolytic enzymes and 
increased expression of MHC class II and or the non-MHC CD1 molecule depending on 
the macrophage receptor utilised for uptake. There is rapid up regulation of the early gene 
KC, a neutrophil-specific chemoattractant belonging to the IL-8 related C-X-C family of 
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small peptide cytokines, production of cytokines such as tumour necrosis factor (TNF) , 
interleukin 1 ~ (lL-l ~), interleukin-2 (lL-2), IL-8 and IL-I0. Activation of macrophages 
also results in up-regulation of natural resistance associated macrophage protein 1 
(NRAMP 1) and nitric oxide synthase, the enzyme that catalyses the production of the free 
radical nitric oxide (NO). The function of NRAMP 1 is discussed in more detail in section 
1.3.2ia. The above macrophage functions are greatly enhanced by the cytokine interferon-
y (IFN-y), produced by T cells and natural killer cells (Nathan et al., 1983). 
Despite the production of such potent molecules, it is known that viable M tuberculosis 
can use several mechanisms to evade killing by macrophages. One such mechanism is to 
inhibit fusion of early endosomes with acidic late endosomes and lysosomes thereby 
disrupting antigen presentation to T cells. This does not occur in the presence of a 
functional NRAMPI protein (Hackam et ai., 1998). 
Murine peritoneal macrophages can be readily activated with IFN -y to inhibit virulent M 
tuberculosis growth (Rook et ai., 1987). Ironically, normal human monocytes in the 
absence or presence of any activating stimulus are less able to inhibit M tuberculosis 
growth than murine macrophages. Even the effect of 1, 25-dihydroxyvitamin D, known to 
exert a slightly greater effect than other stimuli in mice, induces less inhibition of M 
tuberculosis in human macrophages than is readily achieved by incubating murine 
macrophages in IFN-y (Rook et ai., 1987). Other pathways may be more important in 
humans. Lammas et ai., (1997) reported that exogenous ATP mediates lysis of M bovis 
BCG-infected human macrophages via P2Z receptors, resulting in death of mycobacteria. 
1.2.lii Natural killer (NK) Cells 
Natural killer cells are a subset of bone marrow derived leukocytes with a granular 
morphology, originally characterised by their ability to kill tumour cells in a non- MHC 
restricted manner. They do not express a~ or y'6 T cell receptors or surface 
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immunoglobulins and can develop in the absence of functional T and B-Iymphocytes. NK 
cells are involved the in early response to intracellular infections (Trincheri, 1989). They 
are capable of producing IFN -y in response to the macrophage cytokines IL-12 and TNF-
cx, induced by mycobacterial antigens (Bancroft et at., 1993). Reports have suggested 
three mechanisms by which NK cells can contribute to host resistance. Firstly, they can 
bind directly to pathogens and in some cases achieve killing of the organisms directly. 
Secondly, they can mediate cytotoxic activity against host cells infected with intracellular 
pathogens. Finally; they can be triggered to secrete a range of cytokines including IFN-y 
and involved indirectly in resistance of the host. It is possible that alveolar macrophages 
ingest mycobacteria and produce IL-12 thereby favouring the development of T helper 1 
type responses (see below) via the induction of IFN-y production and enhancement of the 
cytotoxicity ofNK cells. 
1.2.liii Dendritic cells (DC) 
Dendritic cells (DC) are antigen presenting cells (APC) that have been shown to be 
powerful tools for manipulating the immunologic function of B and T lymphocytes, the 
main mediators of acquired immunity (Banchereau and Steinman, 1998). They function 
by capturing antigens, process them and on activation express lymphocyte co-stimulatory 
molecules. They migrate to lymphoid organs and secrete cytokines to initiate immune 
responses. They present processed antigens to antigen specific T cells, thereby exhibiting 
an essential role in the initiation of primary T cell responses to foreign antigens. Initially, 
the precise role of DCs in the uptake of M tuberculosis was not clear. An earlier study 
reported that blood DCs were not detect ably phagocytic for mycobacteria and further 
studies failed to show any evidence for the transfer of mycobacterial antigens from 
macrophages to dendritic cells in a form that was stimulatory for T cells (Pancholi et al., 
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1993). However, recent studies demonstrate that DCs generated from human peripheral 
blood by short term culture in medium containing recombinant human granulocyte-
macrophage-colony stimulating factor and IL-4 were capable of phagocytosing M 
tuberculosis. Also, bacilli discharged by engulfing epithelial M cells are taken up by DCs 
and macrophages associated with the T cells of the parafolicular area (Lugton, 1999). It is 
now clear that apart from activation and maturation of DCs, DCs pulsed with bacilli have 
been used to prime antigen specific CD8+T cells for lysis (Mohagheghpour et al., 1998). 
Infection of DCs with live M tuberculosis bacilli resulted in increased APC surface 
expression of the co-stimulatory molecules CD40 and B7.1 as well as MHC class I 
molecules. In addition, infected DC secrete elevated levels of inflammatory cytokines 
including TNF-ex, IL-l and IL-12 (Henderson et al., 1997). Activation of DCs may 
facilitate their migration to lymph nodes and enhance presentation of antigen to T cells 
thereby facilitating the induction of the immune response against M tuberculosis. 
1.2.liv Gamma delta T cells (y8T cells) 
Gamma delta (y8) T cell receptor (TCR) bearing T cells have been identified in murine 
and human TB lesions. Early responses to mycobacterial antigens in naIve individuals 
have been studied in new-borns, where y8T cells were shown to expand in response to M 
tuberculosis (Boom et al., 1994). Activated y8T cells can secrete cytokines such as TNF-
ex, IL-4, IL-5, IL-I0, IL-2, IFNy and also exhibit cytolytic activity against macrophage 
targets pulsed with M tuberculosis (Munk et al., 1990; Follows et al., 1992). The 
protective role of these cells is less certain as they have not been detected in materials 
from tuberculous pleural effusions or tuberculous lymph nodes (Tazi et al., 1992; Barnes 
and Modlin, 1996). They have been shown to recognise phoshorylated M tuberculosis 
antigens (Lang et al., 1995) and a 5' triphosphorylated thymidine compound from AI. 
tuberculosis (Constant et al., 1994). Expansion of M tuberculosis y8T cells is greater in 
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healthy tuberculin reactors and in patients with tuberculous pleuritis than in those with 
advanced pulmonary and miliary tuberculosis, suggesting that y8T cells may contribute to 
immune resistance (Barnes et al., 1992). 
1.2.2 Presentation of mycobacterial antigen to T cells. 
Mycobacterial antigens are presented to T cells by different mechanisms depending on 
the nature and source of antigen been presented. The major histocompatibility complex 
(MHC) restricted pathway involving protein antigens is the classical method. There is 
also a recently unravelled non-MHC restricted pathway utilising CDI b molecules and 
these present non- protein antigens to either double negative IFN-y producing T or CD8+ 
T cells (Lewinshon et al., 1998). 
1.2.2i Human leukocyte antigens (HLA) 
In human, the MHC is referred to as human leukocyte antigens (HLA), is encoded on the 
short arm of chromosome six and is very polymorphic (reviewed by Klein and Sato, 
2000). The HLA restricted pathway consists of four distinct types of molecules, only two 
are involved in antigen presentation: the class I and class II molecules which classically 
recognise peptides in context of either CD8+ or CD4+ T cells respectively. They are cell 
surface glycoproteins receptors that bind peptide and present them to T cells. Virtually, 
all cells of the body express class I and present endogenous antigens whereas, class II 
molecules are expressed by a limited number of host cells; these are B cells, dendritic 
cells and macrophages. Unlike the innate receptors that recognise chemical patterns 
shared by groups of bacteria, the HLA molecules recognise structural specificity, in that 
the antigen has to be processed and refined into small peptides for presentation to T cells. 
The structure of these HLA molecules determine how well they will bind to peptides and 
present them to T cells. Susceptibility or resistance to disease has been related to binding 
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capacity of these molecules to peptides. A number of associations between HLA alleles 
and several diseases have been reported mainly with autoimmune diseases. There are 
many reports of HLA associations with TB. Some have demonstrated positive 
associations (Brahmajothi et al., 1991, Bothamley et al., 1989) some no association 
(Hawkins et al., 1988, Cox et al., 1982) and others negative associations (Singh et al., 
1983). 
1.2.2ii Cluster differentiation Ib (CDlb) Molecule 
Non- peptide antigens such as mycolic acids, lipoarabinomannan related phosphoinositol 
mannosides and glucose mycolates utilise the CD 1 pathway by stimulating either CD8+ or 
CD8-, CD4- double negative and or IFN-y producing T cells (Brenner et aI., 1998). These 
cells are efficient cytolytic T cells capable of lysing infected target cells. Whether CD 1 
associated glycolipid antigens derived from mycobacteria can elicit protective host 
response is under investigation. Studies of human leprosy have provided direct evidence 
for the involvement of CD 1 restricted T cells in host responses to infection. CD 1 a, band 
c are expressed on dendritic cells in granulomata within the skin lesions of leprosy 
patients (Sieling et al., 1998). Furthermore, the frequency of CD 1 + cells correlates with 
levels of cell mediated immunity to M leprae, being more abundant in the granulomata of 
patients with the immunologically responsive tuberculoid form of the disease when 
compared with the unresponsive lepromatous form (Sieling et aI., 1998). Also, IL-I0 
found specifically at the site of infection in the lepromatous form has been shown to 
down regulate CD 1 expression (Sieling et aI., 1998). More recently, M tuberculosis 
reactive CD 1 restricted T cell lines from peripheral blood of patients with tuberculosis 
have been derived. The study of CD 1 restricted T cells from patients with mycobacterial 
infection as well as normal healthy donors showed that all CD 1 restricted T cell lines 
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isolated produced high levels of IFN-y but little or no IL-4 upon stimulation with 
mycobacterial antigens (Sieling et aI., 1998). 
1.2.3 Acquired Imm unity 
There are two main types of lymphocytes (B and T cells). The presence of distinct 
glycoproteins known as clusters of differentiation (CD) antigens on surface of T cells and 
other cells of the immune system serve as phenotypic markers allowing distinction 
between populations or subsets with different functions in the immune system. For 
example, CD 19 and CD22 are expressed on all B cells and CD2 and CD3 on all T 
lymphocytes. The B cells are involved in humoral responses and are thought to have no 
major role in the containment of TB. One the other hand, the T cells are involved in CMI 
and can be differentiated into two main subtypes; CD4+T and CD8+T cells. CD4+ cells are 
described as "helper" cells which release cytokines that attract phagocytes to the site of 
infection, and those expressing CD8+ are said to belong to the "suppressor", "killer" or 
"cytotoxic" subset which kill infected macrophages (Reinherz and Schlossman, 1980). 
Others T cell subsets include the CDI restricted CD4-CD8- double negative T cells, and 
y8T cells. 
1.2.3i Cluster differentiation 4 (CD41 T cells 
Lymphocyte sub-population expressing CD4 have been shown experimentally and 
clinically to have a dominant but not exclusive role in immune defences against TB. Mice 
depleted of CD4+T cells prior to infection with M bovis are unable to control 
mycobacterial growth, whereas depletion of CD8+T cells shows variable effects 
(Pedrazzini et al., 1987). In humans, CD4+T cells are selectively expanded at the site of 
disease in patients with a protective immune response, for example those with 
17 
tuberculous pleuritis (Barnes et al., 1989). Depletion of CD4+ T cells by HIV infection 
markedly increases susceptibility to primary and reactivation TB. 
CD4+T cells can be further subdivided into two functionally distinct groups: T helper 
typel (Thl) and T helper type 2 (Th2) cells based on their cytokine production profile 
(Mosmann et at., 1986). Thl cells produce interleukin 2 (IL-2) and IFN-y and execute 
cell-mediated immune response such as delayed hypersensitivity and macrophage 
activation. Th2 cells produce IL-4, IL-5, IL-9, IL-I0 and IL-13 and assist in antibody 
production for humoral immunity. It is possible that the dominant type of antigen specific 
CD4+ T cell clone present at the site of infection determines the outcome of disease. 
Distinct microbial antigens may favour dominance of Thl or Th2 cells. For instance, in 
leprosy patients, Thl cytokines (IFN-y and IL-2) predominate in the skin lesions of 
tuberculoid leprosy patients who mount a resistant immune response to M leprae, 
whereas Th 2 cytokines (IL-4 and IL-I0) are prominent in lepromatous leprosy lesions 
with ineffective immunity and enormous bacillary burdens (Seiling and Modlin, 1994). 
Published data on cytokine production by human T cells in response to M tuberculosis 
are conflicting. Many studies indicate that most CD4+T M tuberculosis reactive T cell 
clones propagated in vitro are Thl like, producing high concentrations of IFN-y but low 
concentrations ofIL-4 and IL-5 (Del Prete et al., 1991). Boom et at., (1991) demonstrated 
M tuberculosis reactive T cell clones capable of secreting IFN-y and IL-4. Barnes et at., 
(1993) indicated that most M tuberculosis reactive clones produce both Thl and Th 2 
cytokines including IFN-y, IL-2, IL-5 and IL-I0. However, mRNA expression of Thl 
cytokines such as IFN-y and IL-2 in patients with tuberculous pleuritis is greater in 
pleural fluid mononuclear cells than in blood mononuclear cells and concentrations of 
IFN-y are higher than those in serum (Barnes et at., 1993). Pleural fluid lymphocytes 
stimulated with M tuberculosis produce more IFN-y and more IL-2 than do peripheral 
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blood lymphocytes. These results provide strong evidence for selective concentration of 
Thl cells at the site of disease in persons with a protective immune response and suggest 
that Thl cells play an important role in human antimycobacterial defences. IFN-y in 
combination with TNF enhances the antimycobacterial activity of murine macrophages, 
probably through increased production of reactive nitric oxide metabolites (Flesch and 
Kaufmann, 1991). IFN-y also stimulates human macrophages to produce TNF which 
facilitate mycobacterial elimination (Rook et al., 1987). IL-2 causes T cell division 
further increasing the local concentration of macrophage activating factors secreted by T 
cells. In contrast to the effects of Thl cytokines, IL-4 deactivates macrophages and blocks 
T cell proliferation by down regulation of IL-2 receptor expression (Martinez et al., 1990) 
and may therefore inhibit the immune response to M tuberculosis. 
Although CD4+T cells are traditionally known as cytokine producers, they are also 
capable of cytotoxic activity. CD4+ cytotoxic lymphocyte (CTL) clones specific for 
purified protein derivative (PPD) effectively lyse a variety of targets using both the Fas-
Fas ligand (FasL) pathway and the granule exocytosis pathway of cytotoxicity (Oddo et 
al., 1998). Another study showed lysis of monocytes infected with M tuberculosis by 
recombinant FasL resulting in the actual killing of intracellular bacteria (Lewinsohn et al., 
1998). 
1.2.3ii Cluster differentiation 8 (CD 8+) T cells. 
Kaufmann described a potential role of CD8+T cells in protective immunity against TB in 
1988. Several studies using ~2microglobulin (~2 M) knock out mice have been used to 
illustrate the importance of CD8+T cells in mycobacterial infections (Flynn et al., 1992; 
Ladel et al., 1995). One such study demonstrated that disease dissemination to the spleen 
is enhanced in ~2M knock out mice compared to controls (D'Souza et al., 2000). Other 
studies uSIng transporters associated with antigen presentation (TAP) knockout mice 
showed that CD8+ CTLs that are MHC class 1 restricted may present secreted 
mycobacterial antigens through a mechanism that involves the TAP transporter system 
(Mazzaccaro et al., 1996, Behar et aI., 1999). 
Thus far, evidence in favour of a protective role for MHC class I restricted CTLs in 
suppression of M tuberculosis is emerging. In mice, cytolytic CD8+T cells are able to 
recognise and kill culture filtrate pulsed macrophages using the secretion of perforins as 
the main mechanism of cytotoxicity. In humans, small peptide such as ESA T6 specific 
CTLs were used to demonstrate a non-lytic mechanism where T cell cytokines activate 
macrophages to induce factors that accumulate to suppressive levels after 6 days of 
culture (Lalvani et al., 1998). There is evidence that a defined epitope of the 19KD 
lipoprotein of M tuberculosis elicits MHC class I restricted CTLs with the ability to lyse 
autologous monocytes infected with avirulent mycobacteria (Mohagheghpour et al., 
1998). Lewinsohn et al., (1998) identified CD8+CTLs that killed M tuberculosis infected 
dendritic cells. A non-polymorphic MHC class 1 b pathway was proposed rather than a 
MHC class 1 presentation pathway (Lewinsohn et aI., 1998). Work in The Gambia has 
demonstrated a role for CD8+T cells in mycobacterial immunity in response to both BCG 
and M tuberculosis (Turner and Dockrell, 1996; Turner et al., 2000). 
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1.3 Genetic susceptibility to mycobacterial disease 
1.3.1 Evidence that host genetic factors influence susceptibility to tuberculosis 
In the nineteenth century, when the incidence of TB reached epidemic proportions, an 
inherited susceptibility to tuberculosis was suspected based on the observation that the 
incidence of TB in relatives of affected individuals appeared to be increased. Although 
this concept lost credibility when Koch discovered that TB was caused by infection with 
M tuberculosis, a number of observations over the years rekindled interest in the genetic 
component of mycobacterial susceptibility. 
The majority of individuals infected with M tuberculosis do not get disease: only 10% of 
infected persons will develop clinical symptoms during their life (Murray et al., 1990). 
Convincing epidemiological evidence to suggest that host genetic factors play an 
important role in determining susceptibility or resistance to mycobacterial infection 
comes from an incident in Germany, prior to the development of antimycobacterial 
chemotherapy. In 1926 two hundred and fifty-one children from Lubeck were 
accidentally immunised with a virulent strain of M tuberculosis (Smith, 1988). Of these, 
47 (20%) developed no detectable disease, 127 (50%) developed radiologically evident 
disease and 77 (30%) died. This suggests that the ability of the organism to cause disease 
varies between individuals and this variability may largely be attributed to differences in 
the host's ability to resist disease. Geographically remote populations such as Eskimos in 
the North Pole, where M tuberculosis, is not endemic are particularly susceptible and 
develop rapidly progressive, often-fatal, disease. Black people are twice as likely to 
develop clinical disease than whites (Stead, 1992). Considerable evidence of a role for 
genetic factors in the clinical outcome of mycobacterial infections comes from twin 
studies (Kallman and Reisner, 1943). Concordance rates for tuberculosis are higher 
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among monozygotic twins when compared to dizygotic twins, siblings or marnage 
partners. 
The genetics of host resistance or susceptibility to mycobacteria is still poorly understood. 
In terms of Darwinian natural selection, the development of host resistance to a given 
parasite requires that it produce a high mortality for its host before the reproductive 
period. In this way only the more resistant survivors reproduce. Over many generations of 
continued selective pressure from the parasite, the percentage of resistant individuals 
gradually increases. Malaria is a good example of the selective pressure infection might 
have on human evolution - polymorphisms in at least 12 genes confer resistance to 
malaria, the sickle mutation in the beta-globin gene being the best known (Weatherall, 
1996). Since a quarter of all deaths at the time were due to TB, it is possible that the 
epidemic in Europe in the 16th to 19th centuries waned as a result of natural selection, 
though other factors such as the development of isolation facilities were probably equally 
important. In support of this, genetic and epidemiological studies have provided some 
evidence that the high frequency of Tay-Sachs disease in certain Jewish populations 
reflects heterozygous resistance to tuberculosis in some of the ghettos of Eastern Europe 
(O'Brien, 1991). 
1.3.2 Approaches for identifying TB susceptibility genes. 
At least four approaches can be used to identify disease susceptibility genes in complex 
diseases such as TB. Firstly, animal models have obvious logistical advantages, but the 
question remains as to how reliably data from mice extrapolates to man. Secondly, a 
number of rare but informative single gene defects in human families have led to the 
identification of putative mycobacteria susceptibility genes in man. Thirdly, a complex 
phenotype may be viewed as a constellation of sub-phenotypes (quantitative traits), which 
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in tum are regulated by their own sets of genes. Thus by simplifying the phenotype, fewer 
genes are involved, making them easier to identify. Finally, developments in complex 
trait genetic analysis such as semi-automated genotyping of highly polymorphic 
microsatellites dispersed throughout the genome, and the statistical packages to analyse 
the data generated has allowed both linkage and association study designs using 
candidates gene and genome wide scanning approaches in TB in outbred human 
populations. 
1.3.2.i· Animal models 
Animal models offer the opportunity to study hundreds of meioses from a single set of 
parents. The use of animal models is enhanced by the relative ease of genetic 
manipulation, for instance the production of 'knock-out' animals. Animals can be reared 
in the same conditions, reducing variation due to environmental factors. A potential 
disadvantage is that the genes shown to be important in inbred strains of mice could differ 
from those relevant in humans, but findings could still be helpful for identifying 
biochemically similar pathways in humans. Animal studies using selective breeding 
techniques were used to identify two distinct phenotypes of disease after inhaling large 
numbers of M bovis (Lurie, 1952). Highly resistant rabbits had localised chronic 
pulmonary lesions like those found in immunocompetent adult humans with TB, whereas 
susceptible rabbits showed rapidly progressive generalised spread of infection, even with 
smaller numbers of M bovis, similar to that found in infants and immunocompromised 
people. Although not the best model for human TB, developments in immunological and 
genetic technology (e.g. genetically engineered 'knockout' animals and the availability of 
monoclonal antibodies) have favoured the mouse model and a number of candidate TB 
susceptibility genes have subsequently been identified. 
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1.3.2.i.a Natural resistance associated macrophage protein 1 (Nrampl) 
Nrampl, a gene originally identified almost 30 years ago as fty/Lsh/Beg for its role in 
controlling Salmonella typhimurium, Leishmania donovani and M bovis infection in 
mice, was the first murine mycobacteria susceptibility gene to be identified. It regulates a 
cascade of gene induction events mediating inflammation, elimination of invading 
organisms and induction of T-cell memory against re-infection (Blackwell, 1989). 
Following the mapping of Lsh ands fty loci to murine chromosome 1 (Plant et at., 1982), 
Gros et al., (1981 ) showed that resistance to infection with M bovis (BCG Montreal) was 
under the control of a single gene Beg which mapped to the same region of chromosome 
1 in mice. The gene was positionally cloned and renamed Nramp 1 (Natural resistance 
associated macrophage protein, Vidal et at., 1993). A non-conservative amino acid 
substitution of glycine by aspartic acid at position 169 was shown to be responsible for 
the susceptible BegS phenotype in 27 inbred mouse strains (Vidal et at., 1993; Malo et at., 
1995). 
Nramp 1 protein localises to the late endosomal compartment in resting macrophages and 
after phagocytosis is recruited to the membrane of the phagosome (Searle et at., 1998). 
There is evidence that it may restrict the replication of intracellular pathogens by altering 
the phagolysosomal environment. Functional studies using mice and transfected 
macrophage lines have shown that Nramp 1 may be important early in macrophage 
activation. It has many pleiotropic effects on macrophage function including regulation of 
the expression of the chemokine KC, IL-I~, inducible nitric oxide synthase (iNOS), 
MHC class II molecules, and TNF. It also modulates nitric oxide (NO) release, L-arginine 
flux, the oxidative respiratory burst, and tumoricidal and antimicrobial activity 
(Blackwell, 1989, Skamene, 1994, Radzioch et at., 1995). Macrophages carrying the 
susceptible Nramp 1 allele have been shown to have a defect in the ability to process 
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antigens (Lang et aI., 1997), which is compounded by the influence of the gene on 
molecules regulating (TNF, IL-1 f3) or directly involved in (MHC class II) antigen 
presentation. This results in an in vivo bias towards the development of a Th 1 type 
response in mice bearing the wild-type infection resistant allele, while a Th 2 type 
response is elicited in susceptible mice (Kaye and Blackwell, 1989; Kramnick et aI., 
1994). However, a study of NrampJ deletion and M tuberculosis infection in 129vs mice 
failed to show any difference in bacterial growth in major organs and survival times in 
mice infected with the virulent H37Rv strain of M tuberculosis (North et aI., 1999). In 
addition, an earlier study failed to show any influence of Nramp 1 on the growth of M 
tuberculosis and a further mouse strain identified as being BcgT were shown to be more 
susceptible to this infection. The inference that Nrampl mutant mice are susceptible to 
infection with all mycobacterial species may be incorrect for M tuberculosis (Medina and 
North 1996, North 1999). 
1.3.2.i.h Other candidate genes in mice 
Experiments with 'knock out' mice have been used to define the role of many other genes 
in TB. For example, it has been shown that mice with targeted disruption of the gene 
encoding IFN-y (lfny 0/0) or the IFN-y receptor! gene (lfnyrl 0/0) are markedly more 
susceptible to infection with M bovis BCG (Kamijo et aI., 1996) or with virulent M 
tuberculosis (Cooper e tal., 1993). Mice lacking Ifnyr 1 showed a decrease in hepatic 
granuloma formation at 2 weeks after inoculation, decreased MHC class II antigen 
expression, and significantly reduced production of TNF after M bovis BCG infection or 
LPS challenge. Macrophages from mice lacking Ifn-y were unable to produce nitric oxide 
when compared to macrophages from wild type mice. In wild type mice TNF was shown 
to be essential for the recovery from M bovis BCG infection and for mounting of a 
protective immune response against M tuberculosis. Thus IFN-y acting in synergy with 
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TNF is apparently essential for resistance to mycobacterial infection and their major role 
is thought to be the activation of macrophages for monokine production leading to 
activation of other pathways required for the destruction of mycobacteria. 
Other genes which, when disrupted in mice, lead to increased susceptibility to 
mycobacterial infection are summarised in table 1.1 below. As more such models are 
developed, a clearer picture should emerge as to the role of individual genes in protection 
against mycobacterial infection and the ways in which these genes interact. 
Table 1.1. Effect of disruption of various candidate genes on susceptibility to 
mycobacterial infection 
Gene Effect* Reference 
TNF - Receptor (5 5Kd) M bovis (BCG) Flynn et al., 1994 
Interferon -y M tuberculosis Cooper et al., 1993 
Flynn et al., 1993 
Interferon -y receptor M bovis (BCG) Kamijo et a/., 1993 
B2-microglobulin M tuberculosis M bovis (BCG) Flynn et al .,1992, Ladel et a/., 1995 
MHC Class II M bovis (BCG) Ladel et al., 1995a 
T cell receptor M bovis (BCG) Ladel et al., 1995b 
Recombinase activating gene M bovis (BCG) Ladel et al., 1995c 
Interferon regulatory factorl M bovis (BCG) Kamijo et a/., 1994 
Inducible nitric oxide synthase M tuberculosis MacMicking et al., 1997 
Interleukin -12 M tuberculosis Cooper et al., 1997 
Transporter associated with M tuberculosis 
Behar et al., 1998 
antigen processing 1 
* increased susceptIbility to the orgamsm hsted 
1.3.2ii Mendelian susceptibility to mycobacterial infection in man 
A number of families have been identified in which there is an increased susceptibility to 
be inherited as a single gene Mendel ian mycobacterial infection, which appears to 
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disorder (Engbaek, 1964, Uchiyama et at., 1981, Levin et at., 1995). These patients have 
selective susceptibility to poorly pathogenic mycobacteria such as M bovis BeG and 
non-tuberculous mycobacteria (NTM). With the exception of other intracellular 
pathogens such as salmonella, individuals with idiopathic BeG and NTM infections do 
not generally have associated infections suggesting that a highly specific immune 
mechanism controls TB. Although rare, such families provide important insights as to the 
role of a specific gene in the immune response to mycobacteria. 
The first recorded case of idiopathic BeG syndrome was probably in 1951 (Mimouni, 
1951). In a retrospective study of all cases of disseminated BeG infection following 
routine vaccination in France, an underlying immunodeficiency was identified in less than 
half of the cases (Cassanova et at., 1996). The prevalence in France is estimated at 0.59 
cases per million births and the disease is not confined to any particular ethnic group or 
geographic region (Casanova, 1996). A Mendelian disorder of autosomal recessive 
inheritance was initially suggested by the high rates of affected siblings and parental 
consanguinity together with equal number of male and female patients. To date, 
mutations in four genes have been associated with Mendelian susceptibility to 
mycobacterial infection in man (Mendelian Inheritance in Man MIM 209950). 
Figure 1.2 on page 28 illustrates the interaction between IL-12 and IFN-y III 
mycobacterial immunity. 
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FIG.1.2 Mycobacterial immunity - the role of IL-12 and IFN-y 
Infected macrophages become activated and release the heterodimeric IL-12 cytokine which binds to 
its dimeric receptor on either NK cells or T cells. Binding of IL-12 to its receptor activates T cells to 
produce IFNy. IFNy released by NK cells and T cells binds to its dimeric receptor which isfound on 
all cell types except elythrocytes. Mutations leading to increased susceptibility to mycobacterial 
il?fection have been identified infour genes in this pathway (*), highlighting the importance of lL-12 
and IFN-y in antimycobacterial immunity in man. 
1.3.2ii a Interferon-y receptor ligand binding chain (IFNGRl) 
IFN-yexerts its pleiotropic effects via a species-specific receptor, which is expressed on 
all cells except erythrocytes. Upon IFN-y binding, the ligand binding chain (IFN-yRl) 
dimerises and associates with two signal transduction chain molecules (IFN-yR2) to fonn 
a receptor complex. These two chains are encoded by different genes, IFNGRl and 
IFNGR2, located on chromosomes 6 and 21 respectively. A series of phosphorylation 
events involving the Janus kinases Jakl and Jak2 leads to the formation of 
phosphorylated Statl dimers which translocate to the nucleus to activate IFN-y-inducible 
gene transcription (Bach et al., 1997). FIG 1.3 summaries the mechanisms of signal 
transduction for IFNG pathway. In 1996, mutations in IFNGRl were identified as the 
cause of familial susceptibility to mycobacterial infection in two families establishing a 
role for IFN-y pathway in susceptibility to mycobacterial infections. A number of other 
IFNGRl mutations leading to IFN-y Rl deficiency have subsequently been identified 
resulting in two phenotypes according to whether the deficiency is partial or complete. 
Interestingly, both recessive and dominant mutations have been identified. 
Complete IFN-yRl deficiency 
Complete IFN-yRl deficiency was first described in a group of related children from the 
same village in Malta who had disseminated infection with various NTM species, and a 
Tunisian child born to consanguineous parents who developed disseminated BCGosis 
following vaccination (Newport et at., 1996, Jouanguy et aI., 1996). The clinical 
phenotype included wasting, fevers, lymphadenopathy (histology showed multi -bacillary, 
poorly-differentiated lesions) and anaemia (Levin et at., 1995). 
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FIG.I. 3 Schematic drawing of mechanisms of signal transduction for IFN-y pathway 
Upon IFN-y treatment, four components (IFN-yRI, JakI, Jak2 and StatI ex) are 
phosphorylated rapidly at tyrosine residues. The receptor chains associate and this is 
thought to occur via Jak2 which may have a binding site on IFN-yR2 or Jakl. Statl ex 
dimerises and translocates to the nucleus and binds to the gamma activated site of any 
IFN-y inducible gene. 
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A transversion of C to A at nucleotide position 395 was identified in the Maltese kindred, 
and a single nucleotide deletion of C at position 131 was identified in the Tunisian child. 
Both mutations were null recessive mutations resulting in premature stop codons, 
truncating the protein in the extracellular domain and resulting in complete lack of 
expression ofIFN-yR1 on the cell surface. 
Subsequently, a number of other mutations in this gene, resulting in the same phenotype, 
were described. One patient was a compound heterozygote who inherited a 4bp insertion 
(107 ins 4) within IFNGRl exon 2 from her father and a substitution of the first base of 
the consensus splice donor site in intron 3 (200 +1 GA) from her mother (Altare et ai., 
1998). Again, the receptor was not expressed on the cell surface, and responses to IFN-y 
were defective with reduced production of TNF -ex and IL-12 by peripheral blood 
mononuclear cells. A causative relationship between mutant alleles and impaired cellular 
responses to IFN -y was established by complementation of defective cells with the wild 
type gene encoding IFN -yR1. 
Partial IFN -yRl deficiency 
Partial IFN-yR1 deficiency has also been observed. The first report was of a child 
homozygous for a mutation causing an amino acid substitution of isoleucine by threonine 
at position 87 in the extracellular domain of the receptor (Jouanguy et ai., 1997). The 
receptor was expressed at the cell surface but the mutation reduces the affinity of the 
receptor for its ligand. This resulted in an intermediate phenotype, both clinically and in 
vitro. Whilst in vitro cellular responses from children with complete IFN-yRl deficiency 
are abrogated, cells from children with partial deficiency responded to high IFN-y 
concentrations, when compared to normal controls. The outcome of treatment with I FN-y 
was favourable, and the patients are healthy and alive without on going therapy. It was 
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suggested that signalling mediated by IFN-yR, though impaired, was sufficient to promote 
morphologically mature granuloma formation. 
Partial IFN-yRl deficiency also results from autosomal dominant mutations described in 
3 families and 9 sporadic cases with disseminated mycobacterial infection. All cases had 
a 4bp deletion, at nucleotide position 818bp of the 3' region the IFNGR1, thereby 
identifying a mutational hotspot within IFNGRl (Jouanguy et aI., 1999). The truncated 
protein lacks the intracellular signalling domain but is expressed at the cell surface and 
exerts a dominant-negative effect through impaired recycling, abrogated signalling but 
normal binding to IFN-y. Patients developed disseminated infection from poorly virulent 
mycobacteria and M bovis BeG. 
Mutations identified to date in IFNGRl are summarised in figure 1.4. 
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Model 0/ amino acid structure of the IFNyR1 showing the mutations and deletion hotspots. The gray 
shaded areas of the intracellular domain are biological active regions which must be tyrosine 
phosphorylated for binding of the J ak1 (upper) and Stat 1 (lower) molecules. The ex tracellular domain 
consists 0/228 amino acids, the transmembrane domain contains 23 amino acid and the intracelfuar 
domain contains 221 amino acids. Most of the mutations are in the extracellular domain of the gene. 
The dele lion hotspot at nuc /eat ide pos ilion 818 is in the transmenbrane doma in of the molecwe. A 13 
th missense mutation C77Y substitution of cysteine at nucleotide position 182. 
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1.3.2iib Interferon-y receptor signal transduction chain (IFNGR2) 
As with IFN-yRl deficiency, both partial and complete deficiency of IFN-yR2 has been 
reported as a result of mutation in IFNGR2. 
Complete IFN-yR2 deficiency 
Complete deficiency of the IFN-y receptor signal transduction chain (IFN-yR2) has been 
reported in a child with disseminated M fortuitum and M avium complex infections. 
IFN-y signalling was absent and molecular analysis of IFNGR2 revealed a homozygous 
dinucleotide deletion at nucleotides 278 and 279, resulting in a premature stop codon in 
the protein extracellular domain (Dorman and Holland, 1998). Clinical and 
immunological features were similar to those already described for complete IFN-yRI 
deficiency. 
Partial IFN-yR2 deficiency 
Partial IFN-yR2 deficiency has been reported in a young adult with a history of curable 
infections due to M bovis BCG and M abscessus. The patient was homozygous for a 
nucleotide substitution in IFNGR2 (C--7T substitution at position 114) causing an amino 
acid substitution (Arg--7Cys) in the extracellular region of the receptor. Cell surface IFN-
yR2 was detected by flow cytometry and cellular responses to IFN-y were impaired but 
not abolished. Transfection with the wild-type IFNGR2 gene restored full responsiveness 
to IFN-y (Doffinger et aI., 2000). 
1.3.2iic Interleukin-12 p40 subunit (IL12P40) 
IL-12 is composed of two chains (p35 and p40, encoded by separate genes on different 
chromosomes) and mostly secreted by dendritic cells and macrophages. It is a potent 
inducer of IFN-y. Mutation in IL12P40 has been identified in a child with disseminated 
BCGosis and salmonella infection whose parents were first cousins. A homozygous 
frameshift deletion of 4.4kb including two coding exons was identified which abrogated 
IL-12 production (Altare et al, 1998d). This patient responded to treatment with 
recombinant IL-12. 
1.3.2iid Interleukin-12 receptor ~1 subunit (IL12RBl) 
The IL-12 receptor consists of two chains (IL-12R~ 1 and IL-12R~2) they are synthesised 
at certain stages ofNK cell and T cell differentiation. Mutations in the IL12RBl gene (de 
long et al, 1998; Altare et al, 1998a), result in a similar phenotype to the IL-12 
deficiency described above. Interestingly, the patients with defects in the IL-12 pathway 
had less severe disease when compared with those with complete IFNyR deficiency. It 
appears that impaired secretion of IFN -y is the mechanism that accounts for susceptibility 
to mycobacterial infection in patients with IL-12 deficiency. 
Genetic mutations leading to complete deficiency of IFN -yRl, IFNyR2, IL-12 p40 or IL-
12R~ 1 are rare events in nature leading to disseminated infection with poorly pathogenic 
mycobacteria and early death. However, the milder phenotype observed in partial 
deficiency of IFN-yRl and IFN-yR2 raises the possibility that more common variants of 
these genes may be present in the general population (Fig. 1.5). Such polymorphism may 
account for part of the observed variation in susceptibility to more pathogenic 
mycobacteria such as M tuberculosis. 
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FIG. 1.5. Spectrum of genetic susceptibility to mycobacteria 
Figure 1.5 illustrates the severity of mycobacterium infection in relation to host 
genetic defects, highlighting the importance of genetic regulation on the 
integrity of the ensuing immune response. At the extreme end of the spectrum are 
afew individuals with lethal disease such as was seen in the Maltese 
children, who suffered from atypical mycobacterium infection with an underlying 
single gene defect resulting in complete deficiency of the IFN-y receptor. 
Individuals with partial deficiency of IFN- y R, or complete deficiency of IL-12 
p40 or IL-12Rl{3, have a milder phenotype. Although not yet reported, it is 
possible that partial deficiency of these latter proteins could result in a still 
milder phenotype, or polymorphism at the population level leads to a 
individuals who are more susceptible to more virulent pathogens. At the other 
extreme are resistant individuals with no genetic defect. (Figure 1.5 is derived 
from OttenhoJf et al., 1998) 
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1.3.2iii Identification of TB susceptibility genes in human populations 
Infectious diseases such as TB are, from the genetic point of view, complex or polygenic 
traits. Inheritance does not follow the simple Mendelian recessive, dominant or sex linked 
pattern attributable to a single gene locus and the phenotype results from the interaction 
between a number of host genes, the environment and other factors. In the case of 
infection, disease also requires the presence of a pathogen, which has a genome too. It is 
not usually known exactly how many genes influence the phenotype, nor how they 
interact. Mutations in anyone of several genes may result in an identical phenotype 
(genetic or locus heterogeneity), for example, when these genes are required for a 
common biochemical pathway such as macrophage activation. Although much progress 
has been made in mapping single genes disorders, the majority of diseases world-wide 
(e.g. heart disease, asthma, infectious diseases) are polygenic and identification of disease 
susceptibility genes remains a challenge (Lander and Schork, 1994). There is evidence 
from a Brazilian study that TB is under oligogenic control (Shaw et al., 1997a). 
There are two main approaches to identify human tuberculosis susceptibility genes. 
Firstly, one can look at genetic differences between individuals who have the disease 
compared to those who do not. This usually takes the form of an association study in 
which variation in a candidate gene is studied in cases and unrelated unaffected controls. 
Secondly, one can look for genetic similarities in family members who are affected 
(linkage studies). Family based linkage analysis can be used to screen the entire genome 
for chromosomal regions linked to disease, and therefore has the potential to identify 
novel genes. However, linkage analysis has limited power to detect genes with a modest 
effect. Subsequently large numbers of families are required in order to obtain a 
significant result (Risch and Merikangas, 1996). Furthermore, it is possible that an 
individual has inherited the susceptibility gene(s), but is classified as unaffected due to 
lack of exposure to the pathogen. This can be overcome by studying affected family 
members (usually siblings) only. Candidate genes can also be studied by linkage, but a 
comprehensive search for regions associated with tuberculosis with a case control study 
design is currently not feasible for technical reasons. Association studies have the power 
to detect genes with a relatively small effect, but there are many potential candidates and 
the major susceptibility gene(s) may not yet have been discovered. Whereas linkage 
analysis requires families, association studies involve unaffected, unrelated individuals 
for comparisons. It is quicker to recruit study subjects for association (case control) 
studies than family members and siblings of affected individuals, providing a fast robust 
method of investigating the role of a particular gene in a disease. The statistical analysis 
is simple involving only chi square or 2 x 2 contingency table. In the long run, a 
combination of approaches is therefore likely to give the most success. Furthermore, 
family based association studies combine linkage and association for search for disease 
susceptibility gene. 
Genome-wide searching for chromosomal regions linked to disease using affected sibling 
pairs, is currently popular as an approach to identifying disease susceptibility genes. The 
method is statistically robust as a genetic model is not required. Genome screens have 
been completed in several complex diseases. These include type 1 and type 2 diabetes 
(Davies et al., 1994, Hanis et al., 1996), inflammatory bowel disease (Hugot et al., 1996, 
Satsagi et al., 1996), multiple sclerosis (Sawcer at aI., 1996), coeliac disease (Zhong et 
al., 1996), asthma (Daniels et a/., 1996), and psoriasis (Trembath et al., 1997). A genome 
wide search for TB susceptibility genes was carried out in Gambian affected sibling pairs 
and 5 regions were identified (Bellamy, 2000). However, although many regions have 
been identified as putative susceptibility loci for the various diseases, findings have not 
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been replicated in other studies, and genes have yet to be cloned. A number of association 
studies have now been reported for tuberculosis. Given its functional importance in 
immune responses to various antigens and infectious diseases, much effort has focused o~ 
the HLA region. Although associations have been demonstrated with both class I and II 
alleles, the majority have not been reproducible. At the population level the most 
consistent association is between tuberculosis and the HLA class II antigen HLA-DR2 
(e.g. Brahmajothi et al., 1991). 
Given the large amount of data in mice documenting the role of Nrampl in susceptibility 
to intracellular pathogens, the human homologue NRAMP 1 was a good non-HLA 
candidate gene for human susceptibility. Four NRAMP 1 polymorphisms were typed in a 
Gambian population and all found to be associated with tuberculosis (Bellamy et al., 
1998b). Variation in the vitamin D receptor was associated with resistance to tuberculosis 
(Bellamy et al., 1998c) and a marginally significant association between tuberculosis and 
polymorphisms in the IL-1 gene cluster in the same Gambian population (Bellamy et al., 
1998d). So far, negative associations have been reported for the mannose binding lectin, 
fucosyltransferase-2 and IL-10 genes (Bellamy et al., 1998d, 1998e). 
1.3.2iv Quantitative phenotype analysis 
Given the difficulties of mapping complex trait genes outlined above, many investigators 
have turned to quantitative trait analysis in order to simplify the problem. Quantitative 
traits exhibit continuous variation and include such measures as blood pressure, weight, 
serum cholesterol levels and immune responses. Many complex traits may be regarded as 
a constellation of quantitative traits, each having its own set of regulatory genes. By 
simplifying the phenotype, the likelihood of identifying these genes is theoretically 
enhanced. Quantitative trait loci (QTL) mapping has successfully identified susceptibility 
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genes for several traits in rodent models, including TB (Kreutz et al 1995 L b 
" ,ave ratt et 
at., 1999), 
This approach was adopted to identify human asthma susceptibility genes (Daniels et ai" 
1996). A genome wide search for loci linked to eosinophilia, IgE levels, bronchial 
hyperresponsiveness and skin prick reactivity (all quantitative traits underlying asthma) 
identified 6 loci, one of which had been previously identified. As more is understood 
about the processes involved in the pathogenesis of TB, the quantitative traits underlying 
TB are increasingly amenable to genetic analysis. 
1.4 Aims of this study 
This study has investigated the role of specific candidate genes in immunity to 
mycobacteria and susceptibility to tuberculosis in Gambians (Table 5.1). One aim of the 
study was to determine whether the development of clinical TB was as a result of inferior 
ability to activate macrophage function. This study was expanded to search for evidence 
for correlation between cytokine secretion (as a marker of macrophage activation) and 
genetic variation. The next phase was to determine whether these genes influence 
susceptibility to TB. This study is the first to employ this approach towards identification 
of TB susceptibility genes in humans. 
Candidate TB genes were selected based on what is known or suspected about their role 
in innate and acquired anti-mycobacterial immunity. Population based studies have 
reported associations between some candidate genes and clinical tuberculosis. Two recent 
studies of TB in Cambodia and India reported associations of some HLA class II alleles 
with TB (Goldfeld et at., 1998, Ravikumar et at., 1999), Also a study in Indian patients 
reported the influence of certain mannose binding protein alleles on TB (Selvaraj et al., 
40 
1999). Previous study in The Gambia reported a predisposition of individuals by four 
NRAMP1 polymorphisms to TB (Bellamy et aI., 1998b). In the same population, an 
allele of the vitamin D receptor gene was associated with TB (Bellamy et ai., 1999). 
Polymorphisms in the cytokine genes IL-l ~ and its receptor antagonist IL-1 RA were 
found to be associated with tuberculosis in patients of Gujarati origin living in England 
(Wilkinson et al., 1999). The predisposing alleles reported in these studies have only 
moderate effects, and their functional relevance needs to be established before their role 
can be validated. Genes suspected to be important TB susceptibility genes include: -
genes encoding macrophage deactivating cytokines interleukin 4, interleukin 9 and 
interleukin 10, macrophage-activating cytokines for example the TNF locus, the 
interferon gamma pathway, pathway for the generation of the free radical nitric oxide 
(NO) and the regions encoding the small inducible chemokine genes. Table 1.2 overleaf 
gives an overview of the candidate genes selected for this study according to its role in 
innate immunity to mycobacterial infection. 
TABLE 1.2. TB candidate gene products 
PATHWAY 
Macrophage entry by mycobacterium 
Macrophage activation 
Antigen presentation 
Response to macrophage activation 
CANDIDATE GENE PRODUCT 
Complement receptors 1 and 3 
Mannose receptor 
Fibronectin receptor 
NRAMPI 
Toll-like receptors 
CD14 molecule 
Vitamin D receptor 
MHC 
T cell receptor 
TAP 
Cytokines and their receptors 1FNy, TNF -, 1L-I (3 
1L-4, 1L-8, 1L-9, 1L-lO, 1L-12, IL-13, 
CC Chemokines and their receptors :1-309, MCP-
I, M1P-I a, MIP-I (3, RANTES, MCP-3, MCP-2 
Signal transduction proteins protein kinases such 
as JAK I, JAK 2, and Stat la 
Nuclear transcription factors NF-k(3, 1RF-I NF-
1L6, GAF. 
This list contains an overview of genes that are involved in the macrophage activation 
process. This study concentrated on the innate immune responses to TB in humans and 
other genes important in acquired immune responses to TB were not selected. 
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CHAPTER 2 
STUDY SUBJECTS, 
MATERIALS AND METHODS 
-u 
2.1 Recruitment of study subjects 
The study subjects recruited for the studies described in chapters 3-6 can be divided into 
two groups - those with a history of TB (either current or past) and healthy individuals 
who had no history of TB. This project had the approval of the Gambian 
Government/Medical Research Council Joint Ethical Committee. Verbal consent was 
obtained from all patients before entry into the study. For logistical and sociological 
reasons (e.g. women rarely donate blood and present less frequently to medical services 
with TB), all subjects studies were male. All individuals were unrelated. 
2.1.1. Subjects with a history of tuberculosis. 
TB cases were recruited from two centres. Firstly, The Gambia National Tuberculosis and 
Leprosy Control programme runs a TB clinic at Serrekunda Health Centre near the 
capital, Banjul. Secondly, the Medical Research Council (Fajara) runs a chest clinic 
where newly diagnosed cases were recruited in to the study. All cases presented with 
typical clinical features of pulmonary TB and acid fast bacilli were identified in their 
sputa using standard Ziehl-Neelson staining. Ninety-five percent were culture positive by 
BACTEC, and most patients had X-ray changes suggestive of TB. HIV testing was 
carried out on all TB patients using an ELISA method established in the MRC 
Laboratories, Fajara and HIV positive individuals were excluded from the study. The 
prevalence of HIV infection in The Gambia is relatively low (below 20/0 in pregnant 
women, O'Donovan et at., 2000) although the prevalence among TB patients is higher, as 
expected, at approximately 10% (Lienhardt et at., 1999). 
The study subjects with a history of TB could be further divided into those with a past 
history of TB (referred to as ex-cases) who had successfully completed the recommended 
treatment regimen and been off treatment for at least two months, and those with TB at 
the time of enrolment. The former group (n=45) were used to address the hypothesis that 
innate defects of macrophage/monocyte function predispose to TB - since active M 
tuberculosis infection itself and the drugs used to treat TB influence the immune 
response, subjects were recruited after successful completion of TB therapy. These 
subjects were traced using the Serrekunda TB clinic records, and interviewed by a trained 
field assistant to determine whether symptoms suggestive of TB were present. Those 
without such symptoms were recruited into the study. Symptomatic individuals were 
referred to the MRC clinic for further evaluation and not enrolled. The second group of 
cases were recruited for the case control genetic study from both Serrekunda TB clinic 
and the MRC TB clinic (n=276). 
2.1.2 Healthy individuals 
A major part of the work described in this thesis focuses on the genetic regulation of 
monocyte responses in healthy individuals who did not have active tuberculosis (chapters 
3 and 5). Three hundred and twelve blood bank donors form the Royal Victoria Hospital 
Banjul were identified who did not have symptoms or signs suggestive of active 
tuberculosis, who were HIV negative, and who agreed to participate in the study. These 
subjects were used as controls for the TB cases in association genetic studies described in 
chapter 6. 
A second group of healthy individuals were recruited as controls for the study 
. . TB (n=45) These subjects were investigating innate nnrnune responses In ex- cases . 
hn· d drawn from the same locality as the ex-cases. An matched for age, et IC group an 
interview was conducted to exclude symptoms suggestive of active TB and symptomatic 
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individuals (including symptoms suggestive of other disease) were referred to the MRC 
clinic for further evaluation, and excluded from the study. 
Demographic features of the study subjects are shown in tables 2.1 and 2.2, and figures 
2.1 and 2.2. The mean age ofTB cases was 35 years and the mean age for controls was 33 
years. 
2.1.3 Sample collection 
Ten ml of venous blood was collected using an aseptic technique into 3.8% citrate, for 
macrophage function studies and for DNA extraction, as described in sections 2.3.1.i and 
2.3.2.i below. For individuals in whom monocyte function assays were performed, 3 ml 
was placed in sterile eppendorf tubes. DNA was extracted from the remaining whole 
blood either immediately or after storage at -200 C. Two hundred and seventy six active 
TB cases were included for the case control association study in chapter six. Ten mls of 
venous blood was aseptically drawn into 3.8% sodium citrate and transported to the 
laboratories in Fajara. Macrophage function assays was not done on these samples. DNA 
was extracted for use in genotyping as described in section 2.3.2i. 
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Table 2.1 Ethnic structure for case control association study (chapter six) 
Ethnic group Controls TB cases 
Mandinka 104(0.33) 82(0.3) 
Wollof 66(0.21) 35(0.13) 
lola 63(0.2) 60(0.22) 
Fula 38(0.012) 49(0.18) 
Serere 18(0.06) 20(0.072) 
Manjagoe 3(0.0096) 15(0.054) 
Serahuleh 5(0.016) 5(0.018) 
Aku 3(0.0096) 3(0.01) 
Bambara 5(0.016) 5(0.018) 
Other 6(0.019) 2(0.007) 
Total 312 276 
Figures in parentheses represent frequency of the corresponding ethnic group 
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FIG.2.1 Ethnic groups represented in case control association study 
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Table 2.2 Age distribution of TB cases and controls 
Age I:roUI! (:yrs} 
11-15 
16-20 
21-25 
26-30 
31-35 
36-40 
41-45 
46-50 
51-55 
56-60 
61-65 
Total 
140 
~120 
g100 
CD 80 
::J 
C" 60 
E 40 LL 
20 
o --+---==-------.---=--~ 
Controls TB cases 
0(0) 3(0.01) 
9 (0.028) 15 (0.053) 
13 (0.04) 54 (0.19) 
118 (0.37) 41 (0.14) 
68 (0.213) 37 (0.13) 
72 (0.23) 61 (0.22) 
31 (0.97) 19 (0.07) 
6(0.019) 23 (0.08) 
1 (0.003) 7 (0.025) 
0(0) 15 (0.05) 
0(0) 9 (0.32) 
312 276 
Figures in parentheses represent frequency of the corresponding age group 
FIG. 2.2 Age distribution of TB cases and controls 
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2.2 Materials 
2.2.1 Chemical reagents 
Most of the chemicals and reagents used were purchased from Sigma Chemical Company 
(St Louis, MO). Trisodium citrate and Bis N, N' methylene bis acrylamide were obtained 
from British Drug Houses Laboratory Supplies (BDH, U.K.). Ultrapure deoxynucleotide 
triphosphates (dNTPs) and ficoll Hypaque were purchased from Amersham Pharmacia 
Biotech AB, (Uppsala, Sweden). Phenol (tris- equilibrated) was obtained from Gibco 
BRL Life Technologies (Scotland, U.K.). Commercial primers were purchased from 
either Gibco BRL Life Technologies (Scotland, U.K.) or Perkin Elmer Biosystems 
(Warrington, U.K.). Primers for the TNF ARMS PCR were from Cruachem Company 
(Glasgow, U.K.) and were gifts from Professor Kwiatkowski. 
2.2.2 Immunology materials 
Tissue culture medium RPMI 1640 was obtained from Whittaker (Walkersville, MD), 
endotoxin-free water was obtained from Braun (Belgium). Foetal bovine serum was 
purchased from Gibco BRL Life Technologies (Scotland, U.K.). Recombinant IFN-y was 
purchased from Genzyme Diagnostics (Kent, UK). Escherichia coli 0111 :B4, 
Lipopolysaccahride (LPS) was a gift from the Malaria Unit MRC. ManLAM 
97.Rv2.4.25a (endotoxin concentration of 12 ng of endotoxin per mg of LAM as 
determined by quantitative Limulus amoebocyte assay) was provided by Dr John Belisle 
(Colorado state University, Fort Collins, Co) under the provision of National Institute of 
Health. Tetramethybenzedine, primary and secondary monoclonal antibody reagents for 
lNF, IL-l~, and IL-lO were obtained from BioSource International (Fleurus, Belgium). 
Streptavidin and horseradish peroxidase were purchased from Boehringer Mannheim 
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(Germany). Corning Laboratory Sciences Company (Coming, NY) supplied plastic ware 
unless otherwise stated. 
2.2.3 Automated sequencing reagents 
SequaGel concentrate and diluent for denaturing polyacrylamide gel electrophoresis used 
for sequencing was supplied by National Diagnostics (Hull, UK.) and Amresco 
Gene-P AGE Plus for microsatellite analysis was supplied by Amresco company (Solon, 
OH). Genescan 500-TAMRA, and 500-ROX (6-carboxy-rhodamine) size standard and 
fluorescently labelled primers were purchased from Perkin Elmer Biosystems 
(Warrington, UK.) The Wizard ™ PCR preps DNA purification system and the fmolR 
DNA sequencing system were purchased from Promega Corporation (Madison, USA). 
2.2.4 Radioisotopes 
[a 33p] ATP as supplied by Amersham Pharmacia Biotech AB (Amersham, UK). 
2.2.5 Enzymes 
Taq DNA polymerase and Taq Gold were purchased from Perkin Elmer Biosystems 
(Warrington, U.K.). BioI X-act Taq and Buffer were obtained from Bioline (London, 
U.K.). Proteinase K was purchased from Boehringer Mannheim Biochemicals (Germany) 
and Gibco BRL Life Technologies (Scotland, U.K). Restriction endonucleases were 
obtained from New England Biolabs (Beverley, MA). 
2.2.6 Electrophoresis 
Agarose and DNA ladders (1 kb 100 bp and 123 bp) were supplied by Gibco BRL Life 
Technologies (U.K). Bis N, N' methylene bis acrylamide, acrylamide and NNN'N' 
h I d· . (TEMED) were supplied by Bio-Rad Laboratories Incorporated tetramet y ene lamlne 
3nun chromatographic paper was purchased from Whatman limited (Hercules, CA). 
(Clifton, NJ). 
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2.2.7 Photography and auto-radiography 
Agarose gels were photographed using Polaroid 667 film from Polaroid (Cambridge, 
MA). Kodak X Omat K TM LS (24 X30 cm) used for autoradiography was obtained from 
Eastman Kodak company (New Haven, CT). 
2.3 Methods 
2.3.1 Immunological methods 
2.3.1.i Monocyte function assay 
Monocyte function was assessed using a whole blood assay and was carried out as 
already described (De Groote et al., 1992, Levin et al., 1995) with modifications. Briefly, 
one ml of whole blood was diluted with an equal amount of tissue culture medium RPMI 
1640 (Whittaker Walkersville, MD) to achieve a _ dilution. Two hundred ,.,..1 aliquots of 
diluted blood were stimulated in triplicate with either LPS (Escherichia coli 0 III :B4, 
1ng/ml) or manLAM, 2500ng/ml with or without pre-incubation with IFN-y (Genzyme, 
200U/ml) for 2 hours or in tissue culture medium (negative control). Plasma cytokine 
production at 18 hours of incubation in 5%C02 at 370e was measured by enzyme linked 
immunosorbent assay (ELISA). 
2.3.1.ii Plasma cytokine levels by enzyme linked immunosorbent assay 
Cytokine concentrations in plasma were measured using a one step antibody sandwich 
ELISA. Ninety-six well microtitre plates (Nunc™ MaxiSorp F96, Scotland U.K) were 
coated with 100 J.!l per well (2 Ilg/ml) of high-grade anti-cytokine capture monoclonal of 
the cytokine being tested. Plates were stored overnight at 40e for adsorption. The contents 
of the wells were discarded and 200 III of IX PBSIl% bovine serum albumin were added 
for two hours at room temperature after which the contents of the wells were discarded 
and washed four times with 1 X PBS/O.l % Tween. Fifty ,.,..1 of diluted plasma was added to 
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each well followed by the addition of a detector biotinylated anti cytokine monoclonal 
antibody of the cytokine being measured at a concentration of 0.S8Jlg/ml. Plates were 
incubated for 2 hours at room temperature with shaking. Recombinant cytokine was used 
for the standard and I in 2 dilutions were made starting with 1000 pg/ml. Each plate was 
washed four times with IX PBSIl 0% Tween. Streptavidin was conjugated to peroxidase 
in phosphate buffer solution (PBS) according to the specification of the manufacturer 
(Boehringer Mannheim, Germany). One hundred JlI of the conjugated streptavidin 
horseradish peroxidase was added, the plates were incubated for another 30 minutes with 
shaking at room temperature. Wells were washed four times with 1 X PBS/Tween and 
drained. One hundred JlI of tetramethylbenzidine (TMB) in TMB substrate buffer was 
added and the plates incubated at room temperature in the dark for 20 minutes. SO JlI of 
2.SM sulphuric acid was added to stop the reaction and plates were read on a plate reader 
(Dynex Technologies, West Sussex, UK) at a wavelength of 4S0 nm to determine the 
cytokine concentration in each well relative to the standard. A standard curve was 
constructed by plotting the OD on the ordinate against the standard concentrations on the 
abscissa. 
2.3.2 peR Methodologies 
2.3.2.i DNA extraction 
For most samples DNA was extracted using a standard phenol chloroform extraction 
method. Briefly, cells were lysed using lysis buffer (0.32M sucrose, 10Mm Tris, SmM 
MgCb, I % Triton Xl 00), the nuclei pelleted by centrifugation (3000 rpm for IS minutes) 
d· ded The nuclei pellet was re-suspended in 7.S ml and the supernatant was Iscar . 
. M T· H 8 0 0 1 M EDTA pH 8.0 O.S% SDS) and incubated at 
extractIOn buffer (10m ns P .,. 
h P tel·nase K was added at a concentration of 100 )..lg/ml and the 37°C for one our. ro 
. . b t d t SO°C for 3-18 hrs with periodic mixing. An equal volume of 
solutIOn was mcu a e a 
52 
phenol (3 ml) saturated with 100mM Tris HCh pH 8.0 was added. This was rotated for 10 
minutes and then centrifuged for 5 minutes at 3000 rpm at 20°C Th 
. e upper aqueous 
phase was removed and re-extracted further with 3ml phenol. The aqueous phase was 
removed and extracted with 3 ml of chloroform/isoamyl alcohol (24:1). To the aqueous 
phase, 9 ml of ice cold absolute ethanol was added in the presence of either 1.5 ml of 
7.5M ammonium acetate or 3M sodium acetate (PH 5.2). DNA was hooked out with a 
glass pipette or pelleted by centrifugation. The DNA was dissolved overnight in 0.5 ml 
sterile distilled water. At other times the Nucleon kit was used for extraction according to 
the manufacturer's recommendations (Scotlab Scotland, U.K.). 
2.3.2ii Optimising peR conditions for novel polymorphisms 
PCR conditions were first optimised in 20 f..11 master mix consisting of 1 III of 50 ng/1l1 of 
each oligonucleotide, 2 f..11 of lOX reaction buffer, 2 ,.11 of 2mM dNTP's, 13.9 III distilled 
water, 0.1 f..11 of 5 unitlf..11 of Taq polymerase. To optimise PCR conditions, different 
reaction buffers were used and their compositions can be found in appendix 1. 
Whichever, buffer gave the expected product size was then used in subsequent 
experiments. The final concentration of dNTP was 200f..1M. Primers and enzymes were 
stored separately from PCR products. Reactions were set up in a class II hood. 
Nucleotides, primers and enzymes were stored at -20°C. Buffers were prepared in house 
or were supplied by the manufacturer to accompany DNA polymerase enzymes. 
Magnesium ion concentration was optimised for each set of primers. Titration of 
magnesium chloride was achieved usually using ~_ £()l1c~ntration of 0-10 mM free 
magnesIum. Target DNA if in excess can give rise to non-specific amplification. In 
practice 100 ng of DNA was used per PCR reaction. The mastermix was mixed by 
. d h l' t d' 19 III volumes into sterile 0.5-ml eppendorfs. All frozen 
vortexlng an t en a lqUO e III r 
. . d II before use One f..11 of extracted genomic D\:A (100 
stock solutIOns were mlxe we . 
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ng/J..lI) was added to each eppendorf tube and layered with 3 drop f' 1'1 s 0 mlnera 01. A 
negative control was included for all experiments in which 1 III of autoclaved distilled 
water was added instead of DNA. The tube was covered and spun briefly. The cycling 
parameters for each pair of oligonucleotide primer were fIrst determined empirically 
using the guidelines described by Thein and Wallace (1986). The size of the amplified 
product was confirmed by gel electrophoresis through 2% agarose directly and visualised 
by UV light after staining the DNA with ethidium bromide. Gels were photographed 
using Polaroid 667 film. 
2.3.2.iii Polyacrylamide gel electrophoresis 
Glass plates were thoroughly cleaned with detergent and dried with paper towels. The 
inside surfaces of the plates were washed with Tepol detergent and left to dry for 2-3 
minutes. Spacers were placed between the glass plates and the plates were clamped with 
bulldog clips. Gel mix was prepared for manual sequencing as follows: Bis acrylamide 
O.3g, acrylamide 5.7g, Urea 4.8g, lOX TBE buffer 10 ml, Alpha Q water 45 ml. It was 
ensured that all the reagents were fully dissolved before the addition of ammonium 
persulphate (APS, 450 III of a 10% solution) and TEMED (45 Ill). The gel was poured 
between the glass plates. An inverted 48 well sharks-tooth comb was placed between the 
plates at the top of the gel. Bulldog clips were used to clamp the top of gel. Gels were left 
for a minimum of two hours to set before mounting on the M2 sequencing electrophoresis 
apparatus (Life Technologies, Inc.) When the gel had set, the comb was removed and the 
shark-tooth end reinserted to create wells into which samples were loaded prior to 
electrophoresis. For semi-automated sequencing and microsatellite analysis, gels were 
prepared as described above but using 40 III of Sequagel concentrate and diluent for 
. . 1 1 h . d 40 ml (19'1 Acrylamide/Bis-denatUrIng polyacrylamide ge e ectrop oreSlS an . 
acrylamide) Amresco Gene PAGE Plus respectively to which 200 III of 100/0 APS and 20 
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J,tl of TEMED were added. Gels were mounted in an ABI automat d c. e sequencer lor 
electrophoresis (Perkin Elmer, ABI-Prism 377). 
2.3.2.iv Purification of peR products 
PCR products were purified prior to sequencing in order to remove contaminants such as 
primer-dimers and amplified primers. One hundred J,tl of PCR product was purified with 
the Promega wizard kit following the instructions of the manufacturer. The purified DNA 
was stored at 4° C. To confirm that the DNA has been purified a small amount of purified 
product was run on a 2% agarose gel before sequencing reactions. 
2.3.2.v Manual sequencing 
The fmoFM Promega sequencing protocol was employed according to the manufacturer's 
instructions. This involves the use of a thermal cycler and an enzymatic method initially 
developed by Coulson and Sanger (Sanger et aI., 1977). The method takes advantage of 
the intrinsic properties of the DNA polymerase, isolated from Thermus aquaticus (Taq 
DNA polymerase) and extension/termination reactions using direct incorporation of 
radioactivity are employed. For each individual, four micro-centrifuge (0.5 ml) tubes 
were set up for each sequencing reactions, one for each nucleotide, labelled A, C, G and 
T. To the appropriate tube, 2 f,ll of dideoxy and deoxy ribonucleotide triphosphate dNTP, 
ddNTP (A = Adenine, C= Cytosine, G = Guanine and T = Thymine) stock concentration 
of' 
was added. The tubes were capped and placed on ice or at 4 C. For each set 0 sequencmg 
reactions, the following reagents were mixed in a microcentrifuge tube: 9.5 f..ll of template 
DNA (33 ng/ J,tl), 1 f,ll of sequencing primer (50 nglf,ll) , 1 f,ll of [a- 33p] dA TP (1000 
Ci/mmol, 10 uCi / f,ll), 5 f..ll of 5 X fmol R sequencing buffer (250mM Tris-HCh pH 9.0 at 
25 0 C, 10 mM MgCh). A control reaction consisting of 5J..lI of PGEMR-3Zf (+) control 
DNA (500 fmol) and, 2.5 f,ll ofPUC/M13 forward primer (3 pmol), 1 f..ll of [a_Dp] dATP 
(1000Ci/mmol, 10f,lCi/f,lI), 5 f,ll of 5X fmol R sequencing buffer were used instead of 
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template DNA and sequencing primer. To the primer/template mix, 1.0 III of sequencing 
grade Taq DNA polymerase (5U/JlI) was added and the contents mixed by pipetting. 
Finally, to the inside wall of each tube containing dlddNTP, 4 III of enzyme 
primer/template mix was added. One drop of mineral oil was added to each tube, which 
was then spun briefly in a microfuge. The MJ thermal cycler was pre heated to 95°e and 
the cycling program was started. A thermal cycle profile recommended by the 
manufacturer for cycle sequencing was used thus: - 95°e for 2 minutes, 30 cycles of95°e 
for 30 seconds, 42°e for 30 seconds and 700 e for 1 minute. After the thermal cycling 
program was completed, 3 III of fmol sequencing stop solution (95% formamide, 20 mM 
EDTA, 0.05% Bromophenol blue and 0.05% Xylene eyanol FF) was added to the inside 
wall of the each tube. The product was spun briefly in a microcentrifuge to terminate the 
reaction. The sequencing reaction was either processed immediately or stored at -20oe 
for a maximum of four days before being analysed. The reaction was heated at 700e for 2 
minutes immediately before loading on a 6% polyarcylamide sequencing gel. Three III of 
each reaction mixture was loaded on the gel. After electrophoresis, the gel was transferred 
onto Whatman paper, dried, and subjected to autoradiography. 
2.3.2.vi Semi automated Sequencing 
Semi automated sequencing was carried out In Professor Dominic Kwiatkowski's 
laboratory in the Institute of Molecular Medicine (IMM), University of Oxford. Genomic 
DNA extracted using a standard phenol chloroform method as described in section 2.3.2.i 
was used as template for amplification. The procedure employed involved an initial 
primary PCR amplification of the region to be sequenced (in this case IFN-y and IFN-y 
. ) with subsequent secondary amplification using ~ 113 tailed R 1 gene promoter regIons 
PRISM TM S" 0 ™ Primer primers. Thirty-six samples were sequenced using the ABI Ig ye 
" R d Reaction Kit following the instructions of the manufacturer. Cycle Sequencmg ea Y , 
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Briefly, secondary PCR products were diluted 1:6 to achieve DNA concentration of 100 
ng/Jll. Ninety-six well PCR plates were labelled accordingly (A, C, G, T) and a 0.5X 
reaction master mix was prepared as described in the manufacturers manual, consisting of 
2JlI of each nucleotide concentrations and 2111 of milliQ water respectively. One III of 
diluted secondary PCR product was then added. Mineral oil was layered over the reaction 
to avoid evaporation. The plate was spun at 1700 rpm for 2 minutes after which thermal 
cycle sequencing was performed using the GeneAmp 9600 protocol or 2400 thus: - An 
initial 20 times cycles of 96°C for 10 seconds, 55°C for 5 seconds, and 70°C for 1 minute 
and additional 15 cycles of 96°C for 10 seconds and 70°C for 1 minute. Reactions ACGT 
were pooled for each individual into one labelled tube and spun at 13000 rpm for 1 
minute to separate the reaction mixture from the mineral oil. Again, the sequencing 
reaction was either processed immediately or stored at -20°C for a maximum of four days 
before being analysed. Fifty-three III of absolute ethanol was added to a fresh microfuge 
tube and the sequencing reaction was transferred into the tubes without taking any 
mineral oil. This was left to stand for ten minutes at room temperature before spinning at 
13000 rpm for 15 minutes in the microfuge. After centrifugation ethanol was aspirated 
from the opposite side of the hinge so as not to disturb the pelleted DNA. The pellet was 
left to dry and was resuspended in 4 III of loading dye. DNA was denatured at 95°C for 3 
minutes and loaded into individual wells of a polyacrylamide gel using the ABI PRISM 
377 apparatus. The DNA sequence was analysed using the sequence navigator 
programme. 
2.3.2.vii Microsatellite analysis 
Microsatellite analysis was carried out in Professor Adrian Hill's laboratory, (Oxford, a 
microsatellite identified in the interferon-y receptor-l gene) and in Professor lennefer 
(C b 'd UK) Primers used to amplify a panel of ten Blackwell's laboratory am n ge, .,. 
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macrophage candidate genes were designed to create PCR products of different sizes 
without overlap between the first and last alleles of different markers (Appendix 2, table 
2.1) PCR conditions for eight primers had been optimised in the laboratory. Two (IL-I0 
and IFN-y) were added and optimised during the course of this study. One primer of each 
pair was labelled with a 2'7' -dimethoxy-4', 5' -dichloro-carboxy fluorescein compound at 
the 5' end. Three fluorescein dyes were used F AM ™ for blue, NED ™ for yellow and 
HEX ™ for green. PCR conditions were optimised for each primer pair independently. 
This was done in 5 ,.d volumes to include primers used at concentrations as described in 
chapter six, 2.5J.lI of 20ng/J.lI DNA, ABI buffer supplied by the manufacturer, 2.5mM 
each of dNTPs, 1.5 mM MgCh and O.15U of Amplitaq Gold polymerase. peR reactions 
were carried out as stated in chapter six using an MJ research thermal cycler. Products 
were pooled in a standard way such that the product labelled with F AM were at half the 
concentration of those labelled with other dyes. The products were added to 2.5J.lI of 
deionised dimethyl formamide, O.5J.lI of bromophenol blue running buffer (Applied 
Biosystems) and 0.5J.lI of a fluorescein labelled ROX standard (Applied Biosystem). This 
was electrophoresed through a 6 % polyacrylamide gel at 900 Volts on an AB! 377 DNA 
Sequencer (Applied Biosystems). The alleles were detected by an argon ion laser beam 
that scans across the gel at a fix distance from the sample loading wells and analysed 
using GENESCAN TM and Genotyper 2.2 software (Applied Biosystems). The 
microsatellite peR product sizes were determined by reference to the intemallane ROX 
size standards (Carrano et al., 1989). Alleles were globally binned by use of a simple 
b d · d of size and results were presented in a computer program and num ere III or er 
spreadsheet format (Appendix 2, table 2.1). 
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2.3.2.viii Single nucleotide polymorphism (SNP) analysis 
Single nucleotide polymorphisms (SNPs) in candidate genes of interest were analysed 
using two methods. 
2.3.2.viii.a Restriction fragment length polymorhism (RFLP) analysis 
DNA regions containing SNPs of interest were amplified by PCR and the amplicons 
incubated with restriction endonucleases. The presence of the SNP wither created or 
abrogated a restriction enzyme site. PCR was carried out in 12.5 J..lI volume with primer 
concentrations as stated in chapter six. The PCR conditions were as follows: -6.25,.d of 
50ng/J..lI of DNA, 160mM (NR4)2S04, 670mM Tris-RCh pH 8.8 at 25 0 C 0.1 % Tween, 
2.5mM of each dNTP, 1.5 mM MgCh and O.15U of Bioline Taq polymerase. After PCR 
amplification of a segment of DNA containing a SNP, the amplified product was 
subjected to enzyme digestion. If there is a restriction enzyme site, the endonuclease cuts 
the PCR product. Because, there are two chromosome homologues, the homozygote wild 
and mutant genotypes and the heterozygote genotype were easily differentiated by 
electrophoresis of the digested DNA through a 20/0 agarose gel, which was stained with 
ethidium bromide and visualised under UV light. Ten candidate genes were genotyping 
by PCR-RFLP analysis (Appendix 2, table 2.2). 
Amplification refractory mutations system (ARMS) peR 
Amplification refractory mutation system technique (ARMS-PCR) can detect single base 
changes, or insertions or deletions of a few nucleotides resulting in variation in DNA 
sequence. It requires three primers designed for each mutation. Allele-specific primers 
complementary to the wild-type or the mutant sequence, which differ only in their 3' 
nucleotide (according to the SNP present in the gene of interest) are used with a 
. fi h SNP typed Two PCR reactions are set up for each individual, 
consensus pnmer or eac . 
which contain the consensus primer and either of the allele-specific primers. The presence 
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of a mismatch at the 3' end of a primer prevents amplification during PCR. The genotype 
of an individual is determined according to which primer pairs lead to amplification. 
Control primers designed to amplify a different part of the genome are incorporated in to 
the PCR mix to ensure that non-amplification at a given locus is due to the absence of a 
particular allele, rather than PCR failure. Standard PCR was carried out as follows: _ each 
reaction mix of 12.5JlI contained 50ng/JlI DNA, 670mM Tris- HCh, 160mM (NRt)2 S04, 
2mM MgCh, 100uM of each dNTP, 0.1 % Tween-20, 0.5U of Taq polymerase. The 
touch down procedure was employed for all ARMS-PCR carried out. This involves an 
initial denaturation at 96°C for 1 minute followed by five cycles of denaturation at 960C 
for 35 seconds. Annealing was at 70°C for 45 seconds and elongation for 35 seconds at 
72°C. Twenty-one cycles of denaturation at 96°C for 25 seconds, annealing at 65°C for 
50 seconds then elongation for 40 seconds at 72°C, followed. Finally, additional six 
cycles of denaturation at 96°C for 35 seconds, annealing at 55°C for Inunute and 
elongation for Iminute 40 seconds at 72°C followed. The presence or absence of the 
desired band was resolved by running PCR product through a 1.5-% agarose gel stained 
with ethidium bromide and visualised under UV light. Four polymorphisms in TNF gene 
were genotyped using this method (see section 5.3 and appendix 2, table 2.3). 
2.3.2.ix Variable number of tandem repeats (VNTR) analysis 
Standard PCR was performed as described for RFLP analysis above. PCR was carried out 
in 12.5JlI volume with primer concentrations as stated in chapter six respectively, 6.25,.11 
of 50ng/JlI of DNA, 160mM (NH4)2S04, 670mM Tris -HCh pH 8.8, 0.1 % Tween-20, 
2.5mM of each dNTP, 1.5 mM MgCh and 0.15U of Bioline Taq polymerase. The size 
., f VNTR alleles were large enough to be differentiated on a 1.50/0 agarose gel. vanatIons 0 
I h· . the IL-4 and IL-l receptor antagonist genes were genotyped using this Po ymorp Isms In 
method (see section 5.3 and appendix 2, table 2.4). 
60 
2.4 Statistical analysis 
An EXCEL package was used to calculate the concentration of cytokines from OD of 
ELISA data in plasma samples described in chapter 3. Analysis of data was performed 
using Sigma plot version 1. For cytokines measurements, background production was 
subtracted from antigen-stimulated production. Data were logarithm transformed to 
achieve a normal distribution before t test was used for comparisons between groups. 
Spearman's rank and pairwise correlation coefficient was used to calculate the correlation 
co-efficient for LPS and LAM data in chapter 3. Spearman's method assigns a rank to 
each observation in each group separately in contrast to the Kruskall Wallis rank sum 
method were ranks are pooled and then calculates the sums of the squares of the 
differences in paired ranks (dx 2) according to the fonnula below. 
2 d 2 d2 Rs = 1-6 (d 1 + 2 + 3 + 
The Kruskall Wallis one way analysis of variance for non parametric continuous data was 
used to test the hypothesis that the mean cytokine measurement differ among genotypes. 
The data are ranked and the sampling distribution is arranged so that it follows the chi 
square distribution as follows: 
Chi-square = 12 IN (N+1) (R201 no+ R21/nl + R22fN2 + + R
2
xfNx) - 3(N+l) 
Where N = total number of observations, x = number of groups, Ro = the rank sum of 
group o. This statistics is compared against the X2 with N-1 degrees of freedom, and if it 
exceeds the value corresponding to the alpha level the null hypothesis is rejected. This 
test was used to detennine the difference in cytokine induced responses between 
. A I b I w 0 05 was considered significant. Please refer to genotypes In chapter 5. p- va ue eo. 
d '1 d 'ption of the method used for correction multiple testing. chapter 6 for etal escn 
. d . Stata v5 (Stata Corporation, College Station, Tx, 
All statistical analysIs was one usmg 
USA). 
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CHAPTER 3 
STUDIES OF MONOCYTE FUNCTION 
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3.1 Introduction 
Macrophage activation is a key event in the immune response to intracellular pathogens 
.including M tuberculosis. Several stimulants such as bacterial cell wall components can 
activate macrophages. Macrophage activation results in the up regulation of MHC class II 
molecules, production of reactive oxygen and nitrogen intermediates and the release of 
cytokines, for example IL-l p, IL-I0 and TNF necessary for effective containment of 
infection (see section 1.2.1 i). Activation of the macrophage is enhanced by the Thl type 
cytokine interferon-gamma (IFN-y) , produced by T cells and NK cells. Evidence from 
studies of 'knockout' mice (Cooper et al., 1993) and children deficient in IFN-yRl 
(Newport et aI., 1996) have clearly highlighted the importance of this pathway in 
resolving intracellular infections. In-vitro assays of monocyte/macrophage function (for 
example the production of macrophage cytokines in response to certain stimuli) can be 
used to assess responsiveness to IFN-y. For example, a whole blood assay was used to 
determine a lack of IFN-y responsiveness in a group of Maltese children with IFN-y Rl 
deficiency (Levin et al., 1995). 
This method assesses monocyte function in whole blood by measuring cytokine release 
(e.g. TNF) as a result of mononuclear cell stimulation with LPS or LAM and can also 
assess the responsiveness to IFN-y (Wilson et aI., 1991). The whole blood model has been 
applied to study T cell mediated immunity in leprosy (Weir et al., 1994), human 
leishmaniasis (Frankenburg and Klaus, 1991), IFN-y in TB (Takashima et ai., 1990) and 
. t BeG in neonates using mycobacterial antigens (Marchant et to the Immune response 0 
aI., 1999a). This method has also been applied to study cytokine regulation, for example 
I (E kdale et al 1998) The whole blood assay is a functional IL-I0, in healthy peop e s ,,' 
. ., l' tr -' dividual day-to-day variation and is therefore a useful 
assay that gIves mInIma In a In , 
h 1 f genetic variation, A comparison behveen whole 
phenotype used to define t e fO e 0 
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blood assays and those performed on isolated peripheral blood mononuclear cells showed 
that whole blood assays exhibited less day-to-day variation and were more reproducible 
(De Groote et al., 1992). The whole blood cell culture is an elegant ex-vivo technique that 
keeps the blood microenvironment intact and avoids the extraction procedure required for 
• 
PBMC isolation that is associated with modification of cell ratios and activation. It 
requires a smaller blood volume, is relatively rapid and simple and therefore applicable to 
field studies. 
Pro-inflammatory cytokines such as TNF, IL-1 J3 and anti-inflammatory cyokines such as 
IL-1 RA and IL-10 are well-characterised cytokines that are easily detected by enzyme 
linked immunosorbent assay (ELISA). Microbial cell-wall components such as LPS from 
gram-negative bacteria (Wilson et al., 1991) and manLAM from mycobacteria can be 
used to stimulate whole blood to produce these pro and anti-inflammatory cytokines. 
The aim of the study was to find out whether individuals who develop TB in The Gambia 
have innate defects in macrophage function, determined by responsiveness to IFN-y and 
subsequent release of cytokines after stimulation with bacterial cell wall components. 
This study was based on the hypothesis that pathways of monocyte activation are 
abnormal in patients who develop disease as a result of infection with M tuberculosis. 
Cellular studies were carried out using a whole blood model in patients with TB in The 
Gambia. 
Studies were designed to investigate monocyte function in healthy individuals. Initially an 
in house whole blood assay was optimised; optimised conditions were then used to test 
h h
· th t . dividuals who are susceptible to TB have defects in their innate 
the ypot eSls a m 
. ' t d b defects in monocyte activation. Thirty subjects were included 
Immunity, demonstra e y 
. 't' £ r selection into the study have been described in section 
in the study. InclUSIOn cn ena 0 
dl th 
ay was used to evaluate variation in monocyte responses 
2.1.1 and 2.1.2. Secon y, e ass 
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in a healthy population and to generate immune data for subsequent genetic studies aimed 
at identifying genetic factors influencing monocyte responses. 
3.2 Methods 
3.2.1 Study population 
Ten healthy Gambians (healthy research centre staff) were recruited for the optimisation 
of the whole blood assay. For the recoverd-TB versus control study, a sample size of 40 
individuals were presumed sufficient in each group to have 80% power to detect a 250/0 
difference in the mean production between the groups at a significance level of 950/0. The 
TB cases all had microscopically confirmed TB and at the time of study had completed 
treatment at least two months previously and were asymptomatic. This allowed the study 
of innate immune responses that were not affected by M tuberculosis disease or anti-
tuberculosis chemotherapy both of which influence immune response (Takashima et al., 
1990). In order, to investigate the relationship between the immune response and host 
genotype, a larger sample size was required. Three hundred and sixty (360) healthy blood 
donors were recruited in to this study. If an allele at a frequency of 0.2 increases cytokine 
production by 250/0, a sample size of 350 is required to detect this at 80% power and 950/0 
significance. 
3.2.2 Optimisation of whole blood assay conditions. 
Optimal conditions necessary for the release of cytokines in The Gambian population had 
to be established. These conditions were ascertained by determining the effect of varying 
the following parameters: Blood dilution factor, IFN-y concentration, LPS concentration, 
manLAM concentration and the length of culture. 
f h I bl d 
c'rom each healthy volunteer was drawn by venepuncture into 
Three ml 0 woe 00 1J 
. h I bl d has been reported to contain inhibitory substances that may 
3.8% CItrate. Woe 00 
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affect cytokine responses. Whole blood was therefore diluted to achieve 1 in 2 and 1 in 8 
dilutions with 100/0 fetal bovine serum enriched endotoxin-free RPMI 1640 tissue culture 
medium (Bio Whittaker) and cultured with different concentrations of LPS manLAM and , 
recombinant IPN-y. Final concentrations of 0 ng/ml, O.l ng/ml, 1 ng/ml, 10 ng/ml, and 
100 ng/ml of LPS, and, 1 ng/ml, 10 ng/ml 100ng/ml and 2,500 ng/ml of man LAM were 
used. A titration of IFN -y concentration was also performed for each dose of LPS as 
follows: 0 Vlml, 50 Vlml, 100 Vlml, 200 Vlml, 400 Vlml, 800 Vlml of IFN-y. Based 
upon the LPS results, the optimal concentration (200 Vim!) of IFN y was subsequently 
used for studies with LAM. Co- and pre- rIFN-y priming of whole blood was carried out 
to determine the effect of IFN -yon TNF production. Whole blood was either pre-
incubated with 200Vlml rIFN-y for 2 hours at 37°C in 5%C02 prior to the addition of 
LPS and LAM, or it was added simultaneously. A time course assay was also carried out 
by harvesting supernatants at 3hrs, 5hrs, 8hrs and 18hrs after the addition of either LAM 
or LPS. Cytokine levels were measured using an antibody sandwich ELISA as described 
in section 2.3.1 i. 
3.2.3 Finalised whole blood assay protocol 
Based on the results of the experiments described above the following method was used 
to study monocyte function in both studies described. Typically, 9 ml of venous blood 
was collected into 3.80/0 citrate. One ml was centrifuged immediately and plasma was 
separated. This was used to determine baseline cytokine levels. Two ml of blood was 
diluted 1: 2 with foetal bovine serum supplemented tissue culture medium (RPMI 1640): 
2 ml of diluted blood was incubated with rIFN-y (200V/ml) and another 2 ml without 
rIFN-y for 2 hours in 5%C02 at 37°C. The blood was then stimulated with either LPS or 
manLAM in 200, . tl triplicates in a 96 well plate, with a final concentration of 1 ng/ml LPS 
and 2500 ng/ml LAM. In addition, two negative control wells were done for each sample. 
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without LPS and LAM or IFN-y. Blood was then incubated for 18 hours at 37°C in 
5%C02. Supernatants were collected into corresponding positions in a new 96 well plate. 
The production of ILl~ and TNF (pro-inflammatory) and IL-I0 (anti-inflammatory) 
cytokines, was measured using commercially available ELISA kits as already described 
in section 2.3.lii. ManLAM was unavailable at the start of these experiments and was 
therefore not used for the study of TB and matched controls. 
3.3. Results 
3.3.1. Optimisation of assay 
The following conditions were observed as optimal for cytokine release from ten 
individuals used for the optimisation assay. Data presented is the mean cytokine 
concentration of these 10 individuals. Assays were carried out in triplicate per individual, 
when cytokine concentration was similar in all wells, the mean of the triplicate was 
calculated per individual and when there was a great difference between wells, then the 
mean concentration of two wells with similar results was used. Usually cytokine 
concentration was considered to be similar if they were only 5% apart. Mean TNF levels 
did not differ considerably whether 1 ng/ml or 10 ng/ml of LPS was used (TablelFigure 
3.2) nor for whether 200, 400, or 800U of IFN-y. The following concentrations of 
stimulants were therefore selected for of TNF release: 2500 ng/ml LAM (TablelFigure 
3.1) and 1 ng/ml ofLPS and 200 U/ml ofIFN-y (TablelFigure 3.2). 
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Table 3.1 Mean TNF levels induced by LAM in the presence of rIFN-y 
LAM cone. LAM 1/2 LAM 1/10 LAM+IFNy 1/2 LAM+IFNy 1/10 
1ng/ml 444 1276 214 1388 
10ng/ml 526 1619 186 1121 
100ng/ml 452 1536 334 1039 
1000ng/ml 1042 2405 1661 5651 
2500ng/ml 1310 3110 2049 9120 
Table 3.1 shows the mean TNF levels (pg/ml) induced by different concentrations of LAM in the presence 
or absence of a fixed concentration (200U) of rIFN-y. Whole blood was diluted with tissue culture medium 
RPMI 1640 supplemented with foetal bovine serum to obtain either a 1 in 2 or a 1 in 10 dilution and was 
primed with rIFN-y. TNF levels are in picograms per millilitre. The 1 in 10 dilution of whole blood induced 
higher TNF levels whether priming with rIFN-y was done or not. Please refer to appendix 3 table 3.l for the 
raw data for the generation of mean TNF concentration induced by LAM in the presence of rIFNy. 
FIG.3.1 
~ ~~ 
~<::' ~~\j 
LAM corcentratbns 
Mean TNF levels induced by LAM in the presence of rIFN-y. 
Figure 3.1 shows the mean TNF levels in response to either LAM alone .or LA~ and 1FNy. LAM 
concentrations were varied. IFN-y was used at 200 IU/m!. Whole blood was dtluted 1 m 2 and stImulated 
with either LAM alone (closed diamonds) or pre incubated with rIFN-y for 2 hrs prior to the addition of 
LAM (closed triangles). Whole blood was diluted 1 in 10 and stimula~ed with either LAM alone (closed 
squares) or pre incubated with rIFN-y prior to addition of LAM (crossed lmes). 
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Table 3.2 Mean TNF concentration induced by LPS 
IFNy Concentration in IU/ml 
LPS Conc. 0 50 100 200 400 800 
LPS 0 ng/ml 118 215 256 247 296 322 
LPS 0.1ng/ml 1112 1398 1780 2052 2219 2113 
LPS 1nq/ml 3738 4862 5657 5178 6298 6356 
LPS 10nq/ml 4980 5161 5987 6761 7420 7908 
Table 3.2 gives mean TNF levels did not increase appreciably after stimulation with 1 ng/ml and 200 IU/ml 
of rIFN-y. The data for the generation of mean TNF concentration induced by LPS in the presence of rIFN-y 
can be found in appendix 3, table 3.2. 
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FIG. 3.2 Mean TNF levels induced by LPS in the presence of rIFN-y 
Figure 3.2 shows different concentrations of IFN-y were used. Wholeblood was primed with IFN-y alone 
without addition of stimulants (closed diamonds) . Wholeblood was pre incubated with different 
concentrations of rIFN-y prior to stimulated with O.1ng / ml of LPS (closed squares), 1 ng / ml LPS (closed 
triangles) and lOng / ml LPS (crossed lines). 
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Cytokine production was optimal after 18 hours of incubation of whole blood with either 
LAM or LPS (Table/Figure 3.3 & 3.4). The average index of IFN-y up-regulation (the 
ratio between the amount of TNF produced with IFN -y priming to TNF produced without 
IFN-y priming) was highest (4.5) after 18 hours of pre-incubation (TablelFigure 3.4) 
whereas after 18 hours of co-incubation TNF ratios declined to 1.58 (TablelFigure 3.3). 
The highest index of IFN-y up-regUlation after co IFN incubation was seen to be 2.28 at 8 
hours of incubation (TablelFigure 3.3). Enhanced production of TNF was seen in most 
samples when whole blood was pre stimulated with rIFN-y (TablelFigure. 3.3). The 1:2 
dilutions gave better average index of up-regulation of 7.49 after 18 hours of incubation 
(TablelFigure.3.4) compared to the 1: 8 whole blood dilutions (TablelFigure 3.4) with 
average index of up-regulation of 3.8 at 8 hours of incubation that dropped to 3 after 18 
hours of incubation. Although TNF was measured for optimising the assay, there are 
reports that IL-l ~ release is similar to TNF release. 
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Table 3.3 Ratio of TNF induced by co and pre IFN-y incubation with LPS (1 
n~/ml) 
Length of incubation Co- IFN-y incubation Pre-IFN -y incubation 
3 hours 1.33 1.7 
5 hours 1.93 2.08 
8 hours 2.28 2.74 
18 hours 1.58 4.15 
Table 3.3 gives the ratio of TNF induced by co IFN-yand pre IFN-y incubation with LPS. At eight hours of 
incubation there was no significant difference between co- and pre IFN-y incubations for IFN-y up-
regulation. After 18 hours of incubation IFN-y up-regulation of TNF levels dropped for co-incubation of 
IFN-y with LPS, whereas up-regulation of TNF levels continued to increase for pre IFN-y incubation. The 
data for the generation of co and pre IFN- y incubation with LPS can be found in appendix 3, Table 3.3.l 
and 3.3.2. 
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Ratios of TNF induced in response to co- and pre IFN-y incubation 
with LPS. 
Figure 3.3 shows the ratios of TNF induced in responses to co IFN-y and pre IFN-y incubations with LPS. 
Incubation of whole blood with rIFN-y together with LPS, gave the average index of IFNy up regulation of 
2.5 after 8hrs of incubation and this dropped to 1.5 after 18hrs incubation (closed triangles). Whereas when 
whole blood was pre-incubated for 2hrs with rIFN-y and later with LPS, the average index of up regulation 
was 4.5 after 18 hrs of incubation (closed squares). 
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Table 3.4 Ratio of optimal TNF release for 1 in 2 and 1 in 8 whole blood dilution 
Length of incubation Dilution factor 
1 in 2 dilution 1 in 8 dilution 
3 hours 4.64 3.12 
5 hours 5.73 3.4 
8 hours 7.08 4.55 
18 hours 7.49 3.8 
Table 3.4 gives a ratio for TNF release after dilution of whole blood. Whole blood was diluted to give either 
I in 2 or 1 in 8 dilution. The 1:2 dilutions gave a better index of IFN-y up-regulation for TNF release of 7.49 
compared to 3.8 of 1 in 8 dilution after 18 hours of incubation. The data for the generation of ratio of 
optimal TNF release can be found in appendix, 3 table 3.4.1 and 3.4.2. 
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Effect of 1 in 2 and 1 in 8 whole blood dilution on TNF production 
Figure 3.4 shows the effect of whole dilutions. Whole blood was diluted with foetal bovine serum 
supplemented RPMI 1640. The pre-rIFN-y incubation for 2 hrs before addition of LPS was adopted. 
A verage index of rIFN -y up regulation for 1 in 2 dilution was 7.0 after 18 hrs of incubation (closed 
diamonds). Average index of rIFN-y up regulation for 1 in 8 dilution was 4.0 after 8 hrs of incubation and 
dropped to 3.0 after 18hrs of incubation. The raw data for the generation of optimal TNF release can be 
found in appendix 3 table 3.4.1 and 3.4.2. 
72 
From the preliminary optimisation assay for cytokine release the following conditions 
were considered as optimal for 1NF release: whole blood dilution of 1:2 with foetal 
bovine serum supplemented RPMI 1640, pre-incubation of whole blood with 200 D/ml of 
rIFN-y, stimulation of whole blood with either 1 nglml ofLPS or 2500 ng/ml ofmanLAM 
and eighteen hours incubation time after addition of stimulants. The 2 hours pre-
incubation of whole blood with IFN-y (200 D/ml) has been reported by other workers to 
enhance pro-inflammatory cytokine induction (Renz et al., 1988, Rook et al., 1987). 
Therefore these conditions were used during the course of this study. After establishing 
optimal conditions for cytokine release in this population, whole blood assays were 
performed in forty-five recovered TB cases and healthy controls as outlined in section 
3.3.2. Further, cytokine measurements were carried out in an additional three hundred and 
twelve blood donors also outlined in section 3.3.3. 
3.3 2. Whole blood studies in recovered TB cases 
Cytokine levels were compared between recovered TB cases and healthy controls. 1NF, 
IL-1 f3 and IL-10 production was measured in response to LPS using the optimised whole 
blood assay described above. 
Figures 3.5.1 and 3.5.2 overleaf show cytokine production by controls and ex-cases 
respectively, by individual. There are four bars per individual. Individuals have been 
represented as sample numbers. The first bar represents 1NF production upon LPS 
stimulation; the second bar represents TNF induced upon priming of whole blood with 
IFN-y prior to addition ofLPS. The third bar represents IL-10 production and the fourth 
bar represents IL-I f3 production. There were no differences in mean cytokine production 
between ex-cases and controls. However, there was inter-individual variation in cytokine 
production. Some individuals were low responders for all cytokines typical and examples 
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FIG. 3.5.1 Cytokine production in controls 
Figure 3.5.1 shows heterogeneity of cytokine responses to 
LPS in different control individuals. For some of the assays 
there were technical problems and cytokine measurements was 
not done. 
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FIG. 3.5.2 Cytokine production in recovered TB cases 
Figure 3.5.2 shows hetrogeniety of cytokine respones in recovered 
TB cases in response to LPS. Three cytokine responses are shown 
per sample. The first bars shows TNF induced by LPS alone the 
next bar shows TNF induced by LPS in the presence of IFN-y 
followed by IL-l ~ responses and lastly by IL-l o. 
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are sample number 8, 13, 18, and 19 for controls and sample number 6,7, 11 and 13 for 
the ex-cases. 
For most samples IFN-y was shown to enhance TNF production in both cases and 
controls. TNF production by sample number 21 was not enhanced by IFN-y. 
Tables 3.5.l and 3.5.2 summarise the cytokine data shown in Figures 3.5.l and 3.5.2. The 
mean TNF concentration was 3029 pg/ml with a standard error of 647 pg/ml in the 
controls and 2896 pg/ml with a standard error of 543 pg/ml in recovered cases (Table 
3.5.l). These did not differ significantly between groups. The mean IL-I~ concentration 
was 834 pg/ml with a standard error of 263 pg/ml in controls and 994 pg/ml with a 
standard error of 282 pg/ml in cases. Again there was no statistically significant 
difference between groups. Mean IL-IO levels in recovered cases was observed to be 
higher (527 pg/ml with standard error of 90 pg/ml) than in controls (319 pg/ml with 
standard error of 56 pg/ml). Results for mean IL-10 between groups was significantly 
different between recovered TB cases and controls (Table 3.5.1, 3.5.2). The means of the 
logarithm-transformed data are 5.78 for recovered TB cases and 5.4 for controls (Table 
3.5.2, p= 0.02). 
Mean cytokine levels were generally higher for TNF and IL-1 ~ release upon prior IFN-y 
priming before stimulation with LPS (Table 3.5.1, 3.5.2). IL-IO release was repressed 
(Table 3.5.1,3.5.2). The mean TNF levels were 7400 pg/ml in controls and 7155 pg/ml in 
recovered cases. In addition, the mean IL-1 ~ level was 794 pg/ml in controls and 955 
pg/ml in recovered cases. Mean pro-inflammatory cytokine levels were not significantly 
different between the two groups even upon IFN-y priming prior to LPS stimulation 
(Table 3.5.1, 3.5.2). 
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Table 3.5.1. Cytokine production by controls and recovered TB cases in response 
to stimulation. 
CYTOKINES MEAN + SEM in pg/mI (range) 
CONTROLS CASES 
LPS LPS & IFNy LPS LPS & IFNy 
TNF 3029 + 647 7400 + 1434 2896 + 543 7155 + 1001 
(100-20480) (405-26563) (140-17270) (420-26563) 
n=44 n=44 n-43 n=43 
IL-l~ 834 ± 263 794 + 233 994 + 282 955 + 265 
(30-6032) (57-4983) (30-5610) (62-6233) 
n=28 n=28 n=25 n=25 
IL-I0 319 + 56 175 + 28 527 + 90 282 ± 68 
(32-1765) (32-761) (46-2494) (30-1504) 
n=38 n=37 n=38 n=38 
Table 3.5.1 gives the mean and standard error cytokine release in picograrns per mt. The figures in 
parentheses are the minimum and maximum observed values. n is the number of individuals studied using 
each stimulant. There was no significant difference in TNF and IL-l J3 cytokine levels between recovered 
cases and controls. Appendix 4.1, 4.2 & 4.3 gives data for cytokine levels for each individual from which 
data were derived. The data was skewed (not normally distributed), they were log transformed for statistical 
analysis and presented in table 3.5.2 
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Table 3.5.2 Cytokine production by controls and recovered TB cases in response 
to LPS (Logarithm transformed) 
CYTOKINES MEAN+SEM pg/ml 
CONTROLS CASES 
LPS LPS & IFNy LPS LPS& FNy 
TNF 7.23 + 0.18*** 8.36 ± 0.16* 7.27 + 0.19**+ 8.34 + 0.16+ 
n=44 n=44 n=43 n=43 
IL-IB 5.8 ± 0.25** 603 + 0.19 5.95 + 0.3** 6.11 + 0.25 
n=28 n=28 n=25 n=25 
IL-IO 5.4 + 0.79*+ 4.79 ± 0.72+ 5.78 + 1.04*02 5.15 + 0.9302 
n=38 n=37 n=38 n=38 
Table 3.5.2 shows the natural logarithm transformation of data in Table 3.5.1. Data was 
not normally distributed and was transformed to allow for t test analysis. IL-IO levels 
differed significantly between recovered cases* and controls * , p=0.02, IFN-y repressed 
IL-10 levels in both cases (0'2) and controls (+) p = 0.007. There was no significant 
difference in TNF and IL-1 B levels between the two groups of recovered cases* * and 
controls** p=O.4. However, the effect of IFN-y up regulation on TNF in recovered cases 
and controls was statistically significant*, + p=<O.OOOOl. 
77 
Marked inter-individual variation was observed within both groups in the ability to up-
regulate cytokine production in response to IFN-y (Figures 3.6.1 & 3.6.2). By expressing 
the TNF production following IFN-y priming as a ratio of the levels produced by LPS 
alone, we can calculate an index of IFN-y up-regulation for this variability In 
responsiveness. Figures 3.6.1 and 3.6.2 shows the index of IFN-y up-regulation III 
controls and recovered TB cases respectively. There are three bars per individuals. 
Individuals have been represented as sample numbers. The first bar represents the index 
of IFN-y up-regulation for TNF u, the second bar represents the index of IFN-y up-
regulation for IL-I ~ and the third bar represents the index of IFN-y up-regulation for IL-
10. Marked heterogeneity of IFN-y priming was observed in both groups (ranging from 
0.9 to 11.8 fold increase, Figures 3.6.1 & 3.6.2). 
Generally, TNF was up regulated by IFN -y in both controls and recovered cases. Certain 
individuals were poor IFN-y up-regulators of all three cytokines: this was observed more 
in the recovered cases than the controls. For example controls with sample number 20,21 
and 22 and recovered cases with sample numbers 1, 2, 3 and 4. The index of IFN-y up-
regulation was higher in controls for both TNF and IL-I~. For example seven control 
individuals had ratios> 6 whereas only two recovered cases had ratios> 6. However, the 
mean up-regulation of responses to IFN-y priming did not differ significantly between the 
two groups (3.5 in the ex-cases and 4.0 in the control groups (p=0.22)). Generally, levels 
of IL-I ~ were lower than TNF. Based on the amount of TNF produced in response to 
IFN-y priming following LPS stimulation, individuals could further Inter-individual 
variation in the amount of IL-I ~ produced was observed, and up-regulation of IL-I ~ 
production in response to IFN-y occurred, but was less marked than for TNF (Table 3.6). 
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Levels of IL-lO were generally lower than the pro-inflammatory cytokines measured. 
There was no IFN-y up-regulation ofIL-IO. 
Table 3.6 Index of IFN-y up-regulation in controls and recovered cases 
CYTOKINES Index of IFN-y Up-regulation Index ofIFN-y Up-regulation 
Controls Cases 
TNF 4.0 3.5 
IL-l~ l.6 1.4 
Table 3.6 gives the index of IFN y up regulation is calculated by expressing TNF production following IFN-
y priming and LPS stimulation as a ratio of stimulation with LPS alone. This was done for each individual 
and each cytokine measured. IL-IO was not up regulated by IFN-y; therefore the index of IFN-y up 
regulation of IL-I 0 was not included in the table 3.6 above. 
In conclusion, there was no significant difference in pro inflammatory cytokine responses 
to LPS between recovered cases and controls: nor was there any significant difference in 
responsiveness to IFN-y between the groups. However, although the levels of LPS 
induced IL-l 0 were generally low compared with other cytokines measured, IL-I0 levels 
differed significantly between the two groups (p=0.02, Table 3.5.2). IL-I0 levels were 
observed to be higher in recovered cases than in the controls. In addition, there was 
marked inter individual variation in response to LPS and individuals who were responsive 
to IFN-y could be categorised as high, intermediate or low responders to IFN-y priming. 
IL-lO levels were rather repressed by priming with rIFN-y (Tables 3.5.1 and 3.5.2). 
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3.3.3 Cytokine responses to LPS and manLAM in healthy individuals. 
Further whole blood assays using a larger sample size was necessary to understand the 
mechanisms involved in the observed inter-individual variation in levels of cytokines. 
Three hundred and twelve healthy blood donors were studied in this study. 
Again, there was considerable variation in the levels of cytokines produced by different 
individuals as expected given the findings in the study of recovered TB cases and controls 
described above. The mean TNF levels induced by LAM (l050 pg/ml, standard error of 
92 pg/ml) did not differ significantly from that induced by LPS (911 pg/ml standard error 
of 67 pg/ml). In addition, the amount of TNF produced in response to LPS correlated with 
the amount produced in response to LAM (FIG.3.7.l). This was also true for IL-IJ3 
produced in response to LPS and LAM (Table 3.7). Mean IL-IJ3 induced by LAM was 
1749 pg/ml standard error of 245 pglml and that induced by LPS was 1405 pg/ml 
standard error of 142 pg/ml. Also, there was a positive correlation between TNF and IL-
IJ3 production in response to either LPS (FIG.3.7.2) or LAM (Table 3.9). This may 
suggest that the same genes or pathways regulate the responses to LPS and LAM, and the 
same genes may regulate the production of TNF and IL-l J3. IL-I0 levels induced by both 
LAM and LPS were generally low (66 pg/ml and 55 pg/ml respectively). 
Mean cytokine levels were comparable between LPS and LAM stimulated cells on pre-
incubating with IFN-y (Table 3.7). Mean TNF levels were 1749 pglml for IFNy primed 
LAM induced responses and 1758 pg/ml for IFN-y primed LPS induced responses. In 
addition, the mean IL-I J3 level was 1846 pglml for IFN-y primed, LAM-induced 
responses and 1666 pglml for IFN- y primed LPS induced responses. 
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CYTOKINE PROFILE IN GAMBIAN CONTROL INDIVIDUALS 
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FIG. 3.7 Cytokine production in response to LPS and LAM in healthy individuals 
Figure 3.7 shows cytokine levels in response to LPS and LAM stimulation in healthy Gambian 
individuals. The first column represents I!rIO levels followed by IL-I~ levels and lastly TNF-a levels. 
Abitrary "cut offs" of top 30% (II) and bottom 30 % (L) were set for high and low responder 
phenotypes respectively. For IL-I~ there appears to be a binomial distribution and a natural cut off 
was possible. Figure 3.7a represents the cytokine measurements and figure 3.7b represents the 
logarithm transformed data. 
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As previously shown, the pre-incubating of whole blood with IFN-y enhanced cytokine 
responses to LPS and LAM when compared to responses in the absence of IFN-y priming. 
However, the mean TNF up-regulation of responses to IFN-y priming did not differ 
significantly for the two stimulants being 2.11 for LAM and 2.62 for LPS (Table 3.8). 
Compared to TNF a lower index of up regulation was observed for IL-1 ~ induced by both 
LAM (1.44) and LPS (1.88, Table 3.8). LPS was shown to induce higher levels of both 
cytokines. Pre or co incubation of whole blood with rIFN-y did not up-regulate the 
production of IL-1 O. 
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Table 3.7 Mean cytokine values in healthy population 
CYTOKINES Mean+S.EM 
(range) pwml 
LAM LAM & IFN-y LPS LPS & IFN-y 
TNF 1050 + 92.0 1749+141 911 ± 67 1758 + 104 
(35-8100) (35-12345) (25-10040) (30-10515) 
n=150 n=150 n=270 n=275 
IL-l~ 1749 + 245 1846 + 217 1405+ 142 1666 + 155 
(35-15030) (40-12395) (10-16265) (10-14310) 
n=144 n=144 n=270 n=269 
IL-IO 66+7 53+4 55 ± 6 38 +4 
(4-386) (3-372) (0-707) (2-699) 
n=149 n=149 n=279 n=279 
Table 3.7 gives mean and standard error of mean of cytokine released using the different stimulants LAM, 
and LPS in the presence or absence of IFN-y. The figures in parentheses are the minimum and maximum 
observed levels of the corresponding cytokines. n represents the number of individuals studied per 
stimulant. Cytokine measurements are in picograms per ml. . 
Table 3.8 Index of IFN-y upregulation in healthy population 
CYTOKINES Index of IFN-y upregulation 
LAM LPS 
TNF 2.11 2.62 
IL-l~ 1.44 1.88 
Table 3.8 shows the index of IFN y up-regulation that is calculated by expressing TNF production following 
IFN-y priming and either LAM or LPS stimulation as a ratio of stimulation with either LAM or LPS alone. 
This was done for each individual and each cytokine measured. IFN-y did not up-regulate IL-IO production 
therefore index of IFN-y up -regulation of IL-l 0 was not included in the table. 
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Table3.9 Correlation of cytokine induction by LAM or LPS in healthy population 
Stimulants Cytokines Correlation Observations p-values 
LAMvs. LPS IL-1~ 0.70 (0.68) 137 0.00001 
IL-10 0.74 (0.76) 148 0.00001 
TNF 0.77 (0.78) 145 0.00001 
LAM TNF vs. IL-10 0.55 (0.53) 148 0.00001 
TNF vs. IL-1~ 0.60 (0.60) 272 0.00001 
IL-1~ vs IL-10 0.42 (0.41) 143 0.00001 
LPS TNF vs. IL-10 0.55 (0.62) 268 0.00001 
TNF vs. IL-1~ 0.69 (0.72) 143 0.00001 
IL-1 ~ vs IL-1 0 0.53 (0.55) 268 0.00001 
Data was logarithm transformed and the Spearman's and pairwise correlation were 
carried out. Stimulants LAM versus LPS represent the correlation of LPS and LAM 
induced cytokine. LAM induced cytokine values are plotted against LPS for each 
cytokine (see figure 3.8.1). The Spearman's correlation and pair wise correlation were 
obtained. Figures in parenthesis are the Spearman's correlation. A positive correlation 
between 0 and 1 indicates a positive correlation, the higher the value the more correlated 
the data are. The Spearman's correlation was usually higher than the normal correlation 
for LPS induced responses whereas the reverse was the case for LAM induced responses. 
Correlation between induced cytokines by either of the stimulants (LAM or LPS) was 
ascertained. Highly positive correlation was observed for LAM versus LPS induction of 
all cytokines (lNF, IL-1~ and IL-10 (0.70, 0.74, and 0.77 respectively)). Also positive 
correlation was observed between cytokines by either of the stimulants. LAM-induced IL-
l ~ versus IL-10 was the least well correlated (0.42). LPS-induced cytokine responses 
were the most correlated with the highest correlated being TNF versus IL-l ~ (0.69). 
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3.4 Discussion 
In sumnfary, optimal conditions for lNF, IL-l Band IL-l 0 release were ascertained in the 
Gambian population. Parameters for optimal cytokine release using the whole blood assay 
were necessary since this assay formed the basis for further studies on the genetic 
regulation of immune responses. Also, it was important to determine minimal intra-assay 
and inter-individual variation. Conditions obtained were used in subsequent whole blood 
assays. Marked inter-individual variation in response to both LPS and LAM was 
observed. There was a significant difference (p=0.02) in mean IL-I0 levels in response to 
LPS stimulation between recovered TB cases and controls but this was not observed for 
TNF and IL-IB. Pre-IFN-y incubation of whole blood enhanced the production of TNF 
and to a lesser extent IL-l (3; IL-IO production was rather suppressed by pre-IFN-y 
incubation. Positive correlation was observed for LAM and LPS induction ofTNF, IL-l~ 
and IL-IO in addition there was positive correlation for the release ofTNF, IL-l(3 and IL-
10 cytokines. 
I have used a whole blood system rather than studying PBMC responses because the 
whole blood cell culture has many advantages, which were documented in section 3.1. 
3.4.1 Higher IL-I0 levels in recovered TB cases 
IL-IO levels in recovered TB cases are higher than controls (p=0.02, Table 3.5.2). 
Baseline cytokine measurements were done to correct for the effect of differential 
cytokine production in this population by a variety of infectious agents, as a lot of 
infections are endemic. For example, variants of P. falciparium can down regulate T cell 
proliferative response by preferential induction of IL-l 0 (Boussiotis et aI., 2000). 
Mean IL-IO concentrations were lower in controls (319 + 100 pg/ml) than in recovered 
cases (527 ± 282 pg/ml). Corroborating this is a study in leprosy where IL-IO responses 
are also shown to be lower in control subjects than leprosy subjects or the healthy contact 
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group (Weir et aI., 1996). This is not surprising because several experiments show that 
IL-lO is a potent monocyte deactivator controlling LPS toxicity. The Weir leprosy study 
enrolled patients with on going disease. My study selected only people who having 
completed TB treatment regimen had recovered from tuberculosis and had been off 
treatment for two months. Recovered TB cases were selected because it is known that TB 
and treatment would mask any innate underlying defects and could temporarily affect the 
responsiveness to IFN-y in individuals (Turner et aI., 2000). 
The aim was to study the innate system that predisposes to TB and if they had an 
underlying genetic defect it should still be evident. The observed significant difference in 
IL-lO levels may represent real innate defect in IL-lO responses in TB. Recently, a study 
on genetic influence on cytokine production in meningitis demonstrated that it is the 
initial innate anti-inflammatory cytokine profile that contributes to fatal disease outcome 
(Westendorp et al., 1997). A role for IL-lO in M tuberculosis induced programmed cell 
death (PCD) of alveolar macrophages was demonstrated by increasing PCD with anti-IL-
10 antibody treatment and inhibition of PCD by addition of exogenous IL-l O. IL-lO is an 
anti- inflammatory cytokine that has been reported to inhibit TNF, IL-l~, IL-12, IL-8, IL-
6, and GM-CSF production, release of free radicals and nitric- oxide and thereby suppress 
the anti-microbial properties of macrophages against various pathogens. Therefore, IL-I0 
interferes with very early events of monocyte and neutrophil activation by microbial 
products. In endotoxemia, TNF appears to promote, but is not essential for, the production 
of IL-lO by LPS stimulated human monocytes (Marchant et aI., 1999b). Also, IL-l ~ 
derived from monocytes can stimulate the production of IL-l O. It appears that the initial 
production of these molecules is beneficial and indicates immune competence. Therefore, 
if increased level of IL-l 0 may be indicative of fatal disease outcome; it would act earlier 
at the onset of disease and suppress the actions of the other cytokines. A recent study by 
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Boussiotis et al., (2000) showed that constitutively produced IL-1 0 by T cells suppressed 
immune responses in anergic TB cases. They showed that invitro stimulation of T cells in 
PPD+ cases induced IL-10, IFNy, and proliferation whereas only IL-IO was induced in 
PPD" cases. This difference was shown to be as a result of defective hypophosphorylation 
of TCR~ and defective activation of ZAP-70 and MAPK (Boussiotis et al., 2000). We 
may not see any significant difference in pro inflammatory cytokine levels between cases 
and controls as it is assumed that individuals who recover after treatment are able to 
mount an appreciable amount of cellular immunity to augment the actions of treatment. A 
study that demonstrated significant levels of TNF in plasma between TB cases and 
controls used peripheral blood mononuclear (PBMC) cells and this study was in acute TB 
cases and not in recovered patients (Friedland, 1995). 
However, we observed no difference in mean TNF and IL-1f3 levels between recovered 
TB cases and controls (Table 3.5.l & 3.5.2). The explanation for this maybe that 
pulmonary TB being more of a localised infection blood sampling may not necessarily 
depict the true cytokine situation and more localised samples such as lung aspirates or 
broncho-alveolar lavage may be required. Though relevant, it is often not easy to obtain 
and study alveolar macrophages. If blood samples must be used then pro and anti-
inflammatory cytokines produced by other cells such as PNG may be important to 
measure. Such cells first migrate from blood into tissue sites and participate in early 
inflammatory response. Measuring molecules that are chemotactic for macrophages such 
as, the small inducible chemokines may important in TB. 
Interesting data emerging from ex-vivo whole blood studies have suggested an important 
role for IL-8 in TB. A study in Zambian patients with both HIV and tuberculosis showed 
that higher levels of IL -8 were present in plasma of survivors than those who died, after 
ex vivo stimulation of whole blood leukocytes. As already mentioned, measurement of 
90 
secondary inflammatory cytokines such as IL-8 would be important (Friedland et al., 
1995). In addition to whole blood assay and cytokine measurements one could quantify 
cell surface receptors as this may give an idea of correlation between receptor usage and 
cytokine levels observed. This may aid in our understanding of mechanisms involved in 
macrophage function. 
However, this study demonstrates inter-individual variations in cytokine responses 
induced by manLAM and LPS. Priming with IFN-y before stimulating with either LAM 
or LPS was shown to potentiate the release of TNF and IL-l J3. IL-I0 levels were 
depressed. 
3.4.2 Correlations of cytokine responses 
Positive correlation was observed for either LAM or LPS induced TNF and IL-l J3 and 
also there was positive correlation for TNF and IL-l J3 induced responses. 
Positive correlation observed for LAM and LPS induction of TNF and IL-l J3 induction 
suggests that manLAM and LPS may activate macrophages through the same cell surface 
receptors or post receptor pathway. CD 14, a phosphatidylinositol glycan-linked 
membrane protein best known and characterised as the high affinity receptor for 
lipopolysaccharides from gram negative bacteria can also bind LAM from M 
tuberculosis (Pugin et al., 1994). However, Zhang et al (1993) showed that LAM and 
LPS possibly activate polymorphonuclear granulocytes (PNGs) through a receptor 
different from CDI4. They went on to show that cytokine induction in human 
monocytoid cell line THP-l by LAM and LPS was not inhibited by a monoclonal 
antibody to CD14 suggesting other common receptor for LAM and LPS expressed on 
macrophages. The toll like receptor (TLR) signalling systems may be important in this 
mechanism (Kopp and Medzhitov, 1999). 
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TLRs were first described in the fruit fly Drosophila melanogaster where they were 
involved with dorsoventral pattern formation and later on in the adult fly's life, they are 
involved with anti-microbial activity (Rock et al., 1998). Human homologues can mediate 
innate immune recognition by binding to conserved molecular patterns on 
microorganisms. These receptors are coupled to signal transduction pathways that control 
expression of a variety of inducible immune-response genes. The cytoplasmic domain of 
the Toll-family proteins is homologous to the cytoplasmic domain of the IL-l receptor 
(lL-IR) family. Five TLRs have been reported in man (TLRs 1, 2, 3, 4, 5). LPS can 
activate macrophages via TLR 2 (Kirshching et al., 1998,Yang et al., 1998) and TLR4 
(Heine et al., 1999, Chow et al., 1999 and Poltorak et al., 1998). ManLAM can activate 
macrophages via TLR-2 (Means et al., 1999). Means et al., (1999) also showed that 
viable M tuberculosis bacilli activated both Chinese hamster ovary cells and murine 
macrophages that over expressed either TLR2 or TLR4. This suggests that in vivo, M 
tuberculosis can utilise both TLRs for signalling. 
Since TNF and IL-l f3 are pro inflammatory cytokines, induced by the same agents, 
activate the same kinases and induce similar effects such as fever, it is not surprising that 
positive correlation was observed in their induction by LAM or LPS. Both the TNF and 
IL-l f3 genes have a 3' untranslated sequence that is responsive to LPS and which affects 
mRNA stability (Caput et al., 1986). In addition, similar pathways are required for the 
induction of synthesis of these cytokines. This data is in contrast with another study that 
was unable to demonstrate any correlation for the induction of IL-l f3 and TNF in mice 
(Nettea et al., 1998). Nettea et al., (1998) showed that LPS induced production of TNF 
and IL-l f3 was differentially regulated at the receptor level. It was clearly demonstrated 
that TNF production was essentially CD 14 dependent, both in the presence or absence of 
plasma. However, LPS induced IL-l f3 production was mediated by CD 14 dependent 
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mechanisms in the presence of plasma, while in its absence both CD 14-dependent and 
CD 14-independent pathways are involved. A report such as this is awaited for LAM. 
In addition, there was marked heterogeneity of cytokine produced with or without IFN-y 
priming of whole blood. Priming of IFN-y of whole blood prior to LPS or LAM 
incubation, showed that individuals could further be classified according to their ability to 
up regulate monocyte function as judged by levels of TNF or IL-l ~ produced. A study by 
deWitt et al., (1996), demonstrated that IFNy modulates the expression of several 
cytokines by human monocytes at the transcriptional level. Indeed, it was shown that 
priming of human monocytes with IFN-y resulted in the down regulation of c-fos and c-
jun mRNA and AP-l DNA binding capacity in response to stimulation with LPS 
compared to the effects of LPS alone. Interestingly, an increased NF-K~ expression was 
noticed in IFN-y pre-treated monocytes (de Witt et al., 1996). This study observed an 
increase in protein levels of pro inflammatory cytokines in response to IFN -y pre-
treatment of whole blood followed by LPS stimulation. All together, this suggests that the 
IFN -y pathway may therefore be an important contributory factor to the variations 
observed and to inflammatory processes of macrophage activation. 
3.4.3. Molecular basis of heterogeneity of cytokine responses. 
The inter-individual variability observed may result from differences in host genetic 
constitution. It is known that changes in DNA sequence of a gene can cause alterations in 
the function of the gene. Single change in just one base can lead to physiological 
abnormal conditions. A good example is sickle cell anaemia where a CIT to CAT leads 
to an amino acid substitution that alters the way the haemoglobin molecule folds, thereby 
distorting the shape of the red blood cell. Control of gene activity could therefore be at the 
point of transcriptional activation of the gene, stability of mRNA, translational 
modification, intracellular stability of protein, its transport and ultimately at the point of 
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export of the gene product. For example, polymorphisms in or around transcription factor 
binding sites within promoter regions of a gene may affect the rate transcription of the 
gene. A good example of this the OCT -1 binding site the promoter region of the TNF 
gene (Knight et al., 1999b). A polymorphism at this site influences binding of OCT -1 and 
is also associated with susceptibility to malaria. Whilst sickle cell anaemia is an excellent 
illustration of the relationship between a single point mutation in DNA and loss of protein 
function, most changes in DNA sequence may be less dramatic. 
Many pathways require molecules encoded by different genes. A process such 
macrophage activation requires several molecules and therefore many genes. Alterations 
in DNA sequence of genes that are involved in macrophage activation would therefore be 
important in understanding the genetic basis of functional heterogeneity. 
In addition to genetic factors, other factors which may be responsible for observed inter 
individual variation in cytokine responses observed may be explained by differential 
production of soluble inhibitory substances in plasma of individuals. Soluble forms of the 
cytokine receptors are thought to bind cytokines and cause prolonged bioactive half-life 
of cytokine within circulation and inhibit binding of cytokine to membrane associated cell 
surface cytokine receptor for subsequent macrophage activation pathway. In support of 
this is the recent report by McGuire et al., (1998), which demonstrated varied amounts of 
sTNF R often in ng/ml concentrations in both malarial and healthy individuals. 
In conclusion, the demonstrations of marked inter-individual variations in the ability to 
produce these cytokines maybe as result of individual innate genetic variability in 
Inacrophage function. 
Polymorphism at candidate gene loci were therefore studied to determine if these genes 
regulate microbial induced macrophage responses. 
94 
CHAPTER 4 
NOVEL PROMOTER REGION POL YMORPHISMS IN 
THE IFNG AND IFNGRI GENES 
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4.1. Introduction 
The interferon -y pathway has been implicated in the immune response to virtually all 
infectious agents including fungi, viruses, parasites and bacteria. IFN-y is produced by 
NK and T cells and has a modulating role in almost all phases of the immune response 
(Trincheri and Perussia, 1985). This includes stimulation of bactericidal activity of 
phagocytes (Momburg et al., 1986), the stimulation of antigen presentation through 
class I and class II MHC molecules, the orchestration of leukocyte-endothelium 
interactions, cell proliferation and apoptosis. IFN-y is associated with the development 
of Th 1 like cell-mediated immunity, required for protection in mycobacterial diseases 
(Flynn et al., 1993, Newport et al., 1996). 
Figure 1.3 shows a schematic representation of the mechanism of signal transduction 
for the IFN-y pathway. Upon binding of IFN-y, a homodimeric ligand to the receptor 
a chain (IFN-yRI), there is rapid dimerisation of the receptor a chain, and a site 
recognised by the extracellular domain of the receptor ~ subunit (IFN-yR2) is formed 
(Bach et al., 1997). There is juxtapositioning of the intracellular domains of the two-
receptor chains resulting in the transactivation of the enzyme Janus kinases JAKI and 
JAK2. There is phosphorylation of the functional tyrosine residue at position 440 on 
the receptor a subunit, forming a pair of Stat 1 docking sites on the ligated receptor. 
Two Stat 1 molecules associate with the paired docking sites and are brought into 
close proximity with receptor associated activated Janus kinase (JAK) enzymes and 
are activated by phosphorylation of Stat 1 tyrosine residue at position 701. Tyrosine 
phosphorylated Stat 1 molecules dissociate from their receptor and form homodimeric 
complexes. The activated Stat 1 complex is phosphorylated. Activated Stat 1 
translocates from the cytoplasm into the nucleus and after binding to a specific 
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sequence in the promoter regions of immediate early IFN-y inducible genes, termed 
gamma interferon activation site (GAS), and effects gene transcription in the presence 
of RNA polymerase. GAS is a 9 nucleotide site with a consensus sequence of 
TTNCNNNAA (Figure 4.13, Bach et al., 1997). This sequence is present in the 
promoter of all IFN-y inducible genes. 
Given the central role of the IFN- y pathway the immune response to mycobacterial 
infection, it was then determined to test the hypothesis that genetic variation in 
components of the pathway influences the magnitude of the immune response and 
ascertain its effect in determining susceptibility to disease. This in tum requires 
identification of genetic variants (polymorphisms) within the genes of the pathways to 
study in relation to either the immune response or disease susceptibility. Since the 
pathophysiology of many disease's (both infectious and autoimmune) is believed to be 
due to aberrant T helper type 1 (Th 1) responses, and there is epidemiological evidence 
that host genetic factors influence susceptibility to these diseases, many groups have 
searched for variation in IFNG. Interestingly, relatively few polymorphisms have 
been described. The gene for human IFN-y is located at chromosome 12q24.1 (Gray 
& Goeddel, 1982). One variable length CA repeat polymorphisms have been 
described (Ruiz-Linares A, 1993). Homozygotes for allele 2 of the CA repeat located 
within intron 1 of IFNG, have been shown to produce more IFN-y than other alleles 
(Pravica et al., 1999). This allele has also been shown to be associated with 
development of fibrosis in lung allograft (Awad et al., 1999) while allele 3 appears to 
be associated with type 1 diabetes (Jahromi et al., 2000). 
However few SNPs have been reported either in the coding or non-coding regions, to 
, 
the extent that it has been suggested that IFN-y plays such a critical role in host 
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defence that variation within the gene has not been tolerated. A promoter mutation at 
-333 bp of the initiation codon was reported (Giedraitis et al., 1999), but only 
observed in 2 individuals (heterozygotes) with multiple sclerosis out of 300 samples 
typed. Bream et al (2000) sequenced the IFNG non-coding regions in 100 individuals 
and found no promoter polymorphisms. They did however identify a single nucleotide 
insertion in intron 1, three SNP's in intron 3 and a SNP in the 3' untranslated region. 
IFN-y exerts its pleiotrophic effects via its species-specific receptor, IFNyR. IFN-yR is 
expressed on all nucleated cells. The receptor consists of two chains, the alpha chain 
(IFNyRl) which binds ligand and is encoded on chromosome 6q23-24, the beta chain 
(IFNyR2) is responsible for signal transduction and is encoded on chromosome 21. 
Mutations in IFNGRl and IFNGR2 have been shown to confer susceptibility to severe 
infection with nontuberculous mycobacteria (Newport et al 1996, Jouanguy et a/., 
1996, Dorman and Holland, 1998). However, these mutations are extremely rare at 
the population level and have only been found in the families in which the disease is 
segregating. There were only two reported polymorphisms for IFNGR1, one intron six 
CA repeat (FA1, Altare et a/., 1998b) and one reported TaqI RFLP (Hauptschein et 
al., 1992). The intron six repeat of IFNGRl showed marginal association with total 
serum 19E levels in the British population (Gao et a/., 1999). Recently a new 
polymorphism at the COOH terminal of the signal peptide of IFNGR1; a substitution 
of valine for methionine (Va114Met) at amino acid position 14 was shown to be 
associated with systemic lupus erythematosus (SLE). This polymorphism alters 
receptor function (Tanaka et al., 1999). A coding variant of the IFNGR2~ glycine to 
arginine substitution at amino acid position 64 was also associated with total serum 
IgE in the British population (Gao et al., 1999). 
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In chapter 3 I presented data demonstrating that there is a marked inter-individual 
variation in immune responses to LPS and LAM. This occurs both with and without 
IFN-y priming. There may be differences in the level of activation of monocyte 
function in response to IFN-y mediated by variation in receptor function. In order to 
investigate this hypothesis further, it was necessary to identify polymorphisms in 
IFNG and IFNGRl present in the Gambian population. Promoter regions are 
important because they contain regulatory sequences of DNA at which RNA 
polymerase binds to initiate transcription. Variants that exact more subtle effects on 
the function of gene product may be important in susceptibility to TB in an adult 
population. 
The inter-individual variations observed in macrophage activation could be directly or 
indirectly due to individual responsiveness to IFNy, which may be as a reflection the 
effect of IFN-y binding to its receptor. Those lethal, inactivating and rare mutations 
described in chapter 1.2, which are responsible for Mendelian disorders, give 
important evidence that IFN-y activation of macrophage is important for containment 
of mycobacteria. However, these were not typed during the course of this study 
because they are unlikely to be relevant to disease susceptibility at the population 
level. Also for IFN-y there were only two reported polymorphisms. New 
polymorphisms in the promoter regions of both IFN-y and the IFN-y receptor had to 
be identified. 
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4.2. Methods 
Specific promoter regions of the IFNG and IFNGRl genes were sequenced using the 
thermal cycle sequencing method. 
4.2.1. Sequencing promoter regions of IFN-y 
Genomic DNA extracted as stated in chapter 2 by standard phenol/chloroform method 
was used as template for amplification. Samples from 36 genetically independent 
Gambian TB cases were sequenced. 
Thermal cycle sequencing was carried out in two stages. An initial amplification of 
the 1.6kb fragment upstream of the transcription start site was carried out. 
Subsequently, the region was divided into 3 fragments of 569bp, 555bp and 631bp for 
sequencing. Primers to amplify this region were designed by Dr. Jeremy Hull in 
Professor Kwiatkowski's laboratory in Oxford as listed below from published 
sequence. The M13 Big dye primer forward sequencing kit was used and 
polymorphisms and ambiguities were confirmed using M13 Big dye primer reverse 
kit. 
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Table 4.1. Details of primer sequence for the human IFNGR1-y promoter 
region 
Primer name Sequence Position 
relative to 
initiation codon 
Primary primers 
F2 5' ACTCACAA TCATATAGCT AG3' -1486-l466bp 
Rl 5 'CTGATCAGCTTGATACAAGA3' +46-+66bp 
Second round primers M13 tailed 
F3 5 'T AACCAACTCTGATGAAGG3' -54l-485bp 
R2 5 'CAGTT AAGTCCTTTGGACC3' -985-967bp 
R4 5' CTTTCCTTGCTTTCTGGTCATT3 -45l-430bp 
F5 5' TTCAAGCCATTCTCCTGCC3 ' -985-967bp 
F4 5' ACTCACAA TCATATAGCT AG3' -1485-1466bp 
R3 5' GGCT AGGCTGGTCTCAAACT3 ' -875-856bp 
F = forward primer 
R = reverse primer 
Primary peR reaction mixes were in 15 ~l volumes made up of 50ng/ml of primers, 
100ng/ul of DNA, Bioline lOX Opti Buffer, 2.5mM Mg Ch, 5mM dNTPs, O.IV Bio 
Xact Taq DNA polymerase and water. Confirmation of product size was carried out 
on a 1.5- % agarose gel with ethidium bromide staining and visualised by VV light. 
Secondary PCR reaction mixes was in 15~1 volume made up of 50 ng/ml of primers, 1 
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j.ll of primary PCR product, 0.5 mM dNTPs, 2.5 mM MgCb lOX ampliTaq Gold 
Buffer and 0.075U of ampliTaq Gold. 
The thermal cycle conditions for primary PCR were an initial denaturation for 94°C 
for 2 minutes, followed by 9 cycles of 94°C denaturation for 15 seconds, annealing at 
58°C for 30 seconds, then elongation at 68°C for 2 minutes. This was followed by 
additional 19 cycles of 94°C denaturation for 15 seconds, annealing at 58°C for 30 
seconds and elongation at 68°C for 2 minutes. An additional 20 seconds was added 
per cycle and there was final elongation at 68°C for 5 minutes. 
Thermal cycle conditions for secondary PCR were an initial 94°C denaturation for 10 
minutes, followed by 30 cycles of 94°C denaturation for 30 seconds, annealing at 
54°C for 30 seconds and elongation at 72°C for 2 minutes. Final elongation was at 
72°C for 5 minutes. 
PCR product was electrophoresed on an ABI PRISM® 377 DNA sequencer as 
described in chapter 2. 
4.2.2. Sequencing promoter regions of IFNGRI 
Genomic DNA extracted as stated in chapter 2 by standard phenol chloroform method 
was used as template for amplification. Samples from 36 genetically independent 
Gambian TB cases were sequenced using thermal cycle sequencing. 
This was carried out in two stages. An initial amplification of the -964bp fragment 
upstream of the transcription start site was done. Subsequently, a second round 
sequencing of 594 bps relative to the initiation codon was done. Primers to amplify 
this region were designed by Dr. Melanie Newport in The Gambia and secondary 
primer set was by Jeremy Hull in Professor Kwiatkowski's laboratory in Oxford as 
listed. 
Table 4.2. Details of primer sequence for human IFNGRl promoter region 
Primer name Sequence Position 
relative to 
initiation codon 
Primary PCR primers. 
IFNGRI 5 'GAGTGCCAAGT AAAGATGTCAG3' 
-961 to -941bp 
IFNGR4 5' AGATCCGCGGTGCCACTCA3' 
-+51to+71bp 
Second round primers M13 tailed 
GARF2 5' AGT AGTTCTTGGTCAAGCCG -574 to-594bp 
GARR2 5' CTCTCCTCTTTCTCCT ACCC +5 to +24bp 
The M13 Big dye primer forward sequencing kit was used and polymorphisms and 
ambiguities were confirmed using M13 Big dye primer reverse kit. 
Primary PCR was carried out in 100/-l1 volumes consisting of 2/-l1 of 100ng/ml 
template DNA, 100 mM Tris, 500 mM KCI, 1.5Mm MgCh (pH 8.3), 20mM dNTPs 
33 ng/ml primer, O.lunit ampliTaq DNA polymerase and 74.4/-lls of water, using a 
Cyclogene thermal cycler. Confirmation of product size was carried out on a 1.5- % 
agarose gel stained with ethidium bromide and visualised by UV light. 
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After initial amplification of samples, subsequent purification of PCR product was 
done using the Promega miniprep purification kit following manufacturers 
instructions. 
Secondary PCR was done in a total reaction volume of IS~1 made of SOng/ml of 
primers, luI of primary PCR product, O.SmM dNTPs, 2.SmM MgCh, lOX ampliTaq 
Gold Buffer and 0.07SU of ampliTaq. Gold. 
The thermal cycle conditions for primary PCR were an initial denaturation for 9SoC 
for 2 minutes, followed by 30 cycles of 9SoC denaturation for I minute, annealing at 
SO for 30 seconds, then elongation at 72°C for 1.30 minutes followed by a final 
elongation of 72°C for 7 minutes. 
Thermal cycle conditions for secondary PCR were an initial 94°C denaturation for 
10minutes, followed by 30 cycles of 94°C denaturation for 30 seconds annealing at 
S40C for 30 seconds, elongation at 72°C for 2minutes and a final elongation at 720C 
for S minutes. 
PCR product was electrophoresed on a ABI PruSM® 377 DNA sequencer as stated in 
chapter 2 
4.3 Results 
Generally three patterns are expected when novel polymorphisms/mutations are 
detected: the homozygote normal which should be the commoner or wild type 
mutation, the homozygote mutant which should be the less common type, and the 
heterozygote where the two chromosomes homologue carry different variants of the 
mutation. Using the ABI 377 sequencer, the heterozygous individual has t\VO 
detectable peaks at the point of mutation whereas only one peak \vas observed for the 
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homozygous mutant (Figure 4.1). The software programme allows the detection of a 
four-colour trace. Point mutations of the two homozygotes and heterozygote were 
clearly detectable on the traces (Figure. 4.1). Base substitution was either transition or 
transversion change. Also a deletion mutation was identified. Homozygous normal, 
homozygous deleted and heterozygote individuals were also detected (Figure 4.1). 
The heterozygous individuals were recognisable because the sequence traces beyond 
the mutation became unreadable due to overlapping sequences from the two 
chromosome homologues. Five simple point mutations were detected within the IFNG 
gene promoter region while one double deletion, one simple point polymorphism and 
three simple point mutations were detected within the promoter region of the IFNGRl 
gene in the samples analysed (Figure. 4.14). In all 10 new mutations were identified. 
The electropherographs showing the different polymorphisms can be seen below 
through Figure. 4.2 to.4.6 and Figure 4.8 to 4.12. 
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FIG 4.1 Detection of point and deletion variants 
Figure 4.1 shows graphs of point and deletion mutations as detected by the ABI 377 DNA sequencer. 
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4.3.1. Sequence variation in the IFNG promoter region 
Five new variants were observed within the promoter of human IFN-y. All five are 
single point mutations. 
Table 4.3. IFNG promoter variants 
Substitution Position Genotype frequency Allele Frequency 
A~G transition -151 AA (0.97) GG (0) G/A (0.03) A (0.99) G (0.01) 
A ~G transition -234 AA (0.97) GG (0) G/A (0.03) A (0.99) G (0.01) 
G~ A transition -297 AA (0.97) GG (0.33) G/A (0.03) G (0.99) A (0.01) 
C~ T transition -790 TT (0.03) CC (0.86) CIT (0.11) C (0.915) T (0.085) 
A~G transition -1371 
AA (0.95) GG (0) AlG (0.05) A (0.98) G (0.02) 
Evidence for these polymorphisms are documented in Figure 4.3 through 4.7. 
Table 4.3 shows the type of base changes followed by the nucleotide position and then 
the genotype and allele frequency in parentheses. 
The following differences were identified when Gambian sequence was compared to 
the Genbank sequence for IFNG promoter region sequence. They are as follows. 
Insertion of a T at nucleotide position -237, deletion of A at nucleotide position -
1319. Insertions of T at nucleotide positions -908 and -56l. Substitution of T with a 
C at nucleotide position -764. Non of these differences were polymorphic 
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Figure 4.2 Polymorphism ofhmnan IFNG promoter at -151 bases. 
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FIG 4.4 Polymorphism of human IFNG promoter at -297 bases 
110 
; 
I 
! ' 
~~~ l ~ 
i 
I 
! 
l 
Ii'i 
I 
I 
i 
.j. 
i 
. , 
1 
I 
---i 
FIG 4.5 Polymorphism of human IFNG promoter at -790 bases 
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PROMOTER REGION OF HUMAN IFNG 
F orward primer 
AAC TCA CAA TCA TAT AGC TtG TAT GTA GAG GAGTCA GGAATC AAGITT GCC CCA 
TAA CTG CAA TAC TGT TAT GTA CAC AGT ACA GGT AGAAAT GCAAAGTGG GITTGA 
no ~ 37"[ 
G 
ACCAAA GAGTGGAGG GCT TIT TGT GCCATC CCAAAGTGTTGT ACTTCA TAAATA 
AATTAA CAAAGG AGG AGAAAG AAT CCT ATTTTTITTITGTAT CTG AAG ACAAAG 
AAA TAA AAA GIT AAA AAG AIT CTC TGT TAG TAC TGA ITA TIT GGA ACAATA AAT 
TGTITA GAG CATTGCTGT TCAATA TAG TAG TCA CCT AGCAGT ATGTGC CCA ITA 
AGC GIT GAS ATA CGA CTAGAC CAAAIT GAGATGCAC CGT AGG CIT AAAATA TAC 
ACT GTA TIT CIT TCC TIT TIT CIT TIT ITC TIT ITT TIT TIT GAG ACG GAA TCT TAC 
TCC CGTCAC CT A GGC TGG AGT GT A GTG GCG CGA TCT CGG CTC ACT GCA ACC TCC 
ACC TIT CIT GGG ITC AAG CCA ITC TCC TGC CTC AGC CTC CCT AGT AGC TGA GAT 
ins -908 
T 
TAC AGG CAT ACA CCA CCA TGC CTG GCT AAT TTTTTGTATTIT TAG TAG AGA TGG 
GGT TTC ACC ATA ITG GCT AGG CTG GTC TCA AAC TCC TGA CCT TGT GAT CCA CCC 
-790 
T 
GCC TCA ACC TCC CAA AGT GCT GGG A IT ACA GGT GTG AGC CAC TGC GTC TGG AAC 
sub ·."/64 
C 
TCC CCCTGGGAA TATTTT CTA CACTGT AIT TCAAGGAIT TAA TAT GACAAAAAG 
AAT GTC AAA TAC CTT AIT AAG AAT GTAGTA TATTGA TGC ATA CTGAAGTAC TAT 
··700 
A 
TTGGGA TAT AIT GGTTTAAAT ACAATA TAT ITT AAAATT ATA ITT ACCITTTAA 
AAA AAC TIT TAT TAA TGA GGC TAC TAG ATC ATT TAA ATT TAC CTG TGT GGC ITG 
ins ·561 
T 
TAT GTA ITT CTA CTG GGC AGT GCT GAT CTA GAG CAA TIT GAA ACT TGT GGT AGA 
TAT ITT ACT AAC CAA CTC TGA TGAAGG ACTTCCTCACCAAATTGTTCTTIT AAC 
CGC A IT CIT TCC TTG CIT TCT GGT CAT ITG CAA GAA AAA TIT T AA AAG GCT GCC 
CCT ITG TAA AGG ITT GAG AGG CCC TAG AA T ITC GIT TIT CAC TTG ITC CCA ACC <}~ 
-2 .. .' 
A 
ACA AGC AAA TGA TCA ATG TGC TIT GTG AA T GAA GAG TCA ACA TIT T AC CAG GGC 
T C 
AGT GCC TCA ;{AG AAT CCC ACC AGA ATG GCA CAG GTG GGC:~ T A ATG GGT CTG TCT 
-1 ~L 
G 
CAT CGT CAA AGG ACC CAA GGA GTC T AA AGG AAA CTC T AA CT A CAA CAC CCA AA T 
113 
GCC ACAAAA CCTTAGTTA TTAATA CAAACT ATCATC CCT GCCTATCTGTCA CCA 
TCT CAT CTT AAA AAA CTT GTG AAA ATA CGT AAT CCT CAG GAG ACT TCA ATT AGG 
TAT AAA TAC CAG CAG CCA GAG GAG GTG CAG CAC ATT GTT CTG ATC ATC TGA AGA 
TCA GCT ATT AGA AGA GAA AGA TCA GTT AAG TCC TTT GGA CCT GAT CAG CTT GAT 
... R . everse pruner 
ACAAGA 
FIG.4.7. Sequence of human IFNG promoter from -1487 to +66bps of 
initiation codon 
Promoter region of interferon gamma showing all the novel polymorphisms. 
Polymorphisms are highlighted in red. 
Key 
Ins = Insertion, sub = Substitution, insertions and substitutions were observed in all 
samples sequenced and found to be different from already published data 
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4.3.2. Sequence variation in the IFN-yRl promoter region 
Five new variants of the IFNGRI were identified: one single point polymorphism, one 
deletion polymorphism and three simple point mutations. 
Table 4.4. IFNGRI promoter variants 
Substitution Position Genotype frequency Allele frequency 
T ~C transition -56 TT (0.23) CC (0.23) TC (0.54) T (0.5) C (0.5) 
T ~G transversion -181 TT (0.96) GG (0) TG (0.04) T (0.98) G (0.02) 
T ~C transition -270 CC (0.92) TT (0) CIT (0.08) T (0.96) C (0.04) 
Double deletion TT -4711470 TT (0.68) -IT (0.23) -1- (0.09) T (0.8) --(0.2) 
C~ T transition -499 CC (0.97) TT (0) CT (0.03) C (0.98) T (0.02) 
Evidence for these polymorphism are documented in FIG4.9 through FIG4.13 
Table 4.4 shows the type of base changes followed by the nucleotide position and then 
the genotype and allele frequency in parentheses. 
There was an ambiguity at -38 bases of the initiation codon .. The software showed 
that three individuals were homozygous for adenine (A) at this position whereas 
twenty-five other people were shown to be homozygous for the guanine (G) at this 
position. 
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FIG. 4.8 Polymorphism of human IFNGRl promoter at -56 bases 
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FIG. 4.9 Polymorphism of human IFNGRI promoter at -181 bases 
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FIG. 4.10 Polymorphism of human IFNGRl promoter at -270 bases 
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FIG. 4.11 Polymorphism of human IFNGRI promoter at -499 bases 
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IG. 4.12 Double deletion in human IFNGR1 promoter at -470/471 bases 
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PROMOTER REGION OF HUMAN IFNGRl 
Forward primer 
TTC TCC AAG AAC AAA :GttfiLGTt :CTt :t§GT :GAXG~ GAT ITG ATT TGG GCT GTG GGA 
-499 -470/471 
'-1 C-j·,-'\.-S ------, 
T 
ATC TGC ACA AAC CATTTC ACT AGC TAA GTC TCA GGT TCC TCA AAT GAAAAA GCA 
GGG ACT GGA AAT GGC TTT TGA AGT CTC ATT CTC TIC TAA AAA TGT CAG GCT CCA 
AGA CAA CCA GGT GAA GTC CAA GAG TT A GTA AAA T AA GGA ITG TGG CTC GGC TGT 
GGC CTA ATG CAA ACT TGC ACA ACC CCA GGA AAC AGA AAA AAA CTG GAA GAA 
-270 
c 
TTG CAG AAT GGG GTG CCA GGT TGA AAG ACC ITA ACC TIT GCA CTC AAA ITC CTC 
r .. ··H4TF .. ·····i 
! : i_,_~_~ .................... , .. .1 
CCA CAC CCA GAA GTC CAG GTC CCG ACC GCA CGA CGC CGT GCT CAC TGC TGG GTG 
-181 
{'" J 
'-------------------1 I AP-1 
--------------------
: -LTF ---------.. -.. --: 
! U UI Sp 1 r -' ...... _. 
I AP-2 I L __ .... M. _____ • __ •• _. ___ • __ • __ 
CTG CGC CTG AGT CCG CCT CCT GCG GCT TCC CGG ACT TGA CCC CGC CCA CGC CCT 
1 ..· .. ~4TF·· .... 1 
................... 'r-I S--'-p-1---' 
I EIVF/CREB 
i ATF 
l_ ..... _._. __ ._ .... __ .... _._.~ 
GGT CCC GCC TCC TGC CGA CGC CGG CAC AGA CCC CGG TGA CGG AAG TGA CGT AAG 
-56 
D 
c 
I AP_-2 __ --' 
[::~~::~::~::~::~::~::j 
GCC GGG GCT GGA GGG CAG TGC TGG GCT GGT CCC GCA GGC GCT CGG GGT TGG 
+1 
AGC CAG CGA CCGTCG GTA GCA GC ATG GCT CTC CTC TTT CTC CTA CCC CTT GTC 
ATG CAG GGT GTG AGC AGG GCt. GAG ii:\tG. ipG:Q:;\G.Q:·GGP:·i<'iiA.tt QfG GGG CCG TCC 
... 
Reverse primer 
TCAGGT ACC 
Promoter region of hmnan interferon gamma receptor. Novel po1ymorphisms are highlighted in red. 
Boxes represent transcription factor binding sites. Nucleotide positions are relative to initiation codon. 
Forward and reverse primers are highlighted in yellow. 
Transcription factors seen are GAS sequence, Sp1 sequence, AP-1 sequence, AP-2 sequence, 
EIVF/CREB sequence NF-K~ sequence and H4TF-2 sequence as indicated in boxes. 
FIG.4.13. Sequence of human IFNGRl promoter from -976 to + 90bp of 
initiation codon. 
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4.3.3. peR RFLP OF IFNGRI ddel/TT polymorphism 
The deletion polymorphism detected during the course of this study was found to 
occur at a putative gamma activation site GAS (FIG. 4.S & 4.12). Gamma activation 
factor should bind to the gamma-activated site in the promoter ofIFN-y receptor. 
A PCR RFLP was designed for use in screening independent control samples to 
determine the frequency of this polymorphism in the general population and in TB 
cases in The Gambia. 
Primers 5'AGA GAT GCA AAA TAA CAG AC and 5' TTT ACT AAC TCT TGG 
GAC TT 3' were designed to give a 311 bps product. The PCR premix contained 50 
ng/j.ll of primer, 1.5mM MgCh 160mM (N14)2S04, 670mM Tris-HCb (pHS.S) at 25 
DC 0.1 % Tween -20, 25mM dNTPs and 0.15units of Taq DNA polymerase in 12.5j.ll 
volume reaction. The amplification condition was an initial 10 minutes denaturation at 
96DC followed by thirty cycles of denaturation at 94DC for 1 minute, annealing at 57DC 
for 1 minute, elongation at 72 DC for 2 minutes and a final elongation for 7 minutes at 
72 DC. The 311 bps product was digested at 37°C for Ihour 30 minutes with the 
restriction enzymes HaeIII to yield 206bps and 105bps. 
The enzyme HaeIII is isolated from Haemophilus aegyptius and recognises the 
sequence 5' Gt CC 3' The enzyme cleaves in between the G and the C as shown by 
the arrow. The sequence surrounding the deletion polymorphism creates a cleavage 
site for the enzyme Hae III. The deletion is cut to give a 105 bp fragment. 
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4.3.4. PCR RFLP OF IFNGRI -56 CIT polymorphism 
A polymorphism consisting of a substitution of cytosine for thymine was observed at 
position -56 upstream of the transcription start site. This polymorphism is four bases 
away from a putative NF-K~ binding site. An assay was design by PCR RFLP for use 
in screening the larger population to determine the frequency of this polymorphism in 
the general population and in TB cases in The Gambia. 
Primers 5'GCT CAC TGC TGG GTG CTG CGC 3' and 5' AGA TCC GCG GTG 
CCC ATC TCA 3' were designed to amplify a product of 268 bp in size. The PCR 
premix contained 50 ng/l-tl of primer, 1.5mM MgCh 160mM (NIL.)2S04, 670mM 
Tris-RCh (ph8.8) at 25°C 0.1 % Tween -20, 25mM dNTPs and 0.15units of Taq 
DNA polymerase in 12.5 I-tl volume reaction. The amplification condition was an 
initial 10 minutes denaturation at 96°C followed by thirty cycles of denaturation at 94 
°c for 1 minute, annealing at 57°C for 1 minute elongation at 72 °c for 2 minutes and 
a final elongation for 7 minutes at 72°C. The 268 bps product was digested at 37°C 
for Ihour 30 minutes with restriction enzymes Eco47 III to yield 141 bp and 127 bp. 
Similarly enzyme Eco 47111 is isolated from Eshericia coli RFL 47 and recognises the 
sequence 5' AJ GCT 3'. The enzyme cleaves in between the C and the G as shown 
by the arrow. The sequence surrounding the transition polymorphism creates a 
cleavage site for the enzyme Eco 47 III. The C polymorphism is cut to give a 127 bp 
fragment. 
123 
5' 
-1371 
A~G 
-499 
C~T 
-790 
C~T 
-470/471 
ddel/TT 
-297 
G~A 
-270 
T~C 
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-234 -152 
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-181 -56 
T~G T~C 
FIG. 4.14. Nucleotides changes in human a) IFNG and b) IFNGRl promoter 
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4.4. Discussion 
Specific segments of the promoter regions of two genes IFNG and IFNGRI were 
sequenced in TB cases. Ten novel variants were detected. Five variants were observed 
within the promoter of IFNG (Table 4.3) and another five within IFNGRI (Table 4.4). 
The variants detected in the IFNG promoter region occurred at very low frequency 
(Table 4.3) and they may not be very useful tools for further studies. Furthermore, 
they were not found at any known potential transcription factor-binding site and were 
deemed not to be functional. No further analysis was carried out on these mutants. 
However, two polymorphisms detected within the promoter region of IFNGRI are 
informative and suggest specific use in genetic studies (Figures 4.8 and figure 4.12). 
These are firstly, the -470/471 nuc1eotides double deletion polymorphism designated 
delTT -470/471 which has a frequency of 0.8 for the wild type allele (TT) and 0.2 for 
the TT double deletion in the small number of 36 genetically independent samples of 
TB cases sequenced. This double deletion occurs at the first two Thymine bases (TT) 
at a putative transcription factor-binding site (GAS) within the IFNGRI promoter 
(Bach et aI., 1997). Secondly, a single point (TIC) transition polymorphism at position 
- 5 6bp relative to the start of transcription was detected to have allele frequency of 0.5 
for each allele from sequencing of36 genetically independent TB cases. 
The promoter region of the IFNGR 1 contains the specific consensus GAS sequence of 
TTNCNNNAA from -470 bases to -462 bases of the transcription start site (Bach et 
al., 1997; figure 4.13). Sequences corresponding to this consensus GAS sequence has 
been used in several mobility shift assays as a 32 P - end labelled double stranded 
DNA probe (Altare et al., 1998b, Jouanguy et aI., 2000). The double deletion of 
thymine (TT) at position -470/471 reported in this paper is the first two nuc1eotides of 
the GAS sequence required for early IFN-y inducible genes at which a transcription 
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factor GAP binds to initiate transcription of the gene. The presence of a deletion at 
this site is expected to abrogate or abolish the binding of the phosphorylated 
homodimer STAT1 molecule which should translocate from the cytoplasm into the 
nucleus and bind to the gamma activated site of any y- inducible gene. This implies 
that IFN-y is capable of regulating the transcription of its own receptor a chain. A 
deletion at this site should therefore reduce the rate of transcription of the gene. 
However, there are indications from a study carried out in mice cell lines that IFNyR1 
mRNA is constitutively expressed in two cell lines that utilise GAS element 
differently in response to IFN-y (Lucas et al., 1998). 
Free NF -Kf3 can translocate to the nucleus of many genes containing a kf3 consensus 
motif (GGGRNNYYCC). The promoter region of IFNGRI contains a sequence 
(GGGCTGGTCC) at nucleotide positions -52 to - 43 of the initiation codon. This 
sequence differs from the consensus IKf3 motif at only two points. The fourth 
nucleotide of this sequence is a C instead of an A or G and the seventh nucleotide is a 
G instead of a C or T of the consensus sequence. However, these positions could 
adversely affect binding of NF-Kf3 and subsequent gene transcription rate (Suzuki et 
aI., 1999). Studies show that a substitution of A to G at position 4 does not contributes 
to affinity change because these substitutions occur in high, intermediate or low 
affinity NF-Kf3 motifs. However, a substitution of T with G at position 7 has been 
shown to significantly contribute to the binding affinity of NF-Kf3. All high affinity 
NF-Kf3 motifs have T at this position and G is associated with low affinity NF-Kf3 
motifs (Suzuki et aI., 1999). A single point (T ~C) transition polymorphism at 
position -56bp relative to the start of transcription was detected to have allele 
frequency of 0.5 for each of the nucleotide from sequencing of the same 36 TB cases 
described above. This polymorphism is four bases upstream of the putative NF-Kf3 
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binding site in the promoter of IFNGRI gene (Figures 4.8, 4.13). Whether this 
polymorphism affects binding of the NF-K~ motifis not known. peR RFLP assay has 
been designed and used to determine the frequency of these polymorphisms in the 
larger population (section 4.3.3 and 4.3.4). 
Further, biological importance of these polymorphisms maybe assessed by screening 
other African populations and diseases other than TB. Also, studies to carry out 
functional transfection assay using reporter gene construct to show whether alleles of 
these polymorphisms differ in their ability to drive gene expression by affecting the 
rate of gene transcription may be carried out. 
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CHAPTER: 5 
INFLUENCE OF MACROPHAGE CANDIDATE GENES ON 
MONOCYTE FUNCTION 
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5.1 Introduction 
Phenotypic analysis of cellular immune responses to mycobacteria has suggested that the 
ability to resist disease following infection depend partly on the genetic make up of the 
host. This is reflected in epidemiological evidence that host genetics influence 
susceptibility to mycobacterial diseases such as TB and leprosy, and the identification of 
several genes that are linked to or associated with these diseases (Newport, 1999). Host 
responses to mycobacteria involve complex interactions between the innate and acquired 
arms of the immune response (Ellner, 1997), which are described in more detail in 
chapter one. 
M tuberculosis is an intracellular pathogen that multiplies predominantly within the 
macrophage. Restriction of mycobacterial growth within this cell is therefore a crucial 
determinant of immunity and is essential for effective containment of the organism. Upon 
infection, macrophages undergo several changes collectively referred to as activation. 
These include increased expression of surface molecules MHC class II and cytokine 
receptors, up regulation of expression of NRAMP and various cytokines, and the 
production of ROJ and RNJ molecules (see section 1.2.1 i). Convincing evidence that 
activated macrophages form a critical part in the control of M tuberculosis has been 
clearly established by animal and in-vitro studies (e.g. Lurie et at., 1952, Rook et at., 
1986). 
Mycobacterial cell-wall components such as lipoglycans and LAM can stimulate 
macrophage activation by binding to the macrophage mannose receptor (Ernst, 1998), the 
CD14 molecule (Stuber, 1999), or the TLRs (Means et at., 1999). Cytokines (particularly 
TNF), which mediate the initial innate immune responses to M tuberculosis infection, 
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are important determinants in the development of M tuberculosis disease and pathology 
(Orme & Cooper, 1999; Rook et aI., 1987). It is not clear why in some individuals the 
initial immune response controls infection while in others active disease develops. 
However, it is recognised that most immune responses within populations vary 
considerably between individuals and it is possible that the magnitude of the immune 
response is important. Genetic factors in tum are likely to contribute to this variation 
(Westendorp et aI., 1997). 
The data presented in chapter 3 confirms that monocyte responses to LPS and LAM 
within a population of healthy Gambian blood donors vary considerably. The aim of the 
work described in this chapter was to determine the extent to which the observed 
variation can be attributed to host variation in candidate macrophage response genes. 
Candidate genes were selected on the basis of their known function in 
macrophage/monocyte immune responses and published evidence from other groups that 
genetic variation in these genes was associated with variation in immune responses. 
Table 5.1 summarises this rationale. 
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Table 5.1 Summary of selected macrophage candidate genes on the basis of 
function 
Further details are given in section 5.1.1-5.1.8 below. 
Candidate Chromosome Relevance of protein function References 
2ene product region 
IL-I0 lq31-q32 IL lOis produced by macrophages and Murray ef aI., 1997 
down regulates function. It is associated Bousssiotis ef aI., 2000 
with reduced antimycobacterial activity 
and suppression of immune responses in 
TB 
NRAMPI 2q35 NRAMPI has mUltiple pleiotropic effects Blackwell ef al., 1996 
on macrophage function. It was the first Bellamy ef aI., 1998a 
murine mycobacteria susceptibility gene to Abel ef aI., 1998 
be identified and variation in the human Alcais ef al., 2000 
homologue has been associated with TB, 
leprosy and response to lepromin 
IL-l f3 2q14 IL-l is a pro-inflammatory cytokine, Dinarello, 1996 
IL-IRA produced by activated macrophages, 
induces 11-2 production 
Th2 cluster 5q23-q32 IL-4 down regulates macrophage function. Nicolaides ef aI., 1997 
IL-4 IL-4 and IL-9 promote the development of 
IL-9 Th2 responses associated with the development of TB disease 
TNF 6p21.3 TNF is required for protection against Knight et al. 1999 
LT mycobacterial disease, but also contributes Knight and 
to pathology. Promoter region Kwiatkowski, 1999 
polymorphisms associated with functional 
variation in gene expression. 
IFNyRl 6q23-24 First human gene shown to cause increased Newport ef aI., 1996 
susceptibility to mycobacterial infection Jouanguy et al., 1996 
Required for IFN-y function 
IFN-y 12q24.1 IFNy is a potent macrophage activator. Farrar, 1993 
iNOS 17ql1.2-qI2 Repeated exposure of bacterial cell wall Golgring ef al., 1998 
component LPS alters the composition of Nicholson et aI., 1996 
NF-K~ binding to the regulatory regions of 
inducible nitric oxide synthase gene. There 
is reduced macrophage production of nitric 
oxide via the iNOS pathway. NO is 
small important in killing of mycobacteria in 
inducible murine macrophages. The small inducible chemokines genes are 
chemokines located in the same region. 
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5.1.1 IL-I0 
IL-I0 was originally described as a T-cell factor responsible for inhibition of Thl type 
responses (Fiorentino et aI., 1989). It was subsequently shown that monocytes are also a 
major source of IL-l 0, that IL-I0 production is down regulated by IFN-y and that IL-I0 
down regulates monocyte function (de Waal Malefyt et aI., 1991). In 1997, Turner et aI., 
demonstrated a difference in serum IL-I0 in association with the presence or absence of 
A at position -1082 of the human 1L-10 promoter following ConA stimulation of 
peripheral blood mononuclear cells. Also, allele 7 of the proximal and 3 of the distal 
microsatellites identified within the 1L-10 gene promoter region are associated with 
decreased expression of IL-l 0 protein whereas alleles 14 of the proximal and 2 of distal 
repeat were associated with increased IL-l 0 expression (Eskdale et aI., 1998). 
5.1.2 NRAMPI 
In mice, Nrampl regulates a cascade of gene-inductive events mediating inflammation, 
elimination of invading organisms and induction of T cell memory against re invasion 
(Blackwell et aI., 1996). Nrampl appears to influence the polarization of Th cell 
development .in mice (Soo et al., 1999), and development of delayed type 
hypersensitivity reactions to lepromin in humans (Alcais et aI., 2000). Reporter gene 
construct studies suggest a correlation between variations in a functional repeat 
polymorphism in the promoter region of human NRAMP 1 infectious versus autoimmune 
disease susceptibility (Searle & Blackwell, 1999). Various genetic studies have identified 
either linkage or association with mycobacterial disease in humans and NRAMP 1 
(Bellamy et aI., 1998, Abel et aI., 1998, Greenwood et aI., 2000). 
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5.1.3 The IL-l~ and IL-lRA gene cluster. 
lL-1 ~ is a potent pro inflammatory cytokine implicated in numerous physiological 
processes, and in the pathogenesis of a number of inflammatory disorders (Dinarello, 
1996). IFN-y increases lL-1~ production while lL-10 down-regulates lL-1~ production. 
Allele 1 (T) at position +3953 in ILl B has been associated with increased expression of 
lL-1 ~ (Pociot et al., 1992). lL-1 receptor antagonist (1L-1RA) is one of the most 
powerful endogenous anti-inflammatory agents known and competes with lL-1 ~ and IL-
l a for occupancy of its cell surface receptors. Since it does not stimulate signal 
transduction, it acts as an inhibitor of lL-1 action (Blakemore et al., 1995). Intron 2 of 
ILl RN contains an 86bp VNTR repeat of which the allele 2 is associated with increased 
expression oflL-lRA by monocytes in vitro (Tarlow et al., 1993). 
5.1.4 Th2 cytokine cluster 
Several studies have revealed tight linkage between markers on human chromosome 
5q31.1 and a major susceptibility gene controlling total serum IgE levels. Naive CD4 T 
cells develop into one of two major subsets of Ths that produce distinct sets of cytokines 
Thl (1FNy, IL-12 and TNF-a) and Th2 (1L-4 IL-5, IL9, lL10) and lL-13 cell subsets. The 
polarisation of responses to Th 1 or Th2 dominance often determines resistance or 
susceptibility of host to infection and the degree of tissue damage in many autoimmune 
diseases. The region of Human chromosome 5q31 encodes the cluster of Th2 cytokine 
genes. These cytokines include lL-4, IL-5, lL-9 and IL-13. Th2 cytokines are associated 
with antibody production and high serum IgE levels. The hypothesis that: A raise in 
atopic disorders in affluent communities correlates with a decline in infectious disease, is 
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supported by several studies (Shirikawa et al., 1997, Shaheen et al., 1996, Seah et al., 
2000, Aung et al., 2000). Some of these studies show that Th2 cytokines are associated 
with immunopathologic changes in TB patients and could be a cause or consequence of 
disease. Transgenic mice models where IL-4 and IL-9 are either over expressed or where 
the gene is disrupted by recombination have been used to show the importance of IL-4 in 
both IgE synthesis and allergic disease (Song et al., 1996, Nicolaides et al., 1996). Cells 
isolated from atopic individuals have the ability to over express the IL-4 and IL-9 gene 
relative to nonatopic individuals (Song et al., 1996). Allelic forms of the IL4 promoter 
region account for the higher transcriptional activation in atopic patients (Song et al., 
1996). Functional studies in B6 mice showed that alterations of a quantitative trait locus 
that maps to mouse chromosome 13 encoding the IL-9 was associated with reduced 
expression of IL-9 and bronchial hypo responsiveness (Nicolaides et al., 1997). Perhaps, 
cells from TB patients have increased capacity to produce both IL-9 and IL-4. Significant 
inhibition of allergen-specific IgE production, OVA-induced eosinophilia and goblet cell 
development by prior infection with BCG was observed by Yang et al., (1999). In 
addition, intracellular bacterial infection (i.e. BCG) can inhibit antigen-specific IgE and 
airway reactivity induced environmental allergen (Yang et al., 1999). The effect of two 
polymorphic variants of IL4 and one of IL9 on cytokine levels was investigated in 
Gambians. 
5.1.5 TNF and Iymphotoxin-a (LTa) 
TNF plays a critical role in lymphocyte biology as well as in a variety of infectious and 
autoimmune diseases (Beutler, 1989). It is produced by a variety of cell types and is one 
of the first immunological mediators to appear in response to infection. Resting 
macrophages produce virtually no TNF: however, monocytes and macrophages produce 
large amounts of this cytokine within hours of stimulation with an appropriate agent and 
IFN-y potentates its release (Renz et al., 1988). Stable inter-individual variations in 
plasma TNF levels have been observed suggesting heritable differences in TNF 
production (Molvig et a!., 1988, De Groote et al., 1992). A number of polymorphisms 
have been identified in the promoter region, and because production of TNF protein is 
regulated in part at the transcriptional level, there has been much interest in the effect of 
these polymorphisms on this process. The TNFA -308 polymorphism is perhaps the best 
studied. However, there are contradictory reports of the same allele being associated with 
both high and low TNF production, presumably due to the experimental protocol 
followed (reviewed by Knight and Kwiatkowski, 1999). The most convincing data relates 
to a single nucleotide polymorphism at position TNFA-376 relative to the transcriptional 
start site. The mutant allele completes a transcription factor OCT -1 binding site. This site 
is a region of complex protein-DNA interaction such that binding alters gene expression 
in human monocytes resulting in four fold increased susceptibility to cerebral malaria 
(Knight et a!., 1999). 
An increase in L T and TNF secretion is associated with a SNP located in intron 2 of the 
LTA (Messer et a!., 1991, Abraham et a!., 1993). Stuber et al., (1996, 1999) found the 
same allele to be associated with high circulating concentrations of TNF and higher 
mortality for septic patients, despite showing no effect for the TNFA-308 alleles on 
circulating TNF levels. 
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5.1.6 IFN-y 
IFN-y is the major cytokine required for macrophage/monocyte activation, acting via its 
heterodimeric receptor (Farrar, 1993) and a large body of data suggests it is essential for 
mycobacterial immunity in both mouse and man. Intron one of the IFN-y gene contains a 
variable CA repeat element (Ruiz-Linares et al., 1993). In vitro production of IFN-y 
showed significant correlation with the presence of allele 2 (Awad et aI., 1999, Pravicia 
et aI., 1999) suggesting IFN -y production is genetically regulated. Novel promoter 
polymorphisms have been identified in this gene in the Gambian population studied (see 
chapter 4). 
5.1. 7 IFNyRl 
Inherited IFN-y Rl deficiency has been identified as the cause of disseminated 
mycobacterial infection in several kindred (Newport et aI., 1996, Jouanguy et al., 1996), 
highlighting the importance of this pathway in mycobacterial immunity. Novel 
polymorphisms in the IFNGRl gene were identified (chapter 4) and studied subsequently 
in relation to immune responses in the Gambian population. 
5.1.8 Inducible nitric oxide synthase (iNOS) 
LPS induces iNOS expression in several cell types including macro phages and is 
regulated by several cytokines in a species-dependent manner (Nathan et aI., 1994). 
Functional studies show that the critical control element appears to be clustered within 
the first 1700bp region 5' of the transcriptional start site (Xie et aI., 1994). Activation of 
human promoter-reporter occurred with either IL-l ~ or TNF alone but IFN-y was 
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absolutely required for the production of NO (Lowenstein et aI., 1993). The ability of 
differing numbers of (CCTTT) n pentanucleotide repeats to induce transcription of 
NOS2A gene has been analysed using a reporter gene assay in transfected colonic 
carcinoma cells (Warpeha et aI., 1999). IL-l ~ induction was most effective in constructs 
carrying the 14 repeat allele. The carriers of this 14 repeat allele also had lower incidence 
of renal complications and diabetes (Warpeha et aI., 1999). 
5.1.9 Small inducible chemokines 
Chemokines that are preferentially chemotactic for macrophages have been implicated in 
the immune response in tuberculosis (Riedel et aI., 1997, Orme and Cooper, 1999). 
Individual chemokine genes are differentially regulated in response to LPS (Kopydlowski 
et al., 1999). 
5.2 Methods 
In order to determine the influence of macrophage candidate genes on monocyte 
function, cytokine production was measured using a whole blood assay in 312 healthy 
blood bank donors, as described in chapters 2 and 3. The cytokines measured were pro 
inflammatory TNF and IL-l~, and anti-inflammatory IL-I0 after stimulation with 
bacterial endotoxin LPS and mycobacterial LAM. Published polymorphisms at several 
macrophage candidate gene loci were genotyped as described in chapter 2 and below. 
The influence of polymorphisms at these macrophage candidate gene loci on macrophage 
function (cytokine release) was determined using a non-parametric, one-way analysis of 
variance test. 
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5.2.1 Whole blood assays 
Whole blood assays were carried out as described in chapter 3 section 3.2.3. The 
cytokines measured were TNF, 1L-1 ~ and 1L-1 0, all of which are involved in monocyte 
immune responses to M tuberculosis. Furthermore, there is evidence that production of 
these cytokines is genetically regulated in other populations (Molvig, 1988, Eskdale et 
aI., 1998). Cytokine production was measured in response to LAM or LPS stimulation, 
with and without 1FN-y priming. 
5.2.2 DNA genotyping methods 
All genotyping was done using the polymerase chain reaction (PCR) as described in 
chapter 2 section 2.3 .2. Various genotyping methods were employed during the course of 
this project: - microsatellites were analysed using the fluorescent-based semi-automated 
technology developed by Perkin Elmer, while SNPs were typed using restriction enzyme 
digestion or ARMS PCR. 
5.2.2i Microsatellite analysis. 
The PCR conditions were generally the same for all microsatellite polymorphisms 
analysed and have been described in chapter two. However, primer concentrations did 
vary for each micro satellite and are listed below. One primer of each pair was labelled 
with a 2'7' -dimethoxy-4', 5' -dichloro-carboxy fluorescein compound to the 5' end. Three 
fluorescein dyes were used FAMTM for Blue, NEDTM for yellow and HEXTM for green. 
Typically, labeled primers were used at lower concentrations than the unlabelled 
complimentary primer. Each micro satellite was amplified separately and the PCR 
products pooled for gel electrophoresis. Electrophoresis was performed using the AB1 
PRISM system as described in section 2.3.2vii. The primer sequences and annealing 
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Marker Primer sequences (5'-3') Tain Size No of 
C (bp) Alleles 
ILI0 FAM-GGTAGAGCAACACTCCTCGC 60 250-300 1 1 
GTTGTAAGCTTCTGTGGCTGG 
NRAMPl NED-GAGGGGTCTTGGAACTCCA 58 119-123 3 
TACCCCATGACCACACCC 
D2S1471 FAM-TACCATTCACACATCGAAGAAC 50 80-110 20 
GATCTCTCCCCCACAATAAAC 
1L4 HEX-AGCCATCTCGGTTGGATGGA 55 175-219 21 
CTCAAAGTGCTGGGATTAGC 
1L9 FAM-CTAATGCAGAGATTTAGGGC 50 126-146 12 
GTGGTGTAAAGACTGCATAG 
TNFa HEX-TGTGTGTTGCAGGGGAGAGAGG 60 101-127 13 
CCTCTCTCCCCTGCAACACACA 
1FNGRl FAM-GAT TTG TGT ATT GCT TTA AGC 50 180-210 14 
GGC TCT TCA GCC TAT ATT TCC 
1FNG NED-GCT GTC ATA ATA ATA TTC AG 50 142-158 9 
GCC TTC CTG TAG GGT ATT AT 
NOS2A NED-CCCCTGGAAGCCTACAACTGCAT 50 172-217 15 
CCACTGCACCCTAGCCTGTCTCA 
D17S250 HEX-GCTGGCCATATATATATTTAAACC 54 138-172 18 
GGAAGAATCAAATAGACAAT 
Ta represents annealing temperature per primer, C represents degree Celsius 
Table 5.2.1 Microsatellite primer sequences 
temperatures for each micro satellite are shown in table 5.2.1. Figure 5.1 shows a typical 
gel electrophoresis performed as described in section 2.3.2vii. The use of different 
coloured fluorescent dyes for PCR products of similar sizes allows the 10 sets of PCR 
products to be analysed on one gel. The red bands represent internal size standard to 
allow accurate sizing of PCR products required for genotyping. 
139 
MARKERS 
IFNGRI 
NOS2A 
lIA ~ 
D17S250 
IL9 
NRAMP ~ 
TNFa ~ 
D2S1471 ~ 
ROX (RED 
STANDARD 
DYE) ~ 250bp 
+-- 200 bp 
+-- 160 bp 
+-- 150 bp 
+-- 139 bp 
+--100 bp 
+-- 75 bp 
Figure 5.1 Typical ABI genescan image showing microsatellite alleles for candidate 
genes described in table 5.1. IFNGRI (blue), NOS2A (yellow), lIA 
(green), D17S250 (green), NRAMPI (yellow), TNFa (green), D2S1471 
(blue). IL9 (blue) is omitted on this gel due to technical failure. Thr 
standard ROX dye is red. 140 
5.2.2ii Restriction fragment length polymorphism (RFLP) analysis 
The PCR conditions used were generally the same for all polymorphisms analysed by 
restriction enzyme digestion. Details are described chapter two, section 2.3 .2viii. The 
specific primers used and annealing temperatures used are shown in table 5.2.2. All 
primers were used at a concentration of 50 ng/ul. PCR products were digested for 1 hour 
30 minutes with the appropriate restriction enzyme and the products visualised following 
electrophoresis thorough 3-4% agarose. DNA was stained with ethidum bromide prior to 
UV exposure. 
Marker Primer sequences (5' -3') Ta (OC) Size Enzyme 
(bp) 
NRAMPl TGCCACCATCCCTATACCCA 60 216 MnlI 
crr TCTCGAAAGTGTCCCACTCAG 
NRAMPl TCTCTGGCTGAAGGCTCTCC 64 624 Apal 
G/C TGTGCTATCAGTTGAGCCTC 
NRAMPl GCAAGTTGAGGAGCCAAGAC 64 241 Bsrl 
G/A ACCTGCATCAACTCCTCTTC 
ILlB-511 TGGCATTGATCTGGTTCATC 55 304 A val 
GTTTAGGAATCTTCCCACTT 
fLiB 3953 CTCAGGTGTCCTCGAAGAAATCAAA 55 182 Taql 
GCTTTTTTGCTGTGAGTCCCG 
TNFA 
-308 AGGCAATAGGTTTTGAGGGCCAT 60 107 Neol 
TCC TCCCTGCTCCGATTCCG 
LTA CCGTGCTTCGTGCTTTGGACTA 60 740 Neol 
AGAGCTGGTGGGGACATGTCTG 
Table 5.2.2 Primer sequences for peR restriction fragment length polymorphism. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 
100 bp *= 107 bp 
87 bp 
Fig. 5.2 Restriction fragment length polymorphism at position -308 
in the TNFA promoter region 
peR products were digested with the restriction enzyme Neol for 1.5 hours and 
then electrophoresed through a 4% agarose gel containing 0.5 mg/ml ethidi urn bromide. 
DNA was visualised with UV light and photographed. Lane 1 represents a 100 bp 
DNA ladder. Nco I cuts in the presence of the wild type allele 1 (G at position -308) 
and lanes 3 and 4 for example are homo zygotes for the wild type allele. In contrast, 
lane lOis homozygous for the mutant all ele and the peR product remains undigested . 
Lane 13 is heterozy gOllS. 
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S.2.2iii Amplification refractory mutation system PCR 
Anna Richardson in Professor Kwiatkowski's laboratory in Oxford provided primers for 
amplification refractory mutation system (ARMS) PCR. Primers were designed to use a 
conserved primer together with sequence specific primers for either of the TNF mutant 
and wild type alleles as listed below (Table 5.2.3) with the respective product size. The 
method for carrying out ARMS PCR is explained in section 2.3.2vii. 
Markers Primer sequences Size (bp) 
TNFA-238 Wild type 5' CCCCA TCCTCCCTGCTCC 3', 395 
Mutant 5'CCCCATCCTCCCTGCTCT 3' 
Consensus 5'GGGGTCTGTGAATTCCCGG3' 
TNFA -376 Wild type CCTGCATCCTGTCTGGAAG3', 396 
mutant 5'TCCTGCATCCTGTCTGGAAA3' 
consensus 5'GGCTGGGTGTGCCAACAAC3' 
TNFA -857 Wild type 5'TCTACATGGCCCTGTCTTCG3' 270 
mutant 5'TCTACATGGCCCTGTCTTCA3' 
Consensus 5' AAGGATAAGGGCTCAGAGAG 
263 
TNFA-863 Wild type 5'CGAGTATGGGGACCCCCC 3', 
mutant 5,GAGTATGGGGACCCCCA 3' 
Consensus 5' CCGGGAATTCACAGACCCC3' 
HLA class 2 5' TGCCAAGTGGAGCACCCAA 3' 796 
DRB1Exon 3 5' GCATCTTGCTCTGTGCAGAT3' 
Table 5.2.3 ARMS PCR primer sequences 
The 3' mismatch primers are underlined for the mutant allele. A 796 bp fragment of the 
HLA DRBl gene was co-amplified for each PCR reaction as a positive control. 
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TB 363 TB 362 TB 361 TB 360 TB 359 TB 358 
1 2 3 4 5 6 7 8 9 10 11 1 2 
769 bp 
263bp 
Control 
amplicon 
Fig. 5.3 Amplification refractory mu tation systems at 
position - 863 in th e TNF A promoter regio n. 
Amplification of each DNA template was carried out using three primers. Two 
primers were designed such that each one contai ned a matching nuel eotide at the 3' 
end corresponding to either the wild type variant of the mutant variant. Each of 
these primer is expected to anneal to a common complimentary DNA sequence. 
Each template DNA was amplified in two wells. On this gel picture there are 6 
individuals. The odd numbered wells represents the wild type allele and the even 
numbered wells represents the mutant allele. For example, wells 1 and 2 represent 
DNA from the same individual and wells 3 and 4 from another indi vidual etc. 
Each well contains control primers designed to amplify exon 3 DRBl HLA2 and 
should not compete with the allele specific primers. 
Samples TB 363, TB 362, TB 361 are homozygote for the wild type, while TB 360 
is a heterozygote and TB 359, TB 358 are homozygote for the mutant allele. 
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5.2.2iv PCR VNTR 
The PCR was carried out as described in chapter two and there was no further analysis 
because band sizes were large enough to be resolved on a 2% agarose gel. Below (Table 
5.2.4) are the primer sequences used, annealing temprature (Ta) and expected band sizes. 
Markers Primer sequences Tain C Sizebp 
IL1RN 5'CTC AGC AAC ACT CCT AT3' 54° 240-
5' TCC TGG TCT GCA GGT AA3' 595 
IL4P2 5' CTG TTC ACC TCA ACT GCT CC 3' 65° 
5' TAG GCT GAA AGG GGG AAA GC 3' 123-
253 
Table 5.2.4 PCR VNTR primer sequences 
All products from PCR RFLP, VNTR and ARMS PCR were resolved in 2% agarose gel, 
stained with ethidium bromide, and visualised under UV light. 
5.2.3 Statistical analysis 
The Kruskal Wallis test of variance analysis, a non-parametric test was used to test if the 
cytokine measurement differed significantly between genotypes (see section 2.4). P 
valves of < 0.05 were taken as indicating significance. Statistical analysis was done using 
Stata (version 5 Stata Corporation, College Station, TX). 
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Table 5.3 List of macrophage candidate genes genotyped 
Chromosome region Candidate gene/marker Polymorphism 
lq31-q32 lL10 5' proximal promoters (CA) n 
repeats 
2q35 NRAMP 1 5' promoter t (gt) 5ac(gt) 
5ac(gt) ng or t (gt) 5ac(gt) n g 
Intron 4 PCR.RFLP 
Intron 13 PCR.RFLP 
274 CIT Exon 3 PCR RFLP 
2q14 lL1B Exon 5 +3953 PCR RFLP 
Promoter -511 PCR RFLP 
lL1RN Intron 2 86bp VNTR 
5q23-q32 lL4 Intron 270 bp VNTR 
Intron 3 (GT) n repeat (ABI) 
lL9 Intron 4 (TG)n repeat (ABI) 
Exon 5 (TI13M) 
6p2l.3 LTA Intron 2 I Exon 3 PCR RFLP 
TNFA -863 bp GI A SNP 
-857 bp G/A SNP 
-376 bp G/A. SNP 
-308 bp G/A SNP 
-238 bp G/A SNP 
TNF (AC) 13 (ABI) 
6q23-24 IFNGRl Promoter -470del/TT 
Promoter -56 CIT 
Intron 6 (G T) n repeat 
12q24.1 IFNG Intron 1 (CA) n repeat 
17q 11.2-q 12 NOS2A (CCTTT) n repeat (ABI) 
D17S250 (Ae) 25 (AB!) 
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5.3 Results 
Twenty- five polymorphisms at eight macrophage candidate genes were investigated for 
influence on microbial induced responses. These genes encode proteins that are involved 
in macrophage activation and they will be used to determine the human genetic 
background responsible for inter individual differences in cytokine responses to TB. This 
should ultimately make clearer the understanding of the influence of genomic variation 
on gene regulation and cytokine protein expression on TB. 
The result were presented by stratifying genotypes of a particular candidate gene and 
mean cytokine production in response to stimulants; LAM and LPS in the presence or 
absence of IFNy. Cytokines measured are TNF, IL-I~, and IL-IO. The data for chi-
square, degrees of freedom and p-value is presented per cytokine and stimulant. A p-
value of 0.05 or below was considered significant. No correction for mUltiple testing was 
carried for influence of genotype on quantitative trait measurements in this chapter. 
X2: Chi-Square, D.F.: degrees of freedom and p: p value (conditional probability). LPS: 
Lipopolysaccahride, LAM: Lipoarabinomannan and IFNy: interferon gamma . 
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5.3.li NRAMPl (CA repeat, Z DNA promoter polymorphism) 
Four polymorphisms in the NRAMP 1 gene were typed and analysed in relation to 
cytokine production. There was no quantitative trait measurement for LAM induced 
responses for those with the genotype 1.2. P-valves were compared between four 
genotypes for LPS induced by cytokine. Only two genotypes were analysed for LAM 
induced responses. 
None of the alleles of the promoter repeat were shown to influence cytokine production. 
Cytokines Stimulant X2 DF p-value 
TNF LAM 1.57 2 0.5 
IL-1 f3 0.02 2 0.99 
II-10 1.56 2 0.45 
TNF LAM&IFN-y 2.26 2 0.3 
IL-1 f3 0.82 2 0.66 
IL-10 0.51 2 0.78 
TNF LPS 3.58 3 0.3 
IL-1 f3 3.69 3 0.29 
IL-10 3.12 3 0.37 
TNF LPS&IFNy 1.66 3 0.65 
IL-1 f3 3.42 3 0.33 
3.16 3 0.37 IL-10 
Table 5.3.li NRAMP 1 (Z DNA polymorphism CA repeat) 
Table gives statistics for influences ofNRAMP1 Z DNZ polymorphism genotypes on 
cytokine (TNF, IL-1 f3 and IL-1 0) release by stimulants. 
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S.3.lii NRAMPl (274 CIT exon 3) 
P valves were compared between three genotypes for each cytokine and stimulant. 
None of the alleles of the promoter repeat were shown to influence cytokine production. 
Cytokines Stimulant X2 DF p-value 
TNF LAM 0.47 2 0.78 
IL-l~ 0.32 2 0.85 
11-10 1.39 2 0.49 
TNF LAM&IFN-y 0.98 2 0.6 
IL-l~ 0.20 2 0.9 
IL-I0 1.35 2 0.5 
TNF LPS 5.3 2 0.07 
IL-l~ 3.76 2 0.15 
IL-I0 1.58 2 0.45 
TNF LPS&IFNy 3.5 2 0.17 
IL-l~ 2.76 2 0.25 
IL-I0 2.22 2 0.33 
Table S.3.lii NRAMPl (274 CIT exon 3) 
S.3.liiiNRAMPl (469+14 G/C intron 4) 
The genotype 2/2 was not observed. P valves were compared between two genotypes for 
each cytokine and stimulant. 
Table 5.3.1iii shows that whole blood secretion of IL-I0 after LAM stimulation was 
lower in NRAMP intron 4 112 genotypes (p=0.008), and IL-I0 secretion was also lower 
after priming with IFN-y and LAM stimulation (p=0.02). Alleles ofNRAMPl (469+ 14 
G/e) were shown to influence LAM induced IL-l 0 secretion (p=0.008). Genotypes were 
still associated after priming with IFN-y (p=0.02). 
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FIG. 5.4 NRAMPl INT4 genotypes and IL-IO secretion 
Individuals were typed for the NRAMP 1 INT4 polymorphism. The III genotype 
represents homozygous for the NRAMP 1 INT 4 for the allele 1 and 112 heterozygote. 
2/2 homozygous for the NRAMP 1 INT4 allele 2 was not observed. Cytokine 
responses to LAM alone and LAM and IFN-y are shown in relation to host genotype. 
A) LAM induced IL-1 a and NRAMP 1 INT4 genotypes b) IFN-yenhancement ofIL-
Ia and NRAMP 1 INT4 genotypes. 
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Cytokines Stimulant X2 DF p-value 
TNF LAM 0.40 1 0.91 
IL-l~ 0.21 1 0.65 
II-I0 7.13 1 0.008 
TNF LAM&IFN-y 0.83 1 0.36 
IL-l~ 0.13 1 0.72 
IL-I0 5.48 1 0.02 
TNF LPS 0.03 1 0.872 
IL-l~ 0.00 1 1.0 
IL-I0 1.27 1 0.26 
TNF LPS&IFNy 0.31 1 0.58 
IL-l~ 0.51 1 0.45 
IL-I0 1.86 1 0.17 
Table 5.3.liii NRAMPI (469+14 G/C intron 4) 
5.3.liv NRAMPI (1465-85 G/A.intron13) 
In addition, for the NRAMPl intron 13 polymorphism table 5.3.liv shows that whole 
blood secretion of IL-I0 after LPS stimulation was lower in 112 genotype (P=0.04), 
whereas, IL-l ~ secretion after priming with IFN -y and LPS stimulation was lower in the 
same genotypes (p=0.05). 
P valves as compared between three genotypes for each cytokine and stimulant. 
Cytokines Stimulant X2 DF p-value 
TNF LAM 0.91 2 0.63 
IL-l~ 0.54 2 0.76 
II-I0 1.37 2 0.50 
TNF LAM&IFN-y 2.86 2 0.24 
IL-l~ 0.85 2 0.65 
IL-I0 1.5 2 0.48 
TNF LPS 1.8 2 0.41 
IL-l~ 2.8 2 0.25 
IL-I0 6.43 2 
0.04 
TNF LPS&IFNy 1.55 2 
0.46 
IL-l~ 5.97 2 
0.05 
2.6 2 0.27 IL-I0 
Table 5.3.1iv NRAMPI (1465-85 G/A intron13) 
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S.3.2i IL1RN 
The genotypes 1.1 and 1.2 were the most frequent in the population. The influence of 
genotype on LAM induced responses was only possible for these genotypes. The 
influence of genotype on LPS induced responses was possible for the 1.4 genotype. 
Whole blood secretion of lL-l 0 after stimulation with LPS alone or when pre incubated 
with IFNy was lower in individuals with the ILl RN 2/2 genotype those with ILl RN 111 
genotype (p=0.002 and 0.005 respectively). Also, LAM induced lL-10 was lower in the 
2/2 genotypes (p=0.05). All other genotypes occurred at low paired observation 
frequency to allow for any meaningful statistical analysis. 
P valves as compared between three genotypes for each cytokine and stimulant. 
Cytokines Stimulant X2 DF p-value 
TNF LAM 0.66 1 0.42 
1L-l J3 0.04 1 0.83 
II-I0 3.59 1 0.05 
TNF LAM&1FN-y 0.15 1 0.69 
1L-IJ3 0.08 1 0.78 
1L-I0 1.25 1 0.26 
TNF LPS 1.48 2 0.48 
1L-IJ3 0.58 2 0.75 
12.1 2 0.002 1L-I0 
TNF LPS&1FNy 0.55 2 0.76 
1L-l J3 0.53 2 0.77 
19.5 2 0.005 lL-10 
Table S.3.2i IL1RN 
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5.3.2ii ILIB -511 
P valves were compared between three genotypes for each cytokine and stimulant. 
None of the alleles of this polymorphism was shown to be influencing cytokine-induced 
responses (Table 5.3.2ii). 
Cytokines Stimulant X2 DF p-value 
TNF LAM 1.25 2 0.54 
IL-1B 2.l 2 0.35 
11-10 0.92 2 0.63 
TNF LAM&IFN-y 2.6 2 0.27 
IL-1B 3.0 2 0.22 
IL-10 0.45 2 0.8 
TNF LPS 1.94 2 0.4 
IL-1B 0.35 2 0.84 
IL-10 0.45 2 0.79 
TNF LPS&IFNy 4.4 2 0.l1 
IL-1B 2.3 2 0.31 
0.31 2 0.86 IL-10 
Table 5.3.2ii ILIB -511 
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5.3.2iiiIL1B +3953 
P valves were compared between three genotypes for each cytokine and stimulant. 
None of the alleles of this polymorphism was shown to be influencing cytokine-induced 
responses (Table 5.3 .2iii). 
Cytokines Stimulant X2 DF p-value 
TNF LAM 0.16 2 0.92 
IL-1B 0.15 2 0.93 
11-10 1.85 2 0.4 
TNF LAM&IFN-y 1.64 2 0.4 
IL-1B 0.73 2 0.96 
IL-10 0.53 2 0.76 
TNF LPS 4.04 2 0.13 
IL-1B 0.62 2 0.73 
IL-10 2.4 2 0.3 
TNF LPS&IFNy 1.45 2 0.48 
IL-1B 2.8 2 0.25 
IL-10 1.4 2 0.50 
Table 5.3.2iii IL1B +3953 
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5.3.3i IL4P2 
P valves as compared between three genotypes for each cytokine and stimulant. 
Whole blood secretion of TNF after priming with either with IFN-y and LPS or with 
LPS alone was lower in IL-4P2 2/2 genotypes (p=0.03 and p=0.08). 
Whole blood secretion of TNF after priming with IFN-y and LPS or with LPS 
stimulation was significantly different between genotypes (p=0.004, p=0.013). Also 
stimulation with IFN-y and LPS suppressed IL-10 production in IL-4P2 2/2 genotypes 
(p=0.04).' Alleles of IL-4P2 were shown to influence LPS induced TNF secretion (p 
=0.08). The pre-incubation of IFN-y further enhanced the influence of these alleles (p 
=0.03). 
Cytokines Stimulant Xl. DF p-value 
TNF LAM 2.35 2 0.31 
IL-1~ 3.49 2 0.17 
II-10 2.92 2 0.23 
TNF LAM&IFN-y 1.11 2 0.57 
IL-1~ 2.4 2 0.3 
IL-10 2.4 2 0.3 
TNF LPS 4.95 2 0.08 
IL-1~ 3.35 2 0.19 
3.48 2 0.17 IL-10 
TNF LPS&IFNy 6.87 2 0.03 
IL-1~ 2.5 2 0.29 
0.99 2 0.03 IL-10 
Table 5.3.3i IL4P2 
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5.3.4i TNF A -863 
P valves as compared between three genotypes for each cytokine and stimulant. 
Comparison could not be made for LAM induced responses for the rarer genotype 2. 
Whole blood secretion of TNF after stimulation with IFN -y and LPS or LPS alone differ 
between TNFA -863 genotypes (p=0.04, p=0.02 respectively) similarly secretion of IL-1 ~ 
after stimulation with IFN-y and LPS differed between groups (p=0.04). Alleles of TNF -
863 were shown to influence LPS induced TNF (p =0.02) Priming with IFN-y did not 
enhance this effect (p =0.04). 
Cytokines Stimulant X2 DF p-value 
TNF LAM 0.002 1 0.96 
IL-1~ 0.12 1 0.73 
II-10 0.05 1 0.82 
TNF LAM&IFN-y 0.98 1 0.32 
IL-1~ 0.79 1 0.37 
IL-10 0.13 1 0.72 
TNF LPS 7.67 2 0.02 
IL-1~ 4.22 2 0.12 
1.2 2 0.55 IL-10 
TNF LPS&IFNy 6.2 2 0.04 
IL-1~ 6.2 2 0.04 
3.17 2 0.21 IL-10 
Table 5.3.4i TNF A -863 
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5.3.4ii TNF A -857 
P valves as compared between three genotypes for each cytokine and stimulant. 
Comparison could not be made for LAM induced responses for the rarer genotype 2.2 
None of the genotypes are alleles of this variant influenced cytokine response (Table 
5.3.4ii). 
Cytokines Stimulant X2 DF p-value 
TNF LAM 0.013 1 0.91 
IL-1~ 0.05 1 0.82 
11-10 0.17 1 0.68 
TNF LAM&IFN-y 0.35 1 0.55 
IL-1~ 0.006 1 0.94 
IL-10 0.001 1 0.98 
TNF LPS 1.11 2 0.57 
IL-1~ 0.63 2 0.73 
IL-10 1.86 2 0.4 
TNF LPS&IFNy 1.16 2 0.56 
IL-1~ 0.93 2 0.63 
1.77 2 0.41 IL-10 
Table 5.3.4ii TNFA -857 
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5.3.4iii TNFA-376 
P valves as compared between two genotypes for each cytokine and stimulant. 
Homozygotes for the rarer genotype 2.2 were few and thus not possible to compare 
cytokine secretion by this allele. 
Whole blood secretion of IL-l ~ after stimulation with IFN -y and LAM differed between 
TNF A-376 genotypes (p=0.04) also secretion of IL-IO after stimulation with IFN-y and 
LPS differed between groups (p=0.03). Alleles of TNFA -376 were shown to influence 
LPS induced IL-IO secretion (p =0.06). Pre-incubation with IFN-y further enhanced the 
influence of these alleles (p = 0.03). 
Cytokines Stimulant X2 DF p-value 
TNF LAM 0.15 1 0.69 
IL-l~ 1.26 1 0.26 
II-I0 0.65 1 0.42 
TNF LAM&IFN-y 0.07 1 0.79 
IL-l~ 4.36 1 0.04 
IL-IO 1.8 1 0.18 
TNF LPS 1.62 1 0.2 
IL-l~ 1.46 1 0.23 
3.53 1 0.06 IL-I0 
TNF LPS&IFNy 0.8 1 0.37 
IL-l~ 2.55 1 0.11 
4.86 1 0.03 IL-I0 
Table 5.3.4iii TNFA-376 
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5.3.4iv TNF A -308 
None of the alleles of the TNFA-308 polymorphism influenced induced TNF and IL-I0 
responses significantly (Table 5.3.4iv). Alleles of TNFA-308 did marginally influence IL-
1 ~ levels induced when cells were pretreated with rIFNy before stimulation with LAM 
(0.07). 
Cytokines Stimulant X2 DF p-value 
TNF LAM 0.99 2 0.6 
IL-l~ 3.11 2 0.21 
11-10 1.56 2 0.45 
TNF LAM&IFN-y 0.53 2 0.77 
IL-l~ 5.32 2 0.07 
IL-I0 2.6 2 0.27 
TNF LPS 2.6 2 0.27 
IL-l~ 1.5 2 0.47 
IL-I0 0.03 2 0.98 
TNF LPS&IFNy 1.22 2 0.54 
IL-l~ 1.55 2 0.46 
0.83 2 0.66 IL-I0 
P valves obtained after comparing between the three genotypes for each cytokine and 
stimulant. 
Table 5.3.4iv TNFA-308 
Figures 5.7 and 5.8 illustrating cytokine levels between TNFA-308 genotypes are on 
pages 165 and 166. 
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5.3.4v TNF A -238 
p-valves as compared between three genotypes for each cytokine and stimulant whole 
blood secretion off IL-1 ~ after stimulation with IFN-y and LPS differed between TNF -
238 genotypes (p=0.05). 
Cytokines Stimulant X2 DF p-value 
TNF LAM 1.27 2 0.5 
IL-1~ 3.11 2 0.2 
11-10 5.35 2 0.06 
TNF LAM&IFN-y 3.07 2 0.22 
IL-1~ 3.72 2 0.16 
IL-10 2.11 2 0.35 
TNF LPS 4.45 2 0.11 
IL-1~ 3.62 2 0.16 
IL-10 3.93 2 0.14 
TNF LPS&IFNy 1.54 2 0.46 
IL-1~ 6.1 2 0.05 
2.54 2 0.28 IL-10 
Table 5.3.4v TNF A -238 
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5.3.4viia Lymphotoxin alpha (LTA) 
p-valves as compared between three genotypes for each cytokine and stimulant. 
Comparison was made between three genotypes. Whole blood secretion of TNF and IL-
1 ~ upon stimulation by either LPS or LAM differs significantly between genotypes. IL-
10 levels were not influenced by the genotypes of this polymorphism. 
Cytokines Stimulant X2 DF p-value 
TNF LAM 17.02 2 0.0002 
IL-l~ 5.75 2 0.05 
II-I0 4.08 2 0.13 
TNF LAM&IFN-y 11.8 2 0.003 
IL-1~ 5.4 2 0.07 
IL-I0 2.4 2 0.3 
TNF LPS 10.8 2 0.005 
IL-1~ 3.38 2 0.18 
IL-10 4.11 2 0.13 
TNF LPS&IFNy 9.46 2 0.009 
IL-l~ 2.75 2 0.25 
1.7 2 0.42 IL-10 
Table 5.3.4viia LTA 
161 
10000 -,-----------~ 
8000 
~ 6000 
u.Q. 
~ 4000 
2000 
O~----~------~----~~~ 
III 1/2 2/2 
LTA genotypes 
a)LTA NcoI genotypes and LAM 
induced TNF (p-value 0.0002) 
20000 ,-------
• 
• • 
* 
---------J ------1--------- ---I 111 112 2/2 
LTA genotypes 
b) LTA NcoI genotypes and LPS 
induced TNF (p-value 0.005) 
FIG. 5.5 LTA genotypes and TNF secretion 
Individuals were typed for the LTA polymorphism and divided into three groups 
according to their genotypes. III represents homozygous for the LTA 1 allele, 2/2 
represents homozygous for the LTA 2 allele and 112 represents heterozygotes. Cytokine 
responses to either a) LAM and b) LPS are shown in relation to host genotype. The p-
value compares the difference between the three genotypes in their ability to induce 
cytokine responses. 
Stimulant MEAN TNF by genotype 
III 1/2 2/2 
LAM 940 (n=24) 1345 (n=72) 623 (n=48) 
LAM+y 2062 2205 1124 
LPS 1037 (n=32) 1050 (n=115 680 (0=87) 
LPS+y 1892 2067 1457 
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FIG. 5.6 LTA genotypes and effect ofIFN-y on TNF 
TNF produced in response to either LAM or LPS after IFN -y enhancement plotted 
according to host genotype. Individuals were typed for the LTA polymorphism and 
divided into three groups according to their genotypes. 111 represents homozy gous for 
the TNFA allele, 2/2 represents homozygous for the TNFA 2 allele and 112 represents 
heterozygotes. Cytokine responses to either a) LAM and b) LPS are shown in relation to 
host genotype. 
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Secretion of these cytokines were generally higher in individuals with LTA 112 genotypes 
(p=0.0002 and p=0.05 for LAM induced TNF and IL 1 P). TNFP 112 genotype 
demonstrated higher levels for LPS induction of TNF than those with LTA 2/2 genotypes 
did. Priming with IFN-y, had no effect on either LAM or LPS induced secretion of the 
three cytokines. IL-I0 secretion between the three genotypes was not significantly 
affected by either of the stimulants. 
5.3.4viib LTA 
Because of the positive findings when genotypes of LTA were analysed (Table 5.3.4viia) 
comparisons were made between 111 and 2/2 homozygotes alone (Table 5.3.4viib). 
Whole blood secretion of TNF and IL-l P after stimulation with either LAM or LPS 
differed significantly between LTA genotypes. Secretion of these cytokines was generally 
higher in individuals with LTA 111 genotypes (p=0.0001 and p=0.02 for LAM induced 
TNF and ILIP). LTA 111 genotype demonstrated higher levels for LPS induction ofTNF 
than those with LTA 2/2 genotypes. 
Cytokines Stimulant X2 DF p-value 
TNF LAM 16.43 1 0.0001 
IL-IP 5.21 1 0.02 
II-I0 3.93 1 0.05 
TNF LAM&IFN-y 11.73 1 0.0006 
IL-IP 4.69 1 0.03 
2.37 1 0.12 IL-I0 
TNF LPS 10.4 1 0.001 
IL-IP 3.36 1 0.06 
4.09 1 0.04 IL-I0 
8.96 1 0.003 TNF LPS&IFNy 
2.7 1 0.1 IL-IP 
1.6 1 0.21 IL-I0 
Table 5.3.4viib LTA 
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FIG. 5.7 TNFA-308bp genotypes and IL-lf3 secretion. 
Figure 5.7 shows a scatter plot of TNFA -308 bp genotypes and IL-l 13 secretion. It 
demonstrates that the 2/2 homozy gotes are low producers, 112 heterozygotes are 
intermediate producers, and the 111 homozygotes are high producers of IL-l 13. 
However, due to the small number of2/2 homozygotes there is no significant 
difference between the groups. 
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Figure 5.8 shows the scatter plot of indices of IFN- y up-
regulation for both LPS and LAM induced IL-1 ~ production. 
The trend was similar to that observed when LPS or LAM alone 
was used as stimulant and IFN-y did not influence this trend. 
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P valves when compared between homozygote genotypes for each cytokine and 
stimulant. Priming with IFN-y, had no effect on either LAM or LPS induced secretion of 
the three cytokines. IL-I0 secretion between the three genotypes remained unaffected by 
either of the stimulants. 
5.3.5i Ddel/TT IFNGRI 
P valves as compared between three genotypes for each cytokine and stimulant. 
Homozygosity for this double deletion polymorphism is rare in the healthy population 
(0.01). This polymorphism is at the y activated site (GAS) in the promoter of IFNGR1. A 
murine monocyte-like cell-line WEHI-3 was shown to be incapable of utilising GAS 
element present in the promoter of any y inducible gene in response to IFNy. There was 
no particular trend in the ability of alleles of this deletion to induce cytokine responses 
Cytokines Stimulant Xl DF p-value 
TNF LAM 0.69 2 0.7 
IL-lf3 0.21 2 0.9 
II-I0 0.35 2 0.84 
TNF LAM&IFN-y 1.87 2 0.4 
IL-l f3 0.05 2 0.97 
IL-I0 1.52 2 0.47 
TNF LPS 2.31 2 0.32 
IL-l f3 1.35 2 0.5 
1.16 2 0.56 IL-I0 
LPS&IFNy 0.67 2 0.71 TNF 
2 0.48 IL-l f3 1.45 
0.99 2 0.61 IL-I0 
Table 5.3.5i Ddel/TT IFNGRI 
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In summary four SNPs were shown to influence cytokine responses. These were 
NRAMPI 469 polymorphism, ILIRN, TNFA-863, and LTA. IL-I0 production was 
influenced by NRAMP I 469 polymorphism after LAM stimulation and ILl RN 
polymorphism after stimulation with both LAM and LPS. TNF production was 
influenced by LTA polymorphism after both LPS and LAM stimulation. IL-l ~ levels 
were influenced by LTA polymorphism after LPS alone. TNFA -863 genotypes influenced 
LPS induced TNF. This study showed that allelic variants of two genes (TNFA-863 and 
LTA), that encode pro inflammatory molecules influence pro inflammatory cytokine 
responses (TNF and or IL-l ~) whereas, allelic variant of genes that encode anti 
inflammatory molecules (ILl RN and NRAMP I ) influence anti inflammatory cytokine 
responses (IL-I0). Table 5.4 below summaries these findings. An explanation for this 
may be that because TNF A and LTA are encoded on the short arm of chromosome six and 
alleles of both genes that are in linkage disequilibrium are influencing the same 
cytokines. Indeed, haplotype analysis of the TNF -region in table 6.3.5 reveals linkage 
disequilibrium between alleles of the TNFA -863 and LTA. The allele 2 (G) from previous 
studies and allele 1 of this study is in linkage disequilibrium with allele 1 (C) of the 
TNF A -863 polymorphism. Haplotype 4 consists of these variants and they are more in 
controls than cases. (Table 6.3.5) Interestingly, alleles of both genes were shown to be 
influencing measured TNF levels. 
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Table 5.4 SUMMARIES OF CANDIDATE GENES SHOWN TO INFLUENCE 
MICROBIAL INDUCED RESPONSES . 
MARKER STIMULANT G OBS A.SUM CYTOKINE X2 D.F 
NRAMPl LAM 1.1 112 67.2 IL-10 7.13 1 
(469+ 14) 1.2 15 40 
LAM+IFN 1.1 112 66.8 IL-10 5.48 1 
1.2 15 43.1 
LTA LAM 1.1 17 72.4 TNF 17.0 2 
1.2 72 80.7 
2.2 48 50.3 
LAM 1.1 18 66.6 IL-1P 5.75 2 
1.2 69 74.1 
2.2 46 56.5 
LAM+IFN 1.1 18 75.6 TNF 11.8 2 
1.2 72 78.6 
2.2 48 53.5 
LAM+IFN 1.1 18 65.9 IL-1P 5.4 2 
1.2 70 74.5 
2.2 46 57.4 
LPS 1.1 36 143. TNFa 10.8 2 
1.2 124 135 
2.2 90 106 
LPS+IFN 1.1 36 144 TNF 9.46 2 
1.2 124 134 
2.2 91 109 
TNFA-863 LPS 1.1 230 132 TNF 7.7 2 
1.2 26 128 
2.2 3 11 
LPS+IFN 1.1 231 131 TNF 6.2 2 
1.2 26 136 
2.2 3 24 
IL1RN LAM 1.1 111 59.9 IL-10 3.59 1 
1.2 12 80.5 
LPS 1.1 111 95.1 IL-10 12.1 2 
2.2 1 21.5 
1.2 15 144 
LPS+IFN 1.1 180 95 IL-10 19.5 2 
2.2 1 53 
1.2 15 142 
Table 5.4 shows only the markers, which genotypes differ in their ability to regulate 
quantitative cytokine measurements. G represents the genotype at a given locus. OBS 
represents numbers of observations per genotype for each marker. A.SUM is the average-
ranksum and this is the ratio of rank sum and number of observations. The frequency of 
ILIRN2.2 homozygotes was low. 
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p-value 
0.0076 
0.019 
0.0002 
0.05 
0.003 
0.067 
0.005 
0.009 
0.02 
0.04 
0.05 
0.002 
0.005 
5.4 DISCUSSION 
Several single nucleotide polymorphisms SNPs have been analysed along with 
micro satellite markers. Most of the polymorphism shown to be influencing induced 
cytokine production in this study were SNPs that have been reported to have biological 
function. A single base change in DNA sequence can greatly increase or decrease binding 
of a particular transcription factor and affect protein production, (Knight et al., 1999, 
Wilson et al., 1997) whereas micro satellites are tandem repeats without any proven 
biological function. The tables for the micro satellite data are in appendix 5. 
From results obtained it is easy to speculate that the LTA Nco! polymorphism may 
represent a functionally relevant gene variation. However, it is difficult to associate 
intronic polymorphisms with possible functional relevance. The TNFB *1 allele possesses 
a triplet variation coding for asparagine at amino acid position 26, whereas the TNFB * 2 
allele has threonine at this position from previous workers (Messer et al., 1991). This 
study reports the allele 1 from this study (10.5kb fragment) or TNFB*2 homozygotes 
(from previous work) were associated with higher TNF production upon stimulation of 
whole blood system with LPS and LAM. In contrast, an earlier in-vitro study using PBL 
stimulated with PHA demonstrated higher TNFB and not TNFa levels in TNFB* 1 
homozygotes when compared with the TNFB*2 homozygotes (Messer et al., 1991). 
Studies by both Stuber et al., 1999 and Pociot and co workers (1993) found TNFB*2 the 
equivalent of allele 1 of this study to be associated with high TNF. This study also 
demonstrates lower IL-1 B levels upon LAM stimulation of whole blood in TNFB * 1 
homozygotes or allele 2. TNF levels were 25% higher in the TNFB* 1 homozygotes than 
the TNFB*2 homozygotes judged by average ranksum. The average ranksum was 72.4 
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for the TNFB*l homozygote while TNFB*2 homozygote was 50.3. In addition, IL-1~ 
levels were generally 15 % higher in the TNFB * 1 homozygotes. The average ranksum for 
the TNFB*l homozygote was shown to be 66.6 while TNFB*2 homozygote was 56.6. IL-
10 levels were not affected by the LTA genotypes upon stimulation with either of the 
stimulants. 
It may be that this marker is closely linked to another as yet undetected genomic 
variations. A new gene BAT1 has been cloned within the TNF gene cluster. There are 
indications that this gene is functionally important (Patricia Price unpublished). 
Genotype 2/2 of ILl RN is reported to be functionally relevant and has been shown to 
induce higher levels of ILl RN. Induction of IL-1 0 an anti-inflammatory cytokine differed 
significantly between IL1RN genotypes in this study. 
This study shows that the NRAMP 1 469 + 14 G/C variant influence LAM induced IL-1 0 
secretion. An in-vitro study using reporter gene constructs had showed that alleles of the 
NRAMP 1 CA repeat differ in their ability to drive gene expression. This study does not 
show any difference in the ability of the alleles of that polymorphism to influence 
cytokine production using the wholeblood model. Rather, it is the NRAMP 1 intron 4 
variant that was shown to be in linkage disequilibrium with the NRAMP 1 promoter allele 
2 that was shown to be influencing IL-1 0 secretion. 
This study was unable to demonstrate any influence of genotypes of the following 
macrophage candidate genes on microbial induced cytokine levels using the whole blood 
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model: - NRAMP1 Z-DNA polymorphisms, NRAMP1 274 CIT, fL9, D17S250, IFNGR1, 
fL1B -511, fL1B +3953, TNFa, TNFA-308, TNFA -857 and ddelTT fFNGRl-470/471. 
In conclusion, homozygotes for the TNFB*2 allele 1 (G variant) differed in their ability 
to influence induced cytokine secretion by LPS and LAM. LPS and LAM induced TNF 
and IL-113 was significantly affected by LAM in these individuals. Priming with IFN-y 
did not enhance this effect. The significant difference in the ability of alleles of this gene 
to influence pro inflammtory cytokine secretion was more pronounced for TNF, followed 
by IL-113. Secretion of IL-l 0 was not affected. In addition, alleles of NRAMP 1 (469+ 14 
G/C) transversion influenced LAM induced IL-l 0 secretion. This polymorphism was also 
significantly associated with TB in this population from a previous study (Bellamy et al., 
1998b). Allele 2 of this gene is in linkage disequilibrium with allele 2 of the NRAMP 1 
CA Z-DNA polymorphisms previously shown to be poor at driving gene expression after 
LPS stimulation (Searle and Blackwell 1999). Alleles of anti-inflammatory lL-RA 
influenced both LAM and LPS induced anti-inflammatory lL-10 levels. lL-10 has been 
reported to induce higher levels of lL-l RA in people with either one or two copies of 
fL1 RN allele 2 (Wilkinson et al., 1999). 
Differential regulation of genes in response to stimuli such as LAM or LPS may suggest 
unique roles for these stimulants during disease conditions. In chapter six the roles of 
particular alleles of these genes shown to be influencing cytokine induction was 
investigated for possible association with in disease trait TB. 
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CHAPTER 6 
CASE CONTROL STUDY OF MACROPHAGE CANDIDATE 
GENES 
6.1 Introduction 
Immune responses to TB, being a complex disease, do not follow simple Mendelian 
monogenic inheritance patterns. Several genes are likely to be involved in the 
aetiology of disease. The innate mechanism is the first line of defence against 
mycobacteria and a central immunological requirement for a protective Immune 
response in mycobacterial infections is the activation of macrophages for anti 
microbial activity and for the processing and presentation of mycobacterial antigens 
to specific T cells. Genes that influence macrophage activation, or are involved in the 
macrophage cascade are therefore good candidates for disease susceptibility to TB. 
Macrophage candidate gene selection in this study has been based on what is known 
from animal studies and human macrophage responses to mycobacterial infection. 
Published polymorphisms, having biological and functional relevance to macrophage 
activation have been selected. (Table 5.1). 
I - + 
Table 6.1 Macrophage candidate genes and relevance to TB. 
Chromosome re~ion Relevance to TB Reference 
Iq31-q32 (ILIO) IL-I0 is a macrophage deactivator. IL-I0 Murray and Young, 
knockout mice exhibited increased 1999. 
antimycobacterial immunity. 
IL-I0 suppresses immune responses in Boussiotis et a/., 2000 
anergic TB patients. 
Higher IL-l 0 levels in recovered TB cases. Chapter 3, table 3.5.1 & 
3.5.1 
2q35 NRAMPI 1 sl single gene shown to control initial M Vidal et a/., 1995 
bovis infection in mice. NRAMPI promoter Searle & Blackwell, 
CA repeat: -allele 3 protects against 1999 
infectious diseases whereas allele 2 protects Bellamy et a/., 1998b 
against autoimmunity. 
2q 14 (ILIB, ILIRN) IL-IRA is anti-inflammatory cytokine while Dinarello, 1996 
IL-l ~ is pro inflammatory. Allele 2 of the Bellamy et a/., 1998d 
86bp VNTR is marginally associated TB in 
West Africans. 
5q23-q32 Tuberculin responses were inversely related Shirikawa et a/., 1997 
IL4 andIL9 to atopy. IL-9 and IL-4 are linked to high Doull et al., 1996 
total serum IgE levels. High total serum Erb et al., 1998 
levels are hallmarks of asthma and atopy. 
In animal models, mycobacterial exposure 
prevents atopy. 
6p21.3 HLA class III TNF-308 A associated with lepromatous Roy et al., 1997 
TNFA andLTA leprosy. TNF-376 OCT-l binding genotype Knight et a/., 1999 
is found in 5% Africans with a 4-fold risk of McGuire et al., 1994 
increased susceptibility to cerebral malaria. McGuire et a/., 1999 
TNF-238A is clinically associated with Cabrera et al., 1995 
severe anaemic malaria. TNF-308 A is 
clinically associated with increased 
susceptibility to cerebral malaria and 
mucocutaenous leishmaniasis. 
6q23-24 (IFNGRI) 1 sl gene with fatal mutations shown to cause Newport et a/., 1996 
susceptibility to atypical mycobacterial Jouanguy et a/., 1996 
infection in man. 
12q24 1 (IFNG) IFN-y is a potent macrophage activator. It is Flynn et al., 1993 
a Thl cytokine and beneficial in TB. Cooper et a/., 1993 
Disseminated tuberculosis in IFN-y gene 
disrupted mice. Ottenhoff et al., 1998 Strong IFNy response to mycobacteria is 
present in people that contain infection but 
there is a blunted response in those with 
active disease. 
17ql1.2-qI2 iNOS catalyses the production of free radical MacMicking et al., 1997 
NOS2A NO. NO works with TNF in an autocrine 
SCYA manner for enhanced killing of mycobacteria 
in murine macrophages. 
D 17S250 marker is located closely to the 
genes that encode the small inducible 
chemokines. 
A locus on human chromosome 17 linked to Lim, 2000 
TB in a family based genomic screening 
175 
6.1.1 Interleukin 10 (ILlO) 
IL-I0 plays an important role in the development of infectious disease. It was shown 
to affect macrophage responses during mycobacterial infections (Flesch et al., 1994). 
Whole blood studies of monocyte function in chapter 3 show that recovered TB cases 
have higher levels of IL-l 0 when compared with these who had no disease (Table 
3.5.1 & 3.5.2). High levels of IL-I0 produced by T cells were associated with 
suppressed immune responses in anergic TB patients (Boussiotis et al., 2000). High 
serum IL-I0 levels in meningococcal sepsis was associated with poor or fatal 
outcome whereas the opposite was seen in patients with mild disease and good 
prognosis (Derkx et al., 1995). Three different single nucleotide polymorphisms have 
been described in the lL10 gene at nucleotide positions -1082, -819 and -592 (Turner 
et al., 1997). In addition, two micro satellite repeats one 5' proximal at -1064bps of 
the TATA box (Eskdale & Gallagher, 1995) and another 5' distal (Eskdale et aI., 
1996) to the initiation codon were reported. Genetic analysis of the human IL10 
promoter region placed the proximal dinucleotide repeat in a portion of the 5' 
untranslated region as defined by diminishing promoter function. (Kube et aI., 1995). 
This dinucleotide repeat has been associated with systemic lupus erythematosus 
(Eskdale et al., 1997). The proximal IL10 repeat was typed for allelic association with 
TB (Eskdale & Gallagher, 1995). 
6.1.2 Natural resistance associated macrophage protein 1 (NRAMPl) 
NRAMP 1 is the human homologue of NrampJ , a gene originally identified as Ity/ 
Lsh/Bcg for its role in controlling Salmonella typhimurium, Leishmania donovani, 
Mycobacterium bovis infection in mice (Vidal et aI., 1995). Nramp 1 is a metal ion 
transporter regulating and regulated by cellular iron levels (Searle and Blackwell, 
1999). The precise mechanism of antimicrobial activity of NRAMPI is still unclear. 
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However, in-vitro study of a functional NRAMP 1 5' promoter polymorphism suggests 
that allele 3 may protect against infectious disease and allele 2 against autoimmune 
disease (Searle and Blackwell, 1999). Also,' independent case control association 
(Gambian and Brazilian) studies demonstrated significant association between allele 
2 and susceptibility to tuberculosis (Bellamy at aI., 1998, Blackwell et al., 1997). 
Allele 3 of this polymorphism has been associated with rheumatoid arthritis (Shaw et 
al., 1996), juvenile rheumatoid arthritis (Sanjeevi et al., 1999) and in diabetes patients 
with a first or second degree relative with rheumatoid arthritis (Esposito et al., 1998). 
Four NRAMP 1 polymorphisms were typed. They are the functional promoter 
polymorphism containing the Z-DNA t (gt) 5ac(gt) 5ac(gt) ng or t (gt) 5ac(gt) ng 
repeats in the immediate 5' of the gene (Searle and Blackwell, 1999), a single 
nucleotide transition of C to T at nucleotide position 274 in codon 66 (Liu et al., 
1995), a single nucleotide transversion of G to C in intron 4 (Liu et al., 1995), and 
another single nucleotide transition of G to A in intron 13 (Liu et al., 1995). 
6.1.3 Interleukin-l beta (IL1B) & Interleukin-l receptor antagonist (IL-1RN) 
Interleukin-l J3 is involved in regulation of immunological and inflammatory reactions 
and has been implicated as a mediator of tissue destruction (Dinarello, 1991). IL-l J3 
exerts its effects by interaction with the IL-l receptor (IL-IR) and is antagonised by 
IL-IRA. The IL-la, IL-IJ3, IL-IRA and IL-IR genes are located on a cluster on 
chromosome 2q (Steinkasserer et al., 1992, Nicklin et al., 1994). Intron 2 ofIL-1RA 
contains a minisatellite (Tarlow et al., 1993). IL-l J3 contains a single base transition 
at position -511 (Di Giovine et al., 1992) and another at +3953 in exon 5 (Pociot et 
al., 1992). The IL-IRA mini satellite is a pentallelic 86bp repeat sequence and allele 
two contains a potential transcription factor binding site for IFN-silencer A and IFN-
silencer B (Tarlow et al., 1993, Blakemore et al., 1994). The pro-inflammatory 
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haplotype 1L1RN A2- / 1L1B +3953 Al+ is reported to be more common in patients 
with pleural tuberculosis and less common in patients with extrapulmonary disease. 
In addition, this haplotype is associated with reduced Mantoux response (Wilkinson 
et al., 1999). These observations suggest that the ILl RN 2 allele is biologically 
relevant in TB. The 1L1B -511 and +3953 polymorphisms were genotyped. The 
ILl RN 86 bp minisatellite was genotyped. 
6.1.4 Th2 Cytokine cluster 
Mycobacterial antigens such as purified protein derivatives of tuberculin (PPD) 
induce a Thl response, whereas parasite antigens such as Toxocara excretory 
substances induce a Th2 response (Del Prete et al., 1991). Th2 response is deleterious 
for TB; even a small Th2 component exacerbates the infection in mice (Rook & 
Hernandez-Pando, 1996). Given that Th2 cytokines inhibit Thl response, individuals 
mounting prominent Th2 responses may be more susceptible to M tuberculosis. It 
may be that Th2 immune dominance induced by intestinal parasites enhances 
susceptibility to tuberculosis (Bentwich et aI., 1999). Two genes within this cytokine 
cluster were typed for allelic association with TB. These are 1L4 and 1L9 (Marsh et 
al., 1994). Two polymorphisms were genotyped in 1L4, the intron 2, 70bp repeat and 
the intron 3 micro satellite GT repeat (Mout et aI., 1991). For 1L9, a microsatellite 
repeat in intron 4 (Polymeropoulou et al., 1991) was genotyped. Polymorphism in 1L9 
was reported to be associated with serum Ig E levels (Doull et al., 1996). The 70bp 
VNTR in 1L4 intron 2 has been associated with multiple sclerosis (Vandenbroeck et 
al., 1997) but was not associated with myasthenia gravis (Huang et aI., 1998). There 
are reports of associations of allelic forms with bronchial hyper responsiveness in 
mice (Nicolaides et aI., 1997) and one report of an allelic association of allele 118 of 
the human IL-9 microsatellite and atopic condition (Doull et aI., 1996). 
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6.1.5 Tumour necrosis factor (TNFA) 
TNF plays a major role in killing intracellular pathogens and much of the pathology 
of tuberculosis, including fever and weight loss is mediated via TNF. TNF 
concentration in different forms of malaria has been reported to correlate with disease 
severity (Kwiatkowski et al., 1990). Thus, the amount of TNF produced may be 
critical in determining the outcome following infection with mycobacteria (Tracey, 
1995). The TNF A gene is located in the MHC class III region and is polymorphic 
(Nedospasov et al., 1991). Despite, contrasting in-vitro experimental observations on 
the functional importance of TNF A promoter polymorphisms on gene transcription 
there are increasing reports of TNF A allelic association with clinical diseases. The 
, 
TNFA-238 polymorphism has been associated with severe malarial anaemia (Mc 
Guire et al., 1999), chronic hepatitis B (Hohler et al., 1998a), chronic active hepatitis 
C (Hohler et al., 1998b) and psoriasis (Kaluza et al., 2000). There are no associations 
with, scarring trachoma (Conway et al., 1997) and early onset psoriasis (Jacob et ai., 
1999). The TNFA -308 polymorphism has been associated with cerebral malaria 
(McGuire et al., 1994), rheumatoid arthritis (Vinasco et al., 1997), mucocutaneous 
leishmaniaisis (Cabrera et al., 1995) scarring trachoma (Conway et al., 1997) 
lepromatous leprosy (Roy et al., 1997) and both forms of leprosy (Blackwell 
unpublished). Five TNFA promoter polymorphisms described at positions -238, 
(D' Alfonso & Riciardi, 1994), -308 (Wilson et al., 1993), -376 (Hamann et ai., 1995), 
-857 and -863 (U glialoro et al., 1998) within the promoter of the TNFA gene were 
genotyped in this study. were genotyped. In addition an Neol polymorphism in intron 
2 of the lymphotoxin gene was genotyped. 
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6.1.6 Interferon gamma receptor alpha (IFNGR1) 
A micro satellite FAI within intron six of the IFNGRl gene was genetically mapped 
between the microsatellites D6S292 and D6S 1699 (Altare et al., 1998b). Intra-
familial genotyping of an affected child was shown to have a unique pattern for FA 1 
when compared with her other four healthy siblings suggesting an autosomal 
recessive IFNyRl deficiency (Altare et al., 1998b). It was determined if particular 
alleles of this F AI repeat are associated with TB in our Gambian samples. In addition, 
the newly detected promoter deletion polymorphism at -470/471 of the IFNGRl was 
genotyped (section 4.3.3). 
6.1.7 Interferon gamma (IFNG) 
Interferon gamma is a Thl cytokine with pleiotropic effects and has a beneficial role 
in immune responses to tuberculosis. Individuals with strong IFN-y response to 
mycobacteria are able to efficiently contain the infection whereas those individuals 
with active disease have blunted response (Ottenhoff et al., 1998). The intron 1 CA 
repeat has been associated with renal transplant rejection (Asderakis et al., 1998) and 
lung allograft fibrosis (Awad et al., 1998). Increased frequency of allele 5 and 
decreased frequency of allele 2 has been associated with Grave's disease (Siegmund 
et al., 1993). This intron 1 CA repeat was genotyped for allelic association with TB in 
this study. 
6.1.8 Inducible nitric oxide synthase (NOS2A) and small inducible chemokines 
The gene that encodes the human iNOS (NOS2A) in maps to chromosome 17ql1.2-
q12 (Marsden et al., 1994). From mice studies there is compelling evidence from both 
in vitro and in vivo studies that macrophages can kill various mycobacterial species 
including M tuberculosis through NO dependent pathway (MacMicking et al., 1997). 
In humans, the role of NO generated by the induction of nitric oxide synthase in the 
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killing of M tuberculosis is controversial. Nicholson et aI., (1996) observed that 
pulmonary alveolar macrophages from patients with tuberculosis express inducible 
nitric oxide synthase (NOS2A) but thus far, there has been no evidence that human 
macrophages utilise NO to kill M tuberculosis, although killing of other 
mycobacterial species has been described. Perhaps, the only data linking a role for 
NO generated by iNOS in TB is that reported by Rockett et aI., (1998). It was 
demonstrated that 1,25-D3 acts to suppress the growth of M tuberculosis in a 
macrophage-like HL-60 line, through a NO dependent mechanism. Several 
polymorphisms have been described within the promoter of human NOS2A gene. 
These include a bi- allelic AAAT/AAAAT repeat element that occurs at frequencies 
of 0.84 and 0.16 among West Africans (Bellamy and Hill, 1997), and ten single 
nucleotide polymorphisms spanning about 2.5kb, 5'of the initiation codon (Burgner, 
1999). A promoter polymorphism was weakly associated with severe malaria in 
Gabon (Kun et al., 1998). I have analysed the allelic distribution of a functional 
polymorphic pentanucleotide repeat (CCTTT)n within the 2.5kb 5' upstream 
promoter region of the NOS2A gene in this study (Xu et aI., 1996.). Also, on the same 
chromosome, the microsatellite marker D17S250 (Weber et aI., 1990) linked to the 
small inducible cytokine gene cluster have been selected and typed in this study. 
D 17S250 is in close proximity to the small inducible chemokine genes. 
6.2 Genotyping of macrophage candidate genes 
Genomic DNA was extracted from venous blood as described in chapter two from 
three hundred and twelve subjects studied in chapter 3 and 5 and two hundred and 
seventy-six TB cases. This was used as template for the peR based methods as 
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described in 5.2. The polymorphisms typed are the same as chapter 5 with the 
exception of a RFLP in lL9. 
6.2.1 RFLP in IL9 
A RFLP in exon 5 of the lL9 gene results in an amino acid substitution of methionine 
for threonine at codon 113 because of the nucleotide substitution of thymine for 
cytosine (Laitinen et al.,1997). The primers 5' ACT CTG GCT CTT GGC AGG TA 
3' and 5' CCT ATG AGC CTG AGG GTC TG 3' were used to amplify exon 5 of the 
gene, which is 462 bp long. The polymorphism creates an Ncol site and this enzyme 
cuts the PCR fragment to 141 + 321 bp (variant allele). The PCR buffer number 1 
(appendix 1) was used. The PCR conditions were 96° C denaturation for 5 minutes, 
followed by 30 cycles of another denaturation at 96° C for 30 seconds, then annealing 
at 65° C for 30seconds, elongation at 72°C for 30 seconds and a final extension for 5 
minutes at 72°C. A mixture of IJlI of enzyme buffer and 0.5/-!1 (5 units) of Ncol was 
added to 8.5JlI of PCR product and digested for 6 hours at 37 degrees. The digested 
product was run on a 1 % agarose gel containing ethidium bromide and visualised 
with UV light and photograph. 
6.2.2 Data analysis 
To address the problem of multiple testing, the Bonferroni adjustment was done and 
this involves assigning a cut-off based on the formula below. The cut off was done 
only when x2test gave a significant p-value of= / < 0.05 for influence alleles on TB. 
Bonferroni cut off = 0.05 / n 
where 0.05 is an alpha level of 5% and n = number of alleles. If the observed p-value 
falls below this cut-off then the association is accepted as truly significant. 
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462bp -+ 
321 bp ~ 
141 bp~ 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
FIG. 6.1 Analysis of IL9 Tl13M polymorphism 
Figure 6.1 shows a RFLP of the lL9 SNP at amino acid positi on 113 in exon 5, a 
substitution of threonine for methionine. The expected peR product is 462 bp with an 
Ncol digestion site that gives 141 bp and 321 bp. Homozygote for allele 1 should have 
only the 321 bp and the 141 bp. Heterozygote should have all three bands. 
Lane 18 is the molecular weight marker. lane 17 is a negati ve control, lanes 1, 2, 3, 5 
& 6 are homozygotes for allele 2 , lane 4 is a homozygote for allele 1, and lanes 7 and 
12 are heterozygotes. 
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6.3 Results: Influence of candidate genes on TB 
Results were reported according to chromosome locations of markers studied and not 
in order of importance or significant association with TB. The allele number is 
represented in the first column followed by the number of controls and cases per 
alleles, the figure in parentheses are allele frequencies for a given allele. 
6.3.1 ILl 0 
The ILlO proximal promoter repeat was genotyped. Eleven alleles were observed but 
allele one was not observed in the panel studied. There was no significant difference 
in ILl 0 microsatellite alleles between controls and cases. 
ALLELES CONTROLS CASES 
1 0 0 
2 4 (0.007) 2 (0.003) 
3 32 (0.003) 5 (0.008) 
4 36 (0.059) 50 (0.075) 
5 52 (0.085) 72 (0.108) 
6 178 (0.29) 177 (0.266) 
7 100 (0.164) 93 (0.139) 
8 122 (0.2) 115 (0.173) 
9 47 (0.079) 79 (0.119) 
10 48 (0.079) 44 (0.066) 
11 19 (0.031) 27 (0.04) 
12 2 (0.003) 2 (0.003) 
Total 610 666 
Chi square X2 15.18 DF 10 p-value 0.125 NS Heterozygoslty=0.819. 
Table 6.3 Ii ILl 0 
6.3.2i NRAMP 1 5' promoter repeats 
All four reported alleles of the Z- DNA polymorphisms described were observed in 
this population. Analysis was done by both genotype-wise and allele wise method. 
Seven genotypes were observed. The homozygote 2/2 occurred more in cases but was 
not significantly different from the control (p=0.6). The frequency of this genotype 
was low at 0.026 in controls and its effect on TB was not obvious. The frequency of 
heterozygote 2/3 was moderately different between the two groups (p=0.06). The 
184 
homozygote 3/3 occurred more in controls and was significantly different between 
the two groups (p=0.01). Other alleles occurred at very low frequency to allow for 
any statistical analysis. Based on allele-wise method, allele two was observed more in 
cases and differed significantly in frequency from controls (p=0.03). Allele 3 was 
significantly more frequent in controls than in cases (p=0.01). Using allele wise 
method there was an overall significant difference between alleles (X2 10.36, DF2, 
p=0.016), which was not significant after Bonferroni adjustment (0.0125). 
GENOTYPE CONTROLS CASES X2 p-value Odds ratio 
1:1 0(0) 1 (0.004) 
1:2 1 (0.004) 0(0) 
1:3 14 (0.04) 11 (0.046) 
2:2 8 (0.026) 17 (0.06) 0.48 0.49 1.54 
2:3 68 (0.22) 81 (0.29) 3.98 0.046 1.38 
3:3 221 (0.71) 171 (0.6) 6.29 0.01 1.57 
4:4 0(0) 1 
Total 312 282 
Chi square X2 8.8 DF 5 p-value 0.1 NS Heterozygoslty=0.277 
Table 6.3.2ia NRAMPI 5' promoter repeats by genotypes 
ALLELES CONTROLS CASES Xl. p-value Odds ratio 
1 15 (0.02) 19 (0.03) 0.71 0.4 0.7 
2 88 (0.14) 104 (0.184) 4.68 0.03 0.7 
3 524 (0.84) 439 (0.783) 6.06 0.01 1.46 
4 0(0) 2 (0.003) 
Total 624 564 
Chi square X2 10.36 DF 3 and p-valve 0.016 
Table 6.3.2ib NRAMP 1 5' promoter repeats by alleles 
ALLELES CONTROLS CASES x2 p-value Odds ratio 
3:3 221 (0.71) 170 (0.61) 6.29 0.012 0.64 
3:X 82 (0.26) 98 (0.35) 4.9 0.026 1.51. 
X:X 9 (0.03) 12 (0.04) 0.49 0.49 1.51 
Total 312 280 
Chi-square X2 6.79 DF 2 p-value 0.03 
Table 6.3.2ic NRAMP 1 5' promoter repeats by contribution of allele 3 
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6.3.2ii NRAMPl (274 crr) 
For the NRAMP 1 274 C to T transition polymorphism, the frequency of alleles did 
not differ significantly between controls and cases. 
GENOTYPE CONTROLS CASES ALLELE CONTROLS CASES 
1:1 (TT) 5 (0.02) 5(0.03) 1 (T) 92 (0.16) 66(0.18) 
1:2 (TC) 82(0.29) 56(0.3) 2 (C) 478 (0.84) 312(0.82) 
2:2 (CC) 198(0.69) 128(0.67) 
Total 285 189 Total 570 378 
2 Chi square by genotypesx 0.51 DF 2 p-value 0.77, Chi square by alleles X2 1.1, DF 1 p-value 0.3, 
Odds ratio 1.1, NS Heterozygosity=0.268 
Table 6.3.2ii NRAMPl (274 crr) by genotypes and alleles 
6.3.2iiiNRAMP 1 (469+ 14G/C) 
The distribution of alleles of the NRAMP 1 469+ 14 G to C transversion differed 
significantly. The homozygotes mutant condition was not observed. The frequency of 
the heterozygotes was more in the controls (0.35) than in the cases (0.16). This 
contrasts with an earlier study of TB cases and controls in The Gambia. That study 
observed that the frequency of the heterozygous was more in cases than controls 
(Bellamy et aI., 1998b). There are several similarities between the Bellamy study and 
this one; the studies are case control association studies of active TB cases, samples 
are from the same population, and both studies were corrected for ethnic admixture 
by stratification using the Mantel Haenzel test (M-H). B. The only differences are in 
the sample sizes, which is much larger in the Bellamy study and the use of dot blot 
hybridisation method versus RFLP. In any case it may be that this polymorphism 
though within an intron may represent truly functional gene polymorphism. This 
study also shows that alleles of this variant influence LAM induced IL-1 0 
significantly (Table 5.4). 
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GENOTYPE CONTROLS CASES ALLELE CONTROLS CASES 
1:1 (GG) 178 (0.65) 141 (0.84) 1 (G) 453 (0.82) 309 (0.92) 
1:2 (GC) 97 (0.35) 27 (0.16) 2 (C) 97 (0.18) 27 (0.08) 
2:2 (CC) 0(0) 0(0) 
Total 275 168 Total 550 336 
2 ChI-square by genotypes X 19.94 DF 2 p-value 0.000013, ChI square by l 15.93 DF 1 p-value 
0.00006 Odds Ratio 2.5 NS Hetrozygosity=0.113. 
Table 6.3.2iii NRAMP (469+G/C) by genotypes and alleles 
NRAMPl (1465-85G/A) 
The distribution of alleles for the intron 13 transition of 1465-85 G to A transition did 
not differ significantly between the two groups. 
The distribution of alleles were the same in both controls and cases. 
GENOTYPE CONTROLS CASES ALLELE CONTROLS CASES 
1:1 (AA) 45 (0.16) 38 (0.18) 1 (AA) 311 (0.57) 236(0.57) 
1:2 (AG) 221 (0.81) 160 (0.78) 2 (GG) 237 (0.43) 170(0.43) 
2:2 (GG) 8 (0.03) 8 (0.04) 
Total 273 206 Total 548 412 
Chi-square by genotypes X2 0.74 DF 2 p-value 0.69, ChI square by alleles X2 0.03 DF 1 P - value 0.92. 
Odds ratio 1.02 NS Heterozygosity=0.49. 
Table 6.3.2iv NRAMPl (1465-85G/A) by genotypes and alleles. 
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6.3.2v Haplotype analysis of NRAMPl polymorphisms 
Haplotyping enhances the power of a study to detect an association, as functional 
alleles are likely to be in linkage disequilibrium with polymorphic markers typed. 
Unless molecular haplotyping methods are used, linkage phase is not known for 
individuals in a case control study. However, phase may be inferred using a 
likelihood approach based on the allele frequencies at each locus tested to compile the 
haplotype. Dr Frank Dudbridge has developed a computer programme which 
calculates haplotype frequencies within a population. This programme was used to 
analyse data for 3 NRAMP 1 polymorphisms and 1L9 polymorphisms (see section 
6.3.4). Haplotypes were recorded in the following order: The NRAMP1 (CA Z DNA 
polymorphism) NRAMP 1 274 CIT and lastly the NRAMP 11465 G/A variant. 
Haplotype Controls Cases 
3-2-1 0.38 0.29 
3-2-2 0.38 0.31 
2-2-1 0.05 0.16* 
3-1-1 0.05 0.09 
2-1-1 0.06 2.55e-ll 
2-2-2 0.02 0.045 
1-2-1 1.3e-7 0.01 
1-1-1 0.07 0.01 
3-1-2 0.02 0.07 
2-1-2 6.5e-7 3.4e-l0 
1-2-2 0.003 1.1e-4 
4-2-1 0 0.003 
4-2-2 0 0.003 
1-1-2 0.0001 1.ge-12 
Ch ' 261 3 DF 15 p=1 5e-7 * - Haplotype 2-2-1 occurs more in cases than in controls. I-square. X· . 
Table 6.3.2v Haplotype analysis of NRAMPl variants 
188 
6.3.3i IL1RN 
Four alleles were observed and the band sizes are listed in appendix 2. ILl RN allele 
frequencies were not significantly different between cases and controls (Xl 5.05 DF 3, 
p=O .16). Allele 2 had been associated with increased levels of IL-1 RA and increased 
risk of autoimmune diseases (Mansfield et aI., 1994, Clay et aI., 1994, and Blakemore 
et al., 1994, 1995). The frequency of allele 2 differed between groups but was not 
statistically significant as the numbers were low, being more frequent in controls 
(0.04) than cases (0.024). Alleles 3 and 4 were observed at too Iowa frequency in this 
population to allow for any significant testing. There was no significant difference in 
the overall frequency. 
GENOTYPES CONTROLS CASES ALLELES CONTROLS CASES 
1:1 209 (0.88) 162 (0.89) 1 447 (0.94) 343 (0.95) 
1:2 17 (0.07) 9 (0.05) 2 17 (0.04) 9 (0.024) 
1:3 0(0) 3 (0.02) 3 0(0) 3 (0.007) 
1:4 12 (0.05) 7 (0.04) 4 12 (0.02) 7 (0.019) 
Total 238 181 Total 476 362 
Chi square result for allele frequency is X2 5.05 DF 3 p-value 0.16 NS. HeterozygosIty =0.l2 
Table 6.3.3i IL1RN 
6.3.3ii IL1B -511 
Distribution of alleles of the ILlB -511 differed significantly between the two groups 
(p-value=0.002). The homozygote for the wild-type genotype (0.365) was twice as 
frequent as the homozygote mutant genotype (0.185) in TB cases whereas in the 
controls homozygous wild-type (0.24) and mutant (0.25) distribution was even. The 
mutant allele was less frequently seen in TB cases (0.41) than in controls (0.51). 
The frequency of the wild type allele (T) in cases is 0.59 while the frequency of 
mutant allele (C) in cases is 0.41. This study shows that this polymorphism is 
significantly associated with TB in this population (genotype p-value=O.00-l5 and 
allele p-value 0.002). 
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GENOTYPE CONTROLS CASES X2 p-value Odds 
ratio 
1.1 TT 67 (0.24) 85 (0.365) 10.7 0.001 1.93 
1.2 TC 146 (0.51) 105 (0.45) 1.82 0.18 0.78 
2.2 CC 71 (0.25) 43 (0.185) 2.82 0.09 0.68 
Total 283 233 
2, Chi square analysIs IS X 10.78, DF 2,p-value 0.0045 for genotype wise analysis. 
Table 6.3.3iia IL1{3 -511 by genotypes 
ALLELE CONTROLS CASES Xl p-value Odds 
ratio 
IT 280 (0.49) 275 (0.59) 3.142 0.76 0.812 
2C 288 (0.51) 191 (0.41) 
Total 568 466 
.. Chi square analysIs IS X2 9.33 DF 1 p-value 0.002 Odds ratIO 1.48 S Heterozygosity =0.5 
Table 6.3.3iib ILl {3 -511 by alleles 
6.3.3iii ILl {3 +3953 
Neither of the allele frequencies of the single nucleotide polymorphisms in ILl B at 
+3953 bases was found to differ significantly between the two groups. 
GENOTYPE CONTROLS CASES ALLELES CONTROLS CASES 
1:1 (TIT) 208 (0.72) 152 (0.73) 1 (T) 499 (0.837) 494 (0.846) 
1:2 (TIC) 74 (0.25) 52 (0.25) 2 (C) 97 (0.163) 90 (0.154) 
2:2 (C/C) 9 (0.03) 4 (0.02) 
Total 291 208 Total 596 584 
Chi square by genotype wise analYSIS IS X2 0.69, DF 2 p-value 0.7, and by aBele-wise analysIs IS X 
0.26 DF 1 P value 0.61 which is not significant, Odds ratio 1.1 and heterozygosity of 0.27. 
2 
Table 6.3.3iii IL1B-+3953 
6.3.4i IL4 VNTR 
None of the three genotypes of the polymorphic 70bp repeat was found to differ in 
distribution between groups. 
GENOTYPE CONTROLS CASES 
1:1 (183bp) 53 0.18) 43 (0.19) 
1:2 (183/253bp) 143 (0.48) 99 (0.44) 
2:2 (253bp) 103 (0.34) 83 (0.37) 
Total 299 224 
Chi-square by genotypes, 0.68 DF 2 p-value 0.71 NS Heterozygosity = 0.49 
Table 6.3.4i IL4 VNTR 
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6.3.4ii IL9 (TG)n 
Eleven alleles were observed in this study (Table 6.3.4ii). Allele 12 was not observed 
in this population. Distribution of allele 2 differed significantly between controls and 
cases (p=0.036). Allele 2 was more frequent in control (0.178) than in cases (0.13). 
Also the frequency of allele 5 differed significantly between controls and cases 
p=0.0005 being more frequent in cases (0.38) than controls (0.28). Thus, this study 
reports IL-9 allelic association with TB in humans. The overall X2 19.41, DF 10 
p=0.035 and was still very significant after Bonferroni (B) adjustments (0.004). 
ALLELE CONTROLS CASES Xl. p-value Odds ratio 
1 15 (0.025) 16 (0.03) 0.26 0.6 0.78 
2 108 (0.18) 66 (0.13) 4.36 0.036 1.44 
3 131 (0.215) 110 (0.22) 0.00 0.99 0.99 
4 94 (0.155) 67 (0.13) 0.95 0.33 1.2 
5 172 (0.28) 194 (0.38) 12.06 0.0005 0.64 
6 56 (0.091) 30 (0.06) 3.76 0.05 1.61 
7 15 (0.025) 16 (0.03) 0.26 0.6 0.78 
8 3 (0.005) 2 (0.01) 0.932 0.33 1.52 
9 6 (0.01) 3 (0.006) 
10 7 (0.012) 2 (0.004) 
11 1 (0.002) 0(0) 
Total 608 506 
Chi-square, X2 19.41, DF 10, p-value 0.035 S Heterozygosity -0.81. Alleles 8, 9,10 and 11 were 
collapsed into one group. 
Table 6.3.4ii IL9 (TG)n 
6.3.4iiiIL9 Tl13M RFLP 
Given the interesting result of the micro satellite marker above a second 1L9 
polymorphism in the coding region of the gene was typed. It may be that the 
microsatellite alleles are in linkage disequilibrium with coding and functional variant 
of the gene. Unfortunately, the allele frequencies for this 1L9 RFLP did not differ 
significantly between the two groups of cases and controls. The p-value was 0.85 and 
the Chi-square was 0.038. 
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ALLELE CONTROLS CASES 
1 (C) 0.84 0.84 
2 (T) 0.16 0.16 
ChI Square, X2 0.038, DF 1, P 0.85 
Table 6.3.4iiiIL9 Tl13M 
6.3.4 Haplotype frequencies for the two IL9 markers (TGn and SNP) 
Although, there was no significant difference in the haplotype frequencies between 
cases and controls for the 1L9 RFLP, the haplotype frequencies for the two 1L9 
markers gave a significant p value of 0.03 for both micro satellite and SNP. The most 
common haplotype is the allele 5 of TG repeat and allele 1 of SNP. The alleles of 
micro satellite are on the outer side followed by alleles of the SNPs see section 6.3.2v 
for more details on haplotype analysis. 
Haplotypes CONTROLS CASES 
1-1 0.022 0.028 
2-1 0.14 0.11 
3-1 0.19 0.18 
4-1 0.13 0.09 
5-1 0.25 0.32 
6-1 0.07 0.07 
7-1 0.02 0.03 
8-1 0.002 0.002 
9-1 0.005 0.002 
10-1 0.005 0.004 
11-1 0.002 0.0 
1-2 0.003 0.009 
2-2 0.04 0.02 
3-2 0.03 0.02 
4-2 0.03 0.02 
5-2 0.04 0.07 
6-2 0.02 0.006 
7-2 0.002 0.010 
8-2 0.003 0.00 
9-2 0.0014 0.00 
Chi square X2 31.8, DF 19, P value 0.03 
Table 6.3.4 Haplotype frequencies for IL9 markers 
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6.3.5 LTA and TNFA promoter polymorphisms 
There was no significant differences in allele distribution between cases and controls 
for LT intron 2 polymorphism,(0.2 DF I, P=0.64), TNFA-863 G to T transversion 
, 
(x2 0.11 DF 1, p=0.23), TNFA -857 C to T transition (X2 1.15, DF I p=0.523) or the 
TNFA-376 G to A transition (X2 0.2 DF I p=0.85). For the TNFA-308 G to A 
transition, allele 1 was significantly more frequent in cases 0.86 than in controls 0.81 
(x2 3.3, DF 1, p=O.O 18), Odds ratio 1.44. Also, the distribution of alleles for 
TNFA-238 G to A transition differed significantly between groups. Allele 2 the rarer 
allele, was more frequently seen in cases (0.09) than in controls (0.05) whereas the 
more common allele I was more frequent in controls (0.95) than cases (0.91). The 
overall association between groups was significant (X2 =26.73, DF I, P 0.016) after 
Bonferroni adjustments (0.025 for biallelic polymorphism). The TNFA-promoter 
region alleles were found to be in Hardy Weinberg equilibrium. The tables below 
shows the genotype and allele frequencies for the different TNF A polymorphisms. 
6.3.5i LTA 
None of the alleles differ significantly in their distribution. 
GENOTYPE CONTROLS CASES ALLELE CONTROLS CASES 
GG 39 (0.14) 28 (0.13) 1G (Asn 26) 225 (0.39) 163 (0.37) 
GA 147 (0.51) 107 (0.48) 2A (Thr 26) 349 (0.61) 277 (0.63) 
AA 101 (0.35) 85 (0.39) 
Total 287 220 Total 574 440 
2 
-Chi-square by genotypes, X2 0.64, DF 2, p-value 0.73. Chi square by allelesx 0.22 DF 1 P value 0.637 
Odds ratio 0.939 Heterozygosity = 0.48. 
Table 6.3.5i LTA by genotypes and alleles 
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6.3.5ii TNF A 863 
GENOTYPE CONTROLS CASES ALLELE CONTROLS CASES 
CIC 216 (0.84) 239 (0.88) G 471 (0.91) 509 (0.93) 
CIA 39 (0.15) 31 (0.11) T 45 (0.09) 37 (0.7) 
AlA 3 (0.01) 3 (0.01) 
Total 258 273 Total 516 546 
2 Chi-square by genotypes, X 0.14, DF 2, p-value 0.9. Chi square by alleles, X2 0.11, DF 1 P value 0.23 
Odds ratio 1.04, Heterozygosity = 0.14 
Table 6.3.5ii TNF A -863 C/ A SNP 
6.3.5iii TNF A -857 CIT 
GENOTYPE CONTROLS CASES ALLELE CONTROLS CASES 
CC 238 (0.89) 249 (0.87) C 506 (0.94) 531 (0.93) 
CT 30 (0.11) 33 (0.12) T 30 (0.06) 37 (0.07) 
TT o (0.0) 2 (0.07) 
Total 268 284 Total 536 568 
Chi square by genotypes, X21.89, DF 2, p-value 0.39, Chi square by alleles X2 1.15 DF 1 P value 0.52 
Odds ratio 0.75 NS Heterozygosity =0.113 
Table 6.3.5iii TNF A -857 CIT SNP by genotype and allele 
6.3.5iv TNFA -376 G/A SNP 
Homozygotes for the mutant genotype A is rare and was not seen in the cases and 
only one out of two hundred and sixty eight samples was observed in the control 
group. 
GENOTYPE CONTROLS CASES ALLELE CONTROLS CASES 
GG 255 (0.95) 274 (0.94) G 522 (0.97) 562 (0.98) 
GA 12 (0.05) 14 (0.06) A 14 (0.03) 14 (0.02) 
AA 1 (0.0) 0(0) 
268 288 Total 536 576 Total 2 
Chi square by genotypes, X2 0.22 DF 1, p-value 0.64 S Odds ratio 0.84, Chi square by alleles X 0.22, 
DF 1 p-value 0.85 NS Odds ratio 0.84 NS Heterozygosity =0.05 
Table 6.3.5iv TNF A -376 G/ A SNP by genotype and allele 
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6.3.5v TNF A -308 GI A 
The TNF -308 polymorphism has the highest heterozygosity in this population of the 
TNF variants analysed. The heterozygosity is 0.31. The frequency of allele 1 (0) is 
more in TB cases (p=0.018). 
GENOTYPE CONTROLS CASES ALLELE CONTROLS CASES 
GG 202 (0.67) 184 (0.76) G 489 (0.81) 417 (0.86) 
GA 85 (0.28) 49 (0.20) A 113 (0.19) 65 (0.14) 
AA 14 (0.05) 8 (0.03) 
Total 301 241 Total 602 482 
Chi-square, X2 5.57 DF 2 p-value 0.06, Chi-square, X2 3.87, DF 1 p-value 0.018, Odds ratio 1.44 S 
Heterozygosity= 0.31. 
Table 6.3.5v TNF A -308 GI A SNP by genotypes and alleles 
6.3.5vi TNF A -238 GI A 
The distribution of both the genotypes and alleles of this polymorphism differed 
significantly between cases and controls. Allele 2 (A) of this polymorphism is 
significantly associated with TB from this study (p=0.016). 
GENOTYPE CONTROLS CASES X2 I p-value Odds ratio 
GG 200 (0.91) 179 (0.82) 52.68 0.01 4.544 
GA 18 (0.08) 40 (0.18) 41.77 0.01 0.244 
AA 2 (0.009) 0(0) 6.27 0.01 0.208 
Total 220 219 
Chi square by genotype, "lI1.51, DF 2, p-value 0.003 
Table 6.3.5via TNFA -238 G/A SNP by genotypes 
ALLELE CONTROLS. CASES 
GIG 418 (0.95) 398 (0.91) 
AlA 22 (0.05) 40 (0.09) 
Total 440 438 
Chi square by alleles, X2 26.73 DF 1 p-value <0.016 Odds ratio 1.91, Heterozygosity 
= 0.11. 
Table 6.3.5vib TNF A -238 GI A SNP by alleles. 
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6.3.5vii Haplotype analysis of the TNF A region 
In collaboration with Hans Ackerman and Professor D Kwiatkowski, the TNFA 
promoter SNPs by haplotye analysis was carried out. The program (PHASE) used 
was developed by Mathew Stephens working with Professor Peter Donnelly in the 
department of statistics and in Oxford. Individuals for which PCR failed were 
excluded. This resulted in small sample size of 154 cases and 174 controls. Fourteen 
haplotypes were observed in this popUlation. The SNP order is as follows: For 
example, haplotype 1 which is the most common haplotype with the SNP order 
ACCGGG has A (adenine) nucleotide substitution for the wild type LTA Nco/variant, 
C (cytosine) for the wild type TNFA-863 variant, C (cytosine) for the wild type TNFA 
-857 variant, G (guanine) for the wild type TNFA -376 variant, G (guanine) for the 
wild type TNFA -308 variant, and lastly G (guanine) for the wild type TNFA -238 
variant. Linkage disequilibrium occurs more in the wild type alleles for all the TNF A 
SNPs. The frequency of haplotype 4 consisting of GCCGAG is significantly different 
between cases and controls. This haplotype occurs more in controls than in cases. The 
haplotype 4 consists of the mutant L TA allele 1 (G) that in this study is allele 2, 
mutant TNFA -308 allele 2 (A), and the TNFA -238 wild type allele 1 (G). The 
linkage disequilibrium exhibited by these alleles supports our earlier association of 
TNFA -308 allele 1 (G) and allele 2 (A) of TNFA-238 with TB. Haplotype 9 differs 
from haplotype 4 at three points; containing opposite nucleotide variants for the LTA 
wild type (A) nucleotide, wild type G nucleotide variant for TNFA -308, and mutant 
variant A at TNFA -238. These two haplotypes were observed more in controls. 
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Haplotype SNP order Control Cases OR p-value 
C.I 
(95% ) 
1 ACCGGG 141(0.41) 151(0.49) 
2 GCCGGG 65(0.19) 70 (0.23) 
3 GCCAAG 2 (0.01) 5 (0.02) 
4 GCCGAG* 65 (0.19) 35 (0.11) 0.56 0.35-0.89 0.009 
- -5 ACTGGG 21 (0.06) 20 (0.06) 
6 AACGGG 25 (0.07) 18 (0.06) 
7 ACCAGA 6 (0.02) 0(0.00) 
8 ACCAGG 2 (0.01) 6 (0.02) 
9 ACCGGA* 13 (0.04) o (0.00) 0.00 0.00-0.36 0.0006 
- -10 GCTGAG 1 (0.00) 1 (0.00) 
11 ACCGAG 3 (0.01) 1 (0.00) 
12 GACGAG 2 (0.01) 0(0.00) 
13 GACGGG 1 (0.00) 1 (0.00) 
14 AATGGG 1 (0.00) 0(0.00) 
348 308 
The table shows haplotype frequency In both cases and controls and compares a X2 for these 
haplotypes 
~ Haplotypes 4 and 9 with opposite nucleotide changes are more frequent in controls. 
Table 6.3.5vii Haplotype analysis of the TNF A region. 
6.3.5viii TNFa 
TNFa is a microsatellite marker in the TNF gene cluster of the MHC class III 
molecule. Fourteen alleles were observed in this population during this study. A 
trinomial distribution of alleles was observed. The alleles 2, 6 and 11 occurred more 
in both cases and controls and they were at equal frequency. Alleles 5, 8, 9, 12 & 14 
were collapsed. Neither of the TNFa micro satellite alleles differs significantly in 
distribution. 
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ALLELES CONTROLS CASES 
1 16(0.027) 9(0.017) 
2 105(0.18) 73(0.14) 
3 27(0.046) 27(0.054) 
4 34(0.06) 37(0.08) 
5 12(0.02) 10(0.02) 
6 126(0.21) 123(0.23) 
7 70(0.12) 54(0.11) 
8 3(0.005) 1(0.002) 
9 10(0.017) 8(0.015) 
10 60(0.1) 71(0.13) 
11 125(0.21) 102(0.19) 
12 0(0) 7(0.001) 
13 0(0) 0(0) 
14 4(0.005) 6(0.011) 
Total 592 528 
.2 Chl- square, X 9.72 DF 8 P value 0.28 NS Heterozygoslty=0.85. 
Table 6.3.5viii TNFa by alleles 
6.3.6i IFNGRl (TT) deletion 
A dinucleotide deletion of thymine (ddeITT) in the IFNGRl detected during this 
study was analysed by genotype-wise and allele-wise methods. Although there was 
no significant difference in allele frequencies between the groups, owing to the low 
frequency of this polymorphism (X2 0.66 DF 1 p=0.42 Odds ratio 0.84), there was a 
significant association between controls and cases when genotypes were considered. 
The double deletion homozygote mutant was observed more in TB cases (0.09) than 
in controls (0.01) and the frequency differed significantly between groups. The 
frequency of heterozygote was more in controls (0.17) than cases (0.10) but this 
difference was not statistically significant. Overall X2 16.88 DF 2 p=0.0002 and was 
significant after Bonferroni (B) adjustments (0.016). This association may be spurious 
because of low frequency of the deletion but the fact the polymorphism occurs at a 
potential transcription factor binding (GAS) site makes it very interesting and more 
studies will be required to confirm its biological significance in TB. 
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GENOTYPE CONTROLS CASES X2 p-value Odds ratio 
TTITT 243 (0.82) 114 (0.81) 0.01 0.92 0.99 
TTl-- 51 (0.17) 14 (0.10) 3.27 0.07 0.54 
--1-- 4 (0.01) 12 (0.09) 112.16 0.0004 0.6.89 
Total 298 140 
Chi square by genotypes, X2 16.88 DF 2 p-value 0.0002 S Heterozygosity=O.l8 
Table 6.3.6ia IFNGRI (TT) deletion by genotypes 
ALLELE CASES CONTROL 
S 
TT 242 (0.86) 537 (0.9) 
--
38 (0.14) 59 (0.1) 
Total 280 596 
Chi square by alleles X2 0.66 DF 1, p-value 0.42 Odds ratio 0.84 
Table 6.3.6ib IFNGRI (TT) deletion by alleles 
6.3.7 IFNG 
This is the only type able polymorphism in the human IFNG gene. None of the alleles 
of this microsatellite were associated with TB. 
ALLELE CONTROLS CASES 
1 49 (0.08) 44 (0.075) 
2 134 (0.21) 127 (0.215) 
3 277 (0.44) 261 (0.443) 
4 39 (0.062) 33 (0.056) 
5 62 (0.163) 63 (0.107) 
6 21 (0.033) 26 (0.044) 
7 35 (0.055) 28 (0.05) 
8 9 (0.014) 3 (0.005) 
9 4 (0.006) 3 (0.005) 
Total 630 588 
Chi-square,x2 4.44 DF 8, p-value=0.814, NS Heterozygoslty=0.74. 
Table 6.3.7 IFNG by alleles 
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6.3.8i NOS2A 
None of the alleles of the polymorphism differ significantly in distribution between 
cases and controls. There was a binomial distribution of alleles with alleles 3 and 6 
being the highest frequency in this population. 
ALLELE CONTROLS CASES X2 p-value Odds ratio 
1 47 (0.08) 50 (0.096) 9.287 0.76 0.925 
2 78 (0.13) 70 (0.13) 0.179 0.67 1.085 
3 109 (0.18) 78 (0.15) 0.65 0.42 1.139 
4 52 (0.09) 39 (0.07) 1.59 0.21 1.31 
5 77 (0.13) 68 (0.13) 1.86 0.97 0.98 
6 114 (0.19) 110 (0.15) 0.015 0.9 0.974 
7 49 (0.088) 52 (0.21) 0.248 0.62 0.89 
8 27 (0.05) 33 (0.06) 1.16 0.28 0.74 
9 14 (0.024) 8 (0.015) 8.94-04 0.976 1.14 
10 4 (0.006) 5 (0.009) 1.55 0.218 0.38 
11 4 (0.006) 0(0) 3.06 0.08 0.00 
12 0(0) 0(0) 
13 0(0) 1 (0.001) 1.58 0.21 0.00 
14 11 (0.02) 8 (0.015) 2.67 0.1 0.4 
15 4 (0.006) 0(0) 0.79 0.37 0.00 
Total 590 522 
Chi-square by alleles, X2 8.53 DF 8 p-value 0.384 NS.Heterozygosity=0.865. Alleles 9, 10, 11, 12, 13, 
14, 15 were collapsed into one group. 
Table. 6.3.8i NOS2A by alleles 
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6.3.8ii D17S250 
None of the alleles of the marker D17S250 differed significantly in distribution. 
Allele 12 had the highest frequency in this population. Allele 5 had the second 
highest frequency. 
ALLELE CONTROLS CASES X2 p-value Odds ratio 
1 4 (0.0065) 2 (0.0038) 2.76_°2 0.0867 1.22 
2 40 (0.065) 35 (0.067) 2.43_°3 0.96 1.04 
3 98 (0.16) 62 (0.12) 2.23 0.135 1.276 
4 38 (0.06) 33 (0.063) 0.53 0.465 0.83 
5 103 (0.17) 89 (0.17) 2.159 0.88 1.032 
6 86 (0.14) 63 (0.12) 2.45 0.1173 1.307 
7 34 (0.06) 31 (0.056) 0.063 0.801 0.918 
8 45 (0.07) 28 (0.05) 4.30 0.03 1.632 
9 6 (0.0098) 23 (0.04) 9.458 0.0002 0.254 
10 5 (0.008) 5 (0.0095) 5.26 0.02 3.47 
11 5 (0.008) 7 (0.013) 1.231 0.267 0.404 
12 134 (0.22) 135 (0.26) 2.53 0.11 0.81 
13 0(0) 0(0) 
14 0(0) 1 (0.019) 9.822 0.001 0.00 
15 4 (0.0065) 0(0) 5.29 0.021 0.00 
16 3 (0.0049) 0(0.003) 
17 4 (0.0065) 11 (0.021) 2.39 0.12 0.37 
18 0(0) 1 (0.0019) 0.322 0.57 0.00 
19 1 (0.0016) 0(0.0) 
610 526 
Chi-square, X2 6.87 DF 8 p-value 0.55 Heterozygosity =0.86. Alleles 1,10,11,15, 16, 17, 19 were 
collapsed into one group. 
Table 6.3.8ii D 17S250 by alleles 
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FIG.6.2 Analysis of the internal size standard 
using genotyper 2.0. The corresponding size of an 
allele is determined relative to the ROX internal 
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FIG. 6.5 Analysis of the IFNGRl 
microsatellite using Genotyper 2.0. The most 
common allele 9 is usually seen in 
combination with other alleles. 
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Table 6.4 Summary of influence of macrophage candidate genes on TB 
CANDIDATE Chi square X2 DF p-value B OR 
GENE 
1q31-q32 
IL-10 5' 
proximal repeat 15.2 10 0.125 
2q35 
NRAMPl 
5'promoter 
repeat 10.36 3 0.016 0.0125 
274C/T 1.1 1 0.3 1.1 
469+14G/C 15.93 1 0.00006 0.025 2.5 
1465-85G/A 0.03 1 0.92 1.02 
2q14 
IL1RN 5.05 3 0.16 
IL1B-511 9.33 1 0.002 0.025 1.48 
IL1B+3953 0.26 1 0.61 1.1 
5q23-q-32 
IL4VNTR 0.68 2 0.71 
IL9 19.4 10 0.03 0.004 
IL9Tl13M 0.04 1 0.85 
6p23 
LTA 0.44 1 0.53 0.91 
TNFA-863 0.04 1 0.23 1.04 
TNFA-857 1.41 1 0.52 1.04 
TNFA-376 0.22 1 0.85 1.11 
TNFA-308 4.22 1 0.018 0.025 0.67 
TNFA-238 27.73 1 0.016 0.025 1.91 
TNFa 9.72 8 0.28 
6q23-24 
IFNGRl TT/del 16.88 2 0.0002 0.016 
12q24.1 
IFNG 4.44 8 0.814 
17q11.2-q12 
NOS2A 8.53 8 0.38 
D17S250 6.87 8 0.55 
The chi-square is represented with the symbol, X2 DF represents the degrees of freedom, the 
conditional probability is represented by p-value and B represents the Bonferroni adjustments for 
multiple allele analysis correction of statistical significance. 
The summary of result is presented for eight chromosome regions and 22 candidate 
genes. After correction for multiple allele analysis, two genes with allele frequency 
initially associated with TB were no longer significant after Bonferroni adjustments. 
These are the 1L-9 microsatellite repeat and the NRAMP 1 CA Z DNA polymorphism. 
Other genes that are still associated with TB are NRAMP 1 469+ 14G/C intron 4, ILl B 
-511, IFNGRl delTT, and two TNFA promoter polymorphisms at TNFA-308 and 
TNFA-238. Opposing alleles were shown to be associated with TB. 
203 
6.4 Discussion 
Twenty-two macrophage candidate genes were genotyped at eight chromosome 
regions. ILIa on chromosome 1q31-q32, NRAMPI on 2q35, IL-1 on 2q14, Th2 
cytokines 1L4 and 1L9, LTA and TNFA on the short arm of chromosome 6 within the 
MHC class III region, 1FNG on chromosome 12q24.1 and NOS2A and the small 
inducible chemokines on chromosome 17q11.2-q12. 
This study demonstrates association between TB and two NRAMP 1 polymorphisms 
studied. Of the four polymorphisms analysed in this study, two had been reported to 
be associated with TB. The promoter Z DNA repeats and INT 4 (NRAMP 1 469+14 
G/C in this study) polymorphisms were reported to be significantly associated with 
TB in this population (Bellamy et aI., 1998b). The results obtained from this study are 
similar to that of the Bellamy study. Although, the promoter polymorphism showed 
statistically significant difference initially using X2 test analysis, after Bonferroni 
adjustments it just statistically significant. Similarly, studies in mice also failed to 
show any effect of a protective role for the Nrampl gene after M tuberculosis 
infection (North et aI., 1999, Medina and North, 1996). The NRAMPI intron 4 alleles 
showed significant difference in distribution between the two groups. Supporting 
earlier reports of allelic association with TB. 
It may be that polymorphisms within this interval are associated with TB and it may 
be important to find out if there is any linkage disequilibrium between alleles of these 
NRAMP 1 polymorphisms and other neighbouring markers. IL-8 has been suggested 
as possible candidate gene for TB susceptibility (Friedland et al., 1995). 
Demonstrations of elevated levels of IL-8 mRNA and protein in supernatants of 
macrophages and in lavage fluid obtained from patients with pulmonary tuberculosis 
may suggest a protective role for IL-8 in TB. Indeed genetic studies in a Brazilian 
population have weakly linked 1L8RE with susceptibility to TB (Shaw et at., 1997). 
This gene is tightly linked to NRAMP 1 (fL8RE and NRAMP 1 are encoded on the 
same chromosome and are 100 kb apart) and recently, four polymorphisms within the 
NRAMP 1 gene have been associated with TB (Bellamy et al., 1998b). Taken together 
these may indicate important roles for both 1L8RE and NRAMP 1 in TB. 
Of significant importance is the finding that NRAMP 1 (469+ 14 G/C) polymorphism 
is not only significantly associated with TB, it is also shown to be influencing LAM 
induced IL-10 responses (Table 5.4). Soo et al., (1998) using congenic mice 
investigated the influence of host genetics on the ability to induce protective immune 
response to recombinant salmonella vaccines. They showed that mice carrying the 
wild-type Nramp 1 allele mounted a predominant T helper-l response to vaccination 
whereas mice carrying the mutant Nramp1 mounted a T-helper-2 response and 
showed exacerbated lesion growth upon challenge (Soo et. aI., 1998). 
There is evidence from this study that carriage of one copy of the 1LRN allele 2 may 
confer protection against TB. The observed frequency of allele 2 is low in The 
Gambian population (0.04) from this study (Table 6.3.3i) and (0.025) from a previous 
study (Bellamy et al., 1998d). In Caucasians, it occurs at a much higher frequency 
(0.24) (Clay et al., 1994, Mansfield et al., 1994) where it has been associated with 
numerous autoimmune diseases. 
In contrast to an earlier report by Bellamy et at., (1998d) this study failed to 
demonstrate any association between with ILl RN allele 2 and TB. Much greater 
sample size will be required to determine whether homozygotes for allele 2 have 
altered susceptibility to tuberculosis in this population. 
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However, ILl B result from this study is supported by an earlier study by Wilkinson et 
al., (1999) which demonstrated an association between IL-l ~ and TB. The Wilkinson 
study demonstrated significant association between an allele of 1L1B +3953 and TB 
in a panel of migrant Indians, this study however, demonstrates significant 
association between allele 1 of the ILl B -511 polymorphism and TB in The Gambian 
population (Table 6.3.3ii). Although, these studies were carried out in two different 
populations with different genetic background, the fact that the same gene but 
different mutants has been associated with TB may suggest important role for IL-l ~ 
in susceptibility to TB. 
This study also identified an association between TB and allele 5 of the 1L9 
microsatellite (Table 6.3.4iii). Linkage disequilibrium data in humans suggests 1L9 
may be associated with atopy (Doull et al., 1996). In mice, particular alleles of 1L9 
have been associated with bronchial hyper-responsiveness and atopy (Nicolaides et 
al., 1997). A study in 1996 reported an association between allele 118 of 1L9 and 
atopy in humans (Doull et al., 1996). Inverse relation between atopy and DTH has 
been reported in Japanese school children (Shirakawa et al., 1997) leading to the 
hypothesis that opposing factors may be responsible for DTH in TB and atopy. This 
study now reports 1L9 allelic association with TB in the Gambian population. Another 
lL9 polymorphism (TI13M) typed was not found to be associated with TB. 
Haplotype analysis gave a significant p value of 0.03 for both the (TG)n 
microsatellite and the T113M SNP. 
Despite conflicting reports of TNF A allelic association with several diseases, this 
study demonstrates significant association between alleles 1 TNF A -308 (G) and allele 
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2 TNFA -238 (A) and TB. Earlier studies of TNFA-308 polymorphism have shown 
that for the TNFA -308 polymorphism, the TNFA-308A allele is associated with 
increased TNF-a transcription rates (Wilson et al., 1997, Kroeger et al., 1997). 
Association studies carried out in The Gambia found that individuals homozygous for 
the TNFA -308A allele carried a seven fold higher risk of death or severe neurological 
sequelae from cerebral malaria, independently of the presence of predisposing MHC 
class I and class II alleles (McGuire et al., 1994). The pathology of cerebral malaria is 
associated with increased levels of circulating TNF. Also, using the same set of 
samples, McGuire et al., (1999) reports an association between low plasma TNF 
levels in severely anaemic children with Plasmodium Jalciparum infection and TNFA 
-238A allele in Gambian children. This indicates that different forms of a disease may 
be associated with different alleles of the same gene and highlights the biological 
importance of single nucleotide polymorphisms and diseases. Similarly, this study 
also demonstrates associations between TB and two TNF A polymorphisms. The 
TNFA -308A (Table 6.3.5v, p = 0.18) and the TNFA -238G (Table 6.3.5vi, p=0.016) 
were associated with TB. Thus, this study has associated different polymorphisms of 
the same gene with TB. If TNFA -308A is associated with higher TNF levels (Wilson 
et al.,1997, Kroeger et al., 1997) and TNFA -238A is associated with lower TNF 
levels (McGuire et al., 1999), this report may strengthen the hypothesis that 
individuals with TB have sub optimal macrophage function and therefore reduced 
capacity to produce TNF. However, TNF levels were not shown to be lower in 
recovered cases than in controls (Table 3.5) nor was the TNFA-gene shown to be 
influencing measured TNF levels using the whole blood assay (Table 5.3.4iv). 
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Homozygotes for the IFNGRI dinucleotide deletion polymorphism had genotype 
frequency of 0.01 in controls and a frequency of 0.05 in TB cases (Table 6.3.6i, 
p=0.015). Indication of a role for the IFNGRI in susceptibility to intracellular 
diseases comes from independent studies in 1996 firstly, of Maltese children who 
suffered from atypical mycobacterial infection in England by Newport et aI., (1996) 
and then of a Tunisian child by Jouangay et al., (1996) in France. These studies 
demonstrated a lack of IFNyR1 protein on cell surface of children suffering form 
atypical mycobacterial infections due to mutations in coding regions of the gene. This 
study demonstrates an association between the newly detected double deletion 
polymorphism (Table 4.4, FIG. 4.13) and TB in an adult African population. 
None of the markers on chromosome 17, where NOS2A and SCYA (such as RANTES) 
are located were found to be associated with TB in this study. It is not surprising that 
this study was unable to demonstrate allelic association between alleles of NOS2A 
polymorphisms and TB. The role of NO in macrophage killing of M tuberculosis 
though well established in mice is still unclear in humans. In contrast, the frequency 
of a 11 repeat of NOS2A CCTTT promoter variant was significantly more in fatal 
cases of cerebral malaria when compared with other subtypes of malaria in The 
Gambian patients (Burgner et aI., 1998). The D17S250 marker is reported to be close 
to the small inducible chemokine genes. None of the alleles of this marker 
demonstrated statistically significant difference in frequency between controls and 
TB cases in this study. However, this result is surprising because a locus on human 
chromosome 17 is linked to TB in a family based genomic screening (Lim et aI., 
2000). 
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The promoter repeat polymorphism of ILl 0 and the intron one repeat of IFNG were 
not found to be associated with TB in this population and this is in agreement with an 
earlier study carried out in this population (Bellamy, 1998a) 
In conclusion allelic associations were observed between alleles at the following 
candidate gene loci and TB in this study: allele 1 of TNFA-308, allele2 of TNFA-238, 
allele 2 of DDelTT of IFNGR1, allele 1 of IL-l ~ -511, NRAMP 1 (469+ 14 G/C), 
allele 5 of IL9 intron 4 (TG)n marker. 
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CHAPTER 7 
DISCUSSION 
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7.1 Introduction 
Defects in specific components of the immune system have provided many clues to the 
complex immunological mechanisms underlying resistance or susceptibility to infection. 
A beneficial response by host to mycobacterial infection involving both the innate and 
acquired arms of the immune system is an important determinant of disease resistance. 
This response is subject to genetic regulation. The innate immune system represents the 
first line of defense against invading organisms. Studies in animals and humans suggest 
that macrophage activation is essential to killing of mycobacteria and containment of 
mycobacterial infection. The macrophage activation process or pathway involves complex 
networking of several molecules. Due to the complexity of this process, the quantitative 
phenotype analysis is a useful tool for teasing out underlying quantitative traits, which can 
then be analysed separately. Quantitative phenotype analysis has been used to identify 
genetic loci regulating complex diseases including asthma (Daniels, 1996). The 
identification of the real disease gene(s) among candidates relies upon the characterisation 
of specific defects in affected individuals. Essentially, this study was set up to search for 
evidences of genetic markers correlating with cytokine secretion as a marker of 
macrophage activation and thereafter determine whether these genes influence TB. This 
study is the first to employ this method in identifying TB susceptibility genes in humans. 
7.2 Monocyte function in The Gambian population. 
Whole blood of persons who had TB and healthy blood donors were stimulated with 
bacterial cell wall components. Pro inflammatory (TNF and IL-l P) and anti-inflammatory 
(lL-10) cytokines, induced by macrophage stimulating agents were determined as 
quantitative traits. Levels of IL-l 0 induced in response to LPS differed between recovered 
TB cases and controls with IL-I0 levels being higher in cases (p=0.02). This study 
demonstrates that macrophage activation is a heterogeneous process with much inter-
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individual variation. This implies that regulation of this process is dependent in part on 
the individual's genetic constitution. Macrophage activation pathways involve a complex 
networking of several molecules all acting together with many possible points of control 
of synthesis and function. Published functional polymorphisms at macrophage candidate 
gene loci were studied for any influence on quantitative traits in The Gambian population. 
It was later determined whether those found to be regulating microbial induced responses 
also influenced TB susceptibility. 
Positive correlations for cytokine production were observed for LAM and LPS (both 
microbial wall components known to activate macrophage/monocytes). This suggests a 
common pathway of action and implies that they activate macrophage through the same 
cell surface receptors see section 3.3.3 or pathway. The same genes or pathway may be 
involved in initiating the macrophage activation pathway. There was significant 
correlation between TNF and IL-1 f3 production induced by either of the stimulants. This 
suggests again that dependent pathway or genes may be essential for the release of these 
cytokines. This indicates that the intracellular processes required for the production of 
these molecules though different at certain points may have overlapping function and 
therefore are important determinants of macrophage containment or killing of 
mycobacteria. 
The CD14 molecule and TLRs are germ-line-encoded receptors of the innate immune 
system referred to as pattern recognition receptors (PRR). They are both present on 
macrophages and there are described polymorphisms for both genes but they were not 
typed during this study. A mutation designated Asp299Gly interrupts TLR4- mediated 
LPS signaling (Arbour et al., 2000) There are reported polymorphisms for the CD 14 
molecule but one described C~ T polymorphism at position -260 bases appears to be 
absent in the panel of Gambians studied (Hubacek et al., 1999). 
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Interferon-y differentially modulates LPS induced expreSSIOn of transcription factor 
activator protein -1 (AP-I) and NF-KJ3 at the mRNA and protein levels in human 
monocytes. Priming of human monocytes with IFN-y results in the down regulation of c-
los and c-jun mRNA in response to stimulation with LPS whereas the inflammatory 
molecule NF-K~ was up regulated. Also DNA binding capacity of AP-l is reduced. 
However an increased NF-kJ3 expression was noticed in IFN-y pretreated monocytes (de 
Wit et al., 1996). This might explain the enhancing effect on TNF levels in response to 
LPS stimulation by IFN -y priming of monocytes. 
7.3 Novel polymorphisms 
IFNy acting via its receptor is important in macrophage activation but there was a lack of 
described polymorphisms and new polymorphisms had to be detected. Ten new 
polymorphisms were detected in all. Five novel transition base changes were detected in 
the promoter region of IFNG. For the IFNGRI, a deletion polymorphism and four base 
changes were detected. Two polymorphisms detected in the promoter of IFNGRI could be 
functional. One, a double deletion at position -470/-471 bases, occurs at a transcription 
binding site (GAS) and the other a C-7 T transition at position -56 bases is about four 
bases away from a putative NF-KJ3 binding site. Except for one intron six repeat and a 
Taq 1 polymorphism in IFNGRI gene, other reported variants are rare and effectively 
lethal inactivating mutants. Also, the IFNG gene is not known to be extensively 
polymorphic. There was only one reported intron one repeat, only recently a mutant in the 
promoter of the gene at nucleotide position -333 of the initiation codon was reported. 
Specific regions of the promoter of these two genes were sequenced in thirty-six Gambian 
individuals. The finding of base changes in and around a transcription factor binding site 
implies that such variation may affect the way a transcription factor binds to that site and 
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subsequently the of rate transcription of the gene. Detection assays for some of these 
mutations were developed for use in screening the larger population. 
7.4 Genetic regulation of cytokine responses 
It was determined whether particular alleles at candidate gene loci are associated with 
measured levels of pro-inflammatory and anti-inflammatory cytokine production in 
response to LPS and LAM. Evidence for genetic regulation of immune response induced 
by LPS and LAM were observed at three candidate genes. Individuals who are 
homozygous for the LTA Neol polymorphism allele 2 (TNFB* 1 of previous studies) 
produced lower levels of TNF and IL-l J3 in response to both LPS and LAM and did not 
upregulate their responses to IFN -y as much as those carrying the other genotypes. Messer 
et ai., (1991) used PBL but stimulated with PHA and demonstrated lower LTA levels in 
TNFB*l homozygotes (Messer et al., 1991). Individuals who are homozygous for this 
allele in the Messer study did have significantly different TNF levels. Corroborating our 
finding is the study of Stuber et al., (1996, 1999) that showed higher circulating 
concentrations of TNF and higher mortality for septic patients with the TNF-B*2 (allele 1 
in this study) homozygous allele. 
In addition, based on measured cytokine levels, homozygotes for the TNFA-308 allele 2 
were shown to produce lower TNF and IL-l J3 levels when compared to other genotypes. 
There seems to be a trend in cytokine production with those homozygous for allele I 
producing higher cytokine levels than the heterozygous 112. These homozygous for allele 
2 secreted the least amount of cytokines. However, upon statistical analysis of the mean 
cytokine levels among genotypes, no significant difference was found. In support of this 
is the sepsis study of Stuber et aI, 1996 and that of Brinkman et aI., 1996. The Stuber 
study used allele-specific reverse transcriptase (RT)-PCR on donor blood samples and the 
Brinkman study used PMA inducible TNF promoter activity in human T and B cell lines. 
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These studies were unable to find evidence for the causal effect of the variation within 
TNFA -308 and diseas'e. Other studies have demonstrated higher TNF secretion by 
homozygotes for the TNFA-308 allele 2 (Bouma et aI., 1996, Kroeger et al., 1997). Of 
particular interest is the NRAMP I INT4 polymorphism that was shown to influence IL-IO 
secretion. Individuals who are heterozygous for the NRAMP I !NT 4 polymorphism 
produced lower levels of IL-I 0 upon LAM stimulation of whole blood when compared 
with the homozygote for allele 1. A functional study of NRAMP I CA repeat using a 
reporter gene construct demonstrated increased ability of the allele 3 to driving gene 
expression upon stimulation with LPS. Allele 2 was found to have opposite effect by 
driving reduced gene expression. Allele 3 is associated with rheumatoid arthritis and allele 
2 with infectious diseases. The allele 2 of NRAMP I CA repeat is reported to be in linkage 
disequilibrium with allele 2 of another NRAMP I variant, the NRAMP I INT4 SNP in 
intron 4 (Bellamy et al., 1998b). The homozygote 2 genotype was not observed in the 
panel of samples studied. This study used the whole blood model and did not demonstrate 
any influence of the alleles of NRAMP I CA repeat and cytokine production. Inefficient 
NRAMP I protein could affect processes within the macrophage that are essential to 
macrophage activation and therefore control of infection. 
Anti-inflammatory ILl RN was shown to influence IL-I0 secretion upon LAM and LPS 
stimulation. Individuals who are carriers or homozygous for the allele 2 of ILl RN VNTR 
were shown to have increased IL-I RA expression in monocyte cultures (Danis et al., 
1995). Allele 2 is a two 86bp repeat containing IFN silencer A and IFN silencer B 
transcription factor binding sites. Increased levels have been associated with several 
autoimmune diseases. Wilkinson et al., (1999) demonstrated that IL-I0 increased ILl RN 
expression in carriers of allele 2. This study demonstrates higher levels of IL-I0 in 
individuals who are carriers of allele 2 upon LAM and LPS stimulation. IL-IO is an anti-
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inflammatory cytokine and IL-l~ and TNF may suppress the production ofIL-10. IL-IRA 
competes with IL-l ~ for occupancy of the IL 1 R. Increased levels of IL-l RA would 
antagonise the effect of IL-l~. IL-IRA acts as an anti-inflammatory molecule by not 
transducing signals via this receptor whereas IL-l ~ is pro-inflammatory and transduces 
signals via its receptor. It could be that IL-l RA, by blocking the binding of IL-l ~ to its 
receptor, enhances the pathway for the generation of IL-l o. Increased levels of IL-l 0 may 
be indicative of high IL-IRA levels in carriers of the allele 2. Unfortunately, the 
frequency of this allele was found to be too low in this population to allow for significant 
statistical association. 
Contrasting observations by several workers in the ability of alleles of particular genes to 
regulate cytokine secretion have been explained in literature by the types and 
concentrations of stimulants used, therefore this study employed the use of the whole 
blood model. For the purpose of determining genetic variability it has several advantages 
over other methods and these have been described in chapter 3 section 1. 
Most reports on gene expression have employed in-vitro assays that try to but do not 
exactly mimic in-vivo conditions. The reporter gene assay measures the initial process of 
protein synthesis and tells us whether an allele has biological function by how well it 
drives gene expression by relative intensity of signal from the reporter gene. The whole 
blood assay measures the end point of protein synthesis and takes into account all relevant 
checkpoints involved in protein synthesis. In addition assaying a large number of 
individuals may indicate truly functional genetic influence on TB or quantitative trait 
measurement of cytokines. 
7.5 Genetic susceptibility to TB 
Suprisingly, for this study, the ITA gene was not found to be associated with TB in this 
population. Rather it is the TNFA-238 allele 2 and TNFA -308 allele 1 that were shown to 
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be significantly associated with TB before and after applying the Bonferoni test. It could 
be that for TB per se this LTA polymorphism might not be relevant but might be 
important for macrophage function and other macrophage associated diseases such as 
rheumatoid arthritis where most of the genes that have been shown to be associated with 
susceptibility TB are associated with resistance to autoimmune disease. Also, there is a 
report by Lucas et aZ., (1999) suggesting a role for LTA beta-receptor in host defense 
against Mycobacterium bovis BCG infection. It might be that some other components of 
the L T pathway are important in TB. Other results of interest within the TNF A loci are the 
positive association of particular TNFA-variants with TB; yet these variants were not 
shown to be influencing measured cytokine levels. Allele I(G) of the TNFA -308 and 
allele 2 (A) of TNFA -238 variants were found to be associated with TB in this 
population. The result of the TNFA -308 from this study contrast reports from previous 
studies of infectious diseases. The allele 2 of TNFA -308 variant is associated clinically 
with lepromatous leprosy (Roy et aI, 1997), cerebral malaria (McGuire et al., 1994), 
scarring trachoma (Conway et al., 1997) and mucocuteanous leishmaniasis (Cabrera et al., 
1995). However, initial analysis of a Brazilian leprosy study suggests evidence for an 
association with allele I(G) of the TNFA -308 (Blackwell personal communication). It 
could be that for mycobacterial diseases TNF protects from disease but exacerbates 
disease in cerebral malaria, scarring trachoma and mucocuteanous leishmaniasis. 
However, the frequency of homozygotes TNFA -308 allele 2 in this population was very 
low to allow for significance testing. Larger sample size will be required to confirm this 
finding. 
Interleukin If3 is shown to be associated with TB in this study. IL-lf3 is a proinflammatory 
cytokine with similar immunomodulatory functions as TNF. The frequency of promoter 
polymorphism ILl B -511 allele 1 (T) was more in TB cases than in controls. It is difficult 
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to tell which of the fLl B allele is the mutant or wild type variant because both alleles were 
observed at equal frequency in both cases and controls. A role for IL-l f3 is suggested from 
this study as it corroborates the Wilkinson study that associates an allele of IL-l f3 +3953 
with TB in-migrant Indian population (Wilkinson et a/., 1999). 
Another gene found to be associated with TB is the Th2 cytokine IL-9. Alleles of the 
intron 4 repeat were found to be significantly associated with disease in this population. 
Epidemiological studies of migrants from areas of high helminthic infestations show that 
such people are prone to development of TB (Bentwich et al., 1999). Helminthic 
infestation triggers the production of IgE, and activates the immune system towards a Th2 
cytokine profile and perhaps down regulating the Th 1 that is beneficial for containment of 
TB. A recent study also shows that BeG given early in infancy may prevent the 
development of atopy in African children (Aaby et a/., 2000). High serum IgE levels are 
synonymous with the immediate type hypersensitivity characteristic of atopic disorders. 
Serum IgE levels in atopic patients have been associated with a particular allele" 118" of 
an IL-9 marker (Doull et al., 1996). Perhaps, individuals mounting predominant Th2 type 
immune responses favouring IgE production are more susceptible to mycobacterial 
infections. The genetic basis for this was investigated in our Gambian TB cases. This 
study shows that allele 5 of fL9 marker was significantly associated with TB. Other 
published polymorphisms in the fL9 gene were typed and serum IgE levels in TB cases 
are being analysed. The fL9 (e) T113M (T) polymorphism allele 1 with variant e and 
allele 2 with variant T was not found to be associated with TB. Another polymorphism in 
the fL9 appears to be absent in the Gambian samples typed (Holloway, personal 
communication). Since the fL9 repeat shown to be associated with TB is an intronic 
polymorphism little conclusions can be drawn from this finding. 
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The interpretations of marked differences in genotype frequency in a case control 
association study could be either of the following: -a) that the polymorphism predisposes 
to disease, b) the polymorphism is in linkage disequilibrium with a disease susceptibility 
allele either within the same gene or a neighbouring one or c) there is a confounding 
factor such as sex or poor ethnic matching between cases and controls studied. Options a) 
and b) may represent true positive results and c) false positive. In Gambia, more men 
donate blood. For this study, blood donors served as healthy controls and this was 
presumed to be a major bias of sampling moreso as a region within the chromosome Xq 
showed evidence of co-segregation with TB (LOD 1.77) from an earlier study in The 
Gambia (Bellamy 1998a, 2000). To correct for this bias due to sex, all female cases were 
excluded from the analysis. Speculations are that Nramp1 functions as an ion transporter 
regulating and regulated by cellular metal iron levels (Searle and Blackwell, 1999). 
Evidence for a link between iron metabolism and Nramp 1 function in innate resistance 
against mycobacteria comes from work done by Gomes and Appelberg (1998). They 
showed that the amount of available iron correlated with Nramp 1 function. It could be that 
Nramp 1 functions by transporting iron out of the parasite harboring phagosome. In 
humans, there are speculations that females are more resistant to TB due to low iron stores 
and that men, especially mine workers, are more susceptible to TB due to availability of 
iron (Bellamy, 1999). 
7.6 Summary 
This study has employed two strategies to understand genetic regulation of immune 
responses to TB and macrophage activation in humans. The approach was to use 
functional immunological and genetic methods to understand susceptibility or resistance 
to TB in humans. It was proposed that people with TB might have innate defect in their 
ability to upregulate macrophage for effective containment of the bacilli. Genotypic 
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analysis of polymorphisms at candidate gene loci was therefore carried out in relation to 
phenotypic analysis of disease trait and quantitative trait measurements in healthy 
Gambian individuals to determine whether polymorphisms at these loci influence either of 
these phenotypes. 
For the quantitative phenotype analysis, cellular studies of monocyte function were 
carried out using a whole blood model. Whole blood was stimulated with either manLAM 
or LPS in the presence or absence of rIFN-y. Initially, whole blood conditions were 
optimised for The Gambian population and cytokine measurements were compared 
between thirty eight TB cases and matched controls. There was no difference in mean 
1NF and IL-l f3 cytokine levels between the two groups (recovered TB cases and 
controls). However, significant difference was observed for LPS induced IL-IO 
production between recovered cases and controls (p=O.02). This implies an important role 
for IL-IO in pathology of TB. A recent study of anergic TB patients demonstrated the 
presence of IL-I 0 before and after PPD stimulation but demonstrated IL-IO production 
only after PPD stimulation in non-anergic TB patient (Boussiotis et al., 2000). It may be 
that PPD anergic individuals who have inherent defect in the pathways of generation of 
IL-IO will have reactivation TB and treatment failures. 
There were many interindividual variations in cytokine profile. This suggests that 
individuals differ in their ability to upregulate macrophage judged by cytokine production 
in response to stimulants. Samples size was increased to further investigate if this 
interindividual variation was genetically regulated. Three hundred and twelve healthy 
blood bank donors were included. Whole blood assays were carried out in this group. 
Some comparisons of interest were revealed: a positive correlation between LPS and 
manLAM induced IL-l f3 and TNF responses, also IL-l f3 and TNF responses correlated for 
either LPS or man LAM stimulus. It can be inferred that same genes or pathways might 
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regulate LPS and manLAM signals and these pathways may be similar for IL-l ~ and 
TNF. Also, this study shows that priming of whole blood with rlFN-y enhanced the 
production of TNF and to a lesser extent IL-l ~ but rIFN-y rather suppressed the release of 
IL-10. 
Because of the much inter-individual variation observed polymorphisms at several 
macrophage candidate genes were screened to determine whether macrophage candidate 
genes regulate microbial induced responses and whether alleles of macrophage candidate 
gene influence TB. Polymorphisms in genes with known biologic function as being 
involved in macrophage activation were selected and genotyped in both TB and unrelated 
blood bank controls. In all, twenty-two macrophage candidate genes were screened. The 
two groups were matched for ethnicity as much as possible. 
To detennine if alleles of these genes regulate microbial induced responses, quantitative 
phenotype analysis was done. LTA alleles were shown to significantly influence manLAM 
and LPS induced pro-inflammatory cytokines TNF and IL-l ~ secretion (P<0.05), 
whereas, alleles of NRAMP1 (469+14) and IL1RN were shown to influence manLAM 
induced anti inflammatory cytokine IL-10 secretion (p=0.02). 
To detennine if alleles of these genes influence TB, a case control association study was 
also carried out in three hundred and twelve blood bank controls and two hundred and 
seventy-six active TB cases. All female cases were excluded from analysis. This study has 
observed significant association between the following candidate genes and TB. Allele 
1 (G) of TNFA -308, allele 2 (A) of TNFA-238, allele 1 (T) of ILl B, allele 2 (C) NRAMP 1 
(469+ 14) other markers associated with TB include allele 5 of IL9 and 2 of NRAMP 1 
(CA) Z DNA polymorphism. 
Ten novel polymorphisms at specific promoter regions of two candidate gene loci were 
identified. For some of these new polymorphisms detection assays have been developed 
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while others still need to be optimised. One of these polymorphisms is expected to abolish 
a transcription factor binding site (GAS) at which the transcription factor GAF binds to 
initiate transcription of IFNGRJ. Homozygous condition of this same polymorphism was 
also shown to be associated with TB (p<0.015). Another polymorphism at -56 of the 
initiation codon; a C~ T transition was found to be four nucleotides away from a putative 
NF-K~ binding site. 
This study has contributed to the understanding of the susceptibility to tuberculosis. 
Furthermore, the genetic regulation of macrophage activation in humans is poorly 
understood. This study has made an original contribution to both of these fields. 
Conclusions that can be inferred from this study are that ten new polymorphisms have 
been detected, five within the promoter of IFNG and an additional five within the 
promoter of IFNGRJ. It appears that similar genes or activation pathways may regulate 
LPS and ManLAM signals in view of positive correlation between induced TNF and IL-
l ~ response. Alleles of different variants of the same gene (TNFA -308 and TNFA -238 
polymorphism) were associated with TB in the Gambian population. Significant low 
levels of proinfiammatory cytokine released by LTA allele 1 homozygotes upon 
stimulation of wholeblood with LPS or LAM may suggest that alleles of the LTA regulate 
microbial induced macrophage response of TNF and IL-l J3 production. 
7.7 Future work 
This study has concentrated on genetic regulation of susceptibility to TB by macrophage 
candidate genes. However, efficient immune responses to TB require both arms of the 
immune system. This work could be carried on further by looking at genes involved in 
other areas of innate immunity and the acquired immune responses to TB. Results form 
both this and these ones mentioned above will give a more comprehensive data on genes 
that may regulate susceptibility / resistance to TB. 
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Future studies may be to quantify cell surface expression of some known innate receptors 
which may be used by both LPS and ManLAM i.e. the CD 14 molecule and TLRs 2 and 4 
and to see if there is a correlation between cytokine release and cell surface receptor 
expression. Identification of novel polymorphisms at these loci could be used to study 
whether variations at these loci influence cytokine production. Another approach may be 
to study cytokine production in the absence and presence of these cell surface receptors to 
determine if these receptors are utilised by stimulants and therefore needed for cytokine 
production. Kinetics of mRNA expressions of these cytokines after stimulation may be 
studied. As this study has demonstrated significant correlation in TNF and IL-l ~ 
responses, polymorphisms in genes involved in intracellular trafficking of signals maybe 
studied as this may provide clues to mechanisms involved in regulating these responses. 
Population screens of newly detected IFNG and IFNGRJ polymorphisms could be carried 
out to establish their frequency in The Gambian population and several African 
populations. Polymorphisms that appear to be influencing microbial induced responses 
and TB may then be analysed in a second sample set to confirm the associations observed 
in this study. Other sub Saharan African populations in West and East African (Nigeria 
and Kenya) where the ethnic admixture is minimal may be investigated with the aim of 
carrying out studies which may be designed to include twin, family, case control 
association or affected sibs studies. In the western part of Nigeria, for example, among the 
Yoruba's, the twinning rates are higher when compared to other parts of Africa. Also in 
these communities, marriages are more stable and there is minimal intermarriage between 
ethnic groups. In addition, there are areas where first cousin marriages still occurs for 
example, among the Fulani' s, allowing for the detection of rare genetic defects and maybe 
a good source of material for genetic research. 
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Other polymorphisms at candidate gene loci that have proved to be interesting in this 
study in relation to TB may be analysed to further delineate their role in mycobacterial 
diseases. 
For novel polymorphisms that might be functional judged by their being at or around 
putative transcription factor binding sites, assays to determine how alleles of these 
polymorphisms drive rate of gene expression may be carried out. Theses assays may 
range from carrying out electrophoretic mobility shift assay to show binding affinity of 
transcription factors for their binding sites, to transfection assays using gene construct to 
report differences in rate of gene transcription between wild-type and mutant allele. 
Finally, all these mentioned above might be carried out in other mycobacterial diseases 
for example, leprosy caused by Mycobacterium ieprae. Leprosy provides a unique 
opportunity to study genetic regulation of immune responses because of the ease of 
disease classification. It should be interesting to determine if the same genes are 
associated with the two human mycobacterial diseases in The Gambia. This should 
facilitate the development of prophylaxis required for the prevention of mycobacterial 
diseases. 
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APPENDIX 1 BUFFERS FOR OPTIMISING PCR CONDITIONS 
BUFFER pH Tris-HCL MgCh KCL(mM) Tween- Trition-X H2O 
Number (mM) (mM) 20 
1 8.3 10 (1.0mI) 1.5 25 (2500J.!1) 0 0.1% 6.35ml 
(l50J!1) (l00J.!1) 
2 8.3 10 (1.0ml) 1.5 75 (7500J.!1) 0 0.1% 1.35mI 
(l50J!I) (l00J.!I) 
3 8.8 10 (1.0ml) 1.5 25 (25OOIlI) 0 0.1% 6.35ml 
(15OIlI) (lOOJ.!I) 
4 8.8 10 (l.Oml) 1.5 75 (7500J.!1) 0 0.1% 1.35ml 
(l501l1) (l001lI) 
5 9.2 10 (l.Oml) 1.5 25 (2500ul) 0 0.1% 6.35mI 
(15OIlI) (lOOJ.!I) 
6 9.2 10 (1.0ml) 1.5 75 (7500J.!1) 0 0.1% 1.35ml 
(l501l1) (100J.!I) 
7 8.3 10 (1.0ml) 3.5 25 (25OOIlI) 0 0.1% 6.10mI 
(3501l1» (l00J.!1) 
8 8.3 10 (1.0mI) 3.5 75 (7500J.!1) 0 0.1% 1.10ml 
(3501l1) (l00J.!I) 
9 8.8 10 (1.0mI) 3.5 25 (2500J.!1) 0 0.10/0 6.10ml 
(3501l1) (l00J.!1) 
10 8.8 10 (1.0mI) 3.5 75 (7500J.!1) 0 0.1% 1.10mI 
(3501l1) (1001lI) 
1 I 9.2 10 (1.0ml) 3.5 25 (25OOIlI) 0 0.1 0/0 6.10ml 
(3501l1) (l001l1) 
12 9.2 10 (1.0ml) 3.5 75 (75OOIlI) 0 0.1% 1.10ml 
(3501l1) (1001lI) 
13 8.3 10 (l.OmI) 2.0 50 (50001l1) 0 0.1% 3.7ml 
(2OOIlI) (l001lI) 
14 8.8 10 (l.OmI) 2.0 50 (50001l1) 0 0.1% 3.7ml 
(2OOIlI) (l001l1) 
15 9.2 10 (l.OmI) 2.0 50 (50001l1) 0 0.1% 3.7ml 
(2OOIlI) (1001l1) 
16 8.8 67 (6.7mI) 2.0 (NH4)2S04 0.1% 0 1.40ml 
(2OOIlI) 16 (16001l1) ( IOOIlI) 
Buffers were made up in volumes of 10 mls and reagents were made up in IM.stock. 
To make up 10 ml buffer solution. One ml of 1 M stock of Tris -HCh was used at 10ml to 
achieve a final concentration of 10 mM. One hundred and fifty (150 1lI) or three hundred 
and fifty (350 1lI) microliters of MgCh was used to obtain a concentration of 1.5 mM and 
3.5 mM ofMgCh respectively and 2,500 III or 6,750 III ofKCL was used to obtain 25 
mM or 75 mM ofKCl. 
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APENDIX2 Estimates of alleles of candidate genes or markers 
Table 2.1) Estimates of alleles against band sizes in base pairs for microsatellite markers 
ALLELES IL-I0 NRAMPI IL-4 lL-Y TNF Il'NyRl IFNy NOS2A D17s250 
1" L»).) IU.)-ILJ.5 rlU.o-lI1.L 1L4.)-1L).) YU-YY.S HS7.2-HHLL 14J 177.6-180 15U.6-1)1.11 
L LY/ ILU.)-ILl.) In. Y-UY. I 1L6.)-ILI.) lUU.2-IOl.4 HSY-IYU.4 14) 183-184.6 DLL-15J.ISI 
j 259 ll8.5-IIY.S 179.8-lw.8 128.7-129.7 102.5-103.S 191.4-192.4 147 187.4-190 IS4.o-156.U 
'4 LoU lOY-III 181.o-IISLII UU.7-U1.7 104.)-lOS.5 I Yj.4-1 Y4.4 14Y I YI.4-19--l.0 1)1I.6-16U.U 
,- 263.5 183.7-184.7 132.11-133.11 106.6-107.2 19S.S-196.S lSI 197.4-1998 160.0-loL.U 
"0 26).) 1115.6-186.8 lJ)-lJb lUlI.2-109.) lY7.7-lYII.5 15J 203.0-20--l 8 Ib,l,IHb4.L 
7 266.) 187.4-1118.6 U7-lJlI llO.)-1l1.6 IYY./-LUU./ I) LUll.4-2IU-+ 10-+.6-166.2 
"l L611.5 189.4-19U.6 IJY.4-14U.4 112.3-113.4 201.Y-202.9 IS7 213 8-216.2 166.6-168.2 
--y Ltu.5 191.2-192.4 141./-14L/ 114.2-11S.4 LU4.I-LU).1 I)Y ~ 18 8-.:.20.4 lM.o-l/U._ 
10 273 193.6-194.2 122.S-123.5 116.2-117.4 206.1-207.1 223.6-225.8 146.6-IH6 
1I 274.5 lYS.U-IY6.L 14J.Y-144.Y IIS.4-IIY.) LUIS.I-LUY.l 172.3-17),3 144.U-14)U 
12 1970-19S.2 140.2-147.2 120.5-121.5 210.3-211.3 2283-231.3 IJ5.0-IJ6.0 
\3 198-S-200.0 122.5-123.) 212.5-213.5 233.S-23S.Y 171.0-172.U 
14 200.1l-LOL.O 124.5-125.5 214.6-215.6 172.6-175 1/3.U-1/4.U 
15 202.9-204.1 166.8-170 139.U-14U.U 
16 204.II-LU6 14lS.U-14'J.b 
17 206.6-207.8 137.u-lJlS.u 
IK 201l.4-LUY.6 142.U-14J.U 
1'1 2IU.L-LIU.O 
20 212.1-213.3 
LI 2lJ.Y-LI).1 
Table 2.2) Estimates of alleles against band sizes in base pairs for peR RFLP 
NRAMPI NKAMI' NKAMI' 1 IL-I~- IL-1 ~u+ 3953 IL-~lIIIJM) 1 Nt u308 TN 1'-13 IrNyRlddellT 
274 err I INT4 INTI 3 5Jl 
I 107,37, 12 624 142,75,24 304 97,85, 12 462 87, 20 
740 311 
2 102,65,37, 455, 169 102,75,40, 191, 113 182, 12 321, 141 
107 555, 185 206, I u5 
12 24 
Table 2.3) Estimates of alleles against band sizes in base pairs for ARMS peR 
TNF--u857 TNF-u863 control Allele TNF-u-238 TNF-u -376 
203 769 
395 390 270 Wild type 
270 263 
mutant 395 396 
Table 2.4) Estimates of alleles against band sizes in base pairs for peR VNTR 
Alleles IL-IRA IL4P2 
1 410 183 
2 242 
2,3 
3 325 123 
4 500 
APPENDIX 3 Optimisation of TNF levels in response to LAM and LPS 
Table 3.1 TNF concentration induced by different levels of LAM in the presence and absence rIFNy. 
- -
Lam cone Personal LAM undiluted LAM diluted IFN/LAM undiluted IFN/LAM diluted 
Ide ntification 
1ng/ml LAM/GC 001 1491 2910 570 1600 
LAM/GC 002 116 645 114 960 
LAM/GC 003 73 530 96 970 
LAM/GC 004 88 555 76.5 880 
LAM/GC 005 851 2340 335.5 2640 
LAM/GC 006 60.5 480 83.5 895 
LAM/GC 007 756 1885 283.5 1625 
LAM/GC 008 116.5 860 156.5 1535 
10ng/ml LAM/GC 001 1495.5 2880 613.5 1535 
LAM/GC 002 149.5 800 74.5 785 
LAM/GC 003 117 690 75.5 750 
LAM/GC 004 132 800 71.5 960 
LAM/GC 005 1016 2395 305.5 1760 
LAM/GC 006 117 615 65.5 720 
LAM/GC 007 1004.5 2165 172.5 1250 
LAM/GC 008 172.5 1115 110 1205 
100ng/ml LAM/GC 001 1407.5 2945 864.5 1770 
LAM/GC 002 127 830 324 1005 
LAM/GC 003 91.5 855 127 670 
LAM/GC 004 109.5 820 153 740 
LAM/GC 005 703.5 2260 392 1295 
LAM/GC 006 92 780 350 1005 
LAM/GC 007 938 2610 315 985 
--- - -
LAM/GC 008 148.5 1185 143 845 
1000ng/ml LAM/GC 001 2072 5635 2195.5 7825 
LAM/GC 002 1193.5 3450 2020 4570 
LAM/GC 003 428 1150 1305.5 2850 
LAM/GC 004 398 1085 1399.5 4070 
LAM/GC 005 2218 1023.5 2323 13780 
LAM/GC 006 187.5 1150 1724 4415 
LAM/GC 007 1632.5 4750 1662 5510 
LAM/GC 008 206.5 1000 659.5 2190 
2500ng/ml LAM/GC 001 2090.5 6930 2150 10570 
LAM/GC 002 1398.5 3450 2164.5 10765 
LAM/GC 003 1055 2010 1857 5905 
LAM/GC 004 752 1595 1763.5 5770 
LAM/GC 005 2431.5 1490 2701.5 18870 
LAM/GC 006 263 870 2086 6845 
LAM/GC 007 2124 7555 2184 933~ 
LAM/GC 008 366 982 1482.5 490C 
Table 3.2 TNF concentration induced by different levels of LPS 
--
STIMULANT PERSONAL IDENTIFICATION 
IFN-y LPS GCI001 GCI002 GCI003 GCI004 GCI005 GCI006 GCI007 GCI008 GCI009 GCIOI0 MEAN 
U/ml ng I ml 
0 0 106 276 103 58 49 76 228 110 130 48 118.4 
50 0 185 919 40 24 22 234 190 122 168 244 214.8 
100 0 260 1274 158 108 178 138 118 132 126 66 255.8 
200 0 347 1071 136 110 266 54 141 132 158 50 246.5 
400 0 501 1042 138 134 234 184 166 296 86 182 296.3 
800 0 525 1092 282 194 226 330 192 162 162 54 321.9 
0 0.1 1320 1410 275 285 520 2680 1855 812 1085 880 1112.2 
50 0.1 1380 1950 405 131 405 605 2460 3465 2630 545 1397.6 
100 0.1 1795 2150 455 460 1370 2330 1455 1535 3605 3020 1817.5 
200 0.1 1980 2260 565 580 1075 3830 1815 1570 3230 3615 2052 
'400 0.1 1730 1890 675 395 1000 2135 3945 3245 3815 3355 2218.5 
800 0.1 1890 1810 565 745 1395 4080 2120 3040 4460 1025 2113 
0 1.0 2550 3700 530 880 1870 5450 3590 5750 9650 4310 3738 
50 1.0 5800 5150 730 840 1360 5000 5240 8160 11370 4970 4862 
100 1.0 7500 6150 1140 1210 2440 5990 4490 4640 13620 9390 5657 
200 1.0 7550 6850 1010 1480 3390 6510 3190 5470 14420 1910 5178 
400 1.0 7900 2950 1010 1170 2770 8410 4900 7740 16420 9710 6298 
800 1.0 8600 4300 1160 1790 4220 11490 7740 7950 15230 1083 6356.3 
0 10 5900 3750 840 1770 650 6690 5630 4880 15650 4040 4980 
50 10 8050 4050 810 1710 1860 6690 6710 8140 12560 1030 5161 
100 10 6400 4750 980 3800 2580 7050 3650 6680 15510 8470 5987 
200 10 9400 5050 1180 3710 2900 9490 1940 5810 17620 10510 6761 
400 10 7850 5000 1070 2310 3130 7460 7950 9630 20270 9530 7420 
800 10 890_Q _ 4650 1320 3730 1940 11970 8580 10370 19270 8350 7908 
_ .. _-
-.- ----- - - -
Table 3.3.1 Effect of Co IFN-y-incubation on TNF levels 
PERSONAL IDENTIFICATION 
GCI007 GCI003 GCI011 GCI012 MEAN 
INCUBATION LPS LPS LPS LPS LPS LPS LPS LPS LPS LPS 
TIME alone IFN-y Alone IFN-y alone IFN-y alone IFN-y alone IFN-y 
3 hours 359 486 81 82 107 124 194 291 185.2 245.7 
5 hours 537 978 158 223 246 333 371 804 303 584.5 
8 hours 2500 4830 450 1170 860 1610 960 3270 1192.5 2720 
18 hours 2970 7250 3020 2010 1270 2650 910 1020 2042.5 3232.5 
--
Table 3.3.2 Effect of Pre IFN-y incubation on TNF levels 
PERSONAL IDENTIFICATION 
aC/007 GC/003 GC/011 GCI012 MEAN 
INCUBATION LPS LPS LPS LPS LPS LPS LPS LPS LPS LPS 
TIME alone IFN-y Alone IFN-y Alone IFN-y alone IFN-y alone IFN-y 
3 hours 474 1108 205 210 419 642 255 346 338.3 576.5 
5 hours 701 1938 414 441 444 837 349 765 477 995.2 
8 hours 2740 9230 810 500 850 2740 630 1300 1257.5 3442.5 
18 hours 2280 14180 650 830 850 1900 370 1060 1037.5 4305.7 
Table 3.4.1 Effect of 1 I 2 whole blood dilution on TNF levels 
PERSONAL IDENTIFICATION 
GCI013 GCI014 GCI015 GCI016 GCI017 GCI018 
INCUBATION LPS LPS LPS LPS LPS LPS LPS LPS LPS LPS LPS LPS 
TIME alone IFN-y alone IFN-y alone IFN-y alone IFN-y alone IFN-y alone IFN-y 
3 hours 421 1538 85 677 285 1162 330 1405 335 1356 332 1268 
5 hours 706 2052 111 1317 456 2130 351 1883 417 1948 362 1771 
8 hours 1610 5450 200 2640 1240 7160 750 370 850 4730 580 4290 
18 hours 1280 5930 180 2400 1180 7270 550 4320 760 4950 480 3140 
- -
Table 3.4.2 Effect of 1 I 8 whole blood dilution on TNF levels 
PERSONAL IDENTIFICATION 
GCI013 GCI014 GCI015 GCI016 GCI017 GCI018 
INCUBATION LPS LPS LPS LPS LPS LPS LPS LPS LPS LPS LPS LPS 
, 
TIME alone IFN-y alone IFN-y alone IFN-y alone IFN-y alone IFN-y alone IFN-y 
3 hours 389 1063 165 627 234 810 414 1116 378 1057 399 1294 
5 hours 714 1319 228 1279 417 1698 868 1980 604 1950 637 2194 
8 hours 2180 9150 580 4110 1970 8900 3050 9130 2300 8800 1690 8140 
18 hours 4120 11510 710 5540 4070 13340 5190 12140 4270 11550 2310 9530 
- -
Recovered cases Controls 
LPS In (LPS) LPS +IFN In (LPS+IFN) LPS In (LPS) 
4390 8.387 9805 9.1906 1215 7.1025 
6075 8.712 8470 9.0443 930 6.8352 
3335 8.112 9900 9.2003 1210 7.0984 
945 6.851 5245 8.5650 1605 7.3809 
4125 8.325 7765 8.9574 695 6.5439 
190 5.247 420 6.0403 685 6.5294 
140 4.942 1265 7.1428 305 5.7203 
210 5.347 2480 7.8160 615 6.4216 
600 6.397 2675 7.8917 1020 6.9276 
1285 7.159 4815 8.4795 485 6.1841 
490 6.194 840 6.7334 430 6.0638 
735 6.600 1850 7.5229 2185 7.6894 
335 5.814 895 6.7968 120 4.7875 
1466 7.290 3025 8.0147 976 6.8835 
863 6.760 3553 8.1755 550 6.3099 
886 6.787 4596 8.4329 546 6.3026 
736 6.601 1660 7.4146 1330 7.1929 
556 6.321 1860 7.5283 756 6.6280 
680 6.522 2766 7.9252 666 6.5013 
953 6.860 3690 8.2134 580 6.3630 
5410 8.596 5290 8.5736 3770 8.2348 
393 5.974 1206 7.0951 993 6.9007 
470 6.153 1130 7.0300 4610 8.4360 
3650 8.202 5500 8.6125 420 6.0403 
2440 7.800 5070 8.5311 1456 7.2834 
4096 8.318 8880 9.0916 2270 7.7275 
1140 7.039 3346 8.1155 4750 8.4659 
446 6.100 2760 7.9230 726 6.5876 
1793 7.492 18560 9.8288 10580 9.2667 
1696 7.436 7725 8.9522 483 6.1800 
2296 7.739 15903 9.6743 1256 7.1357 
17270 9.757 26563 10.1873 17270 9.7567 
6903 8.840 26200 10.1735 3926 8.2754 
6300 8.748 11493 9.3495 9283 9.1359 
8805 9.083 7120 8.8707 2883 7.9666 
9160 9.123 14646 9.5919 4286 8.3631 
3416 8.136 8640 9.0642 4715 8.4585 
776 6.654 1576 7.3626 7140 8.8735 
Appendix 4.1 
TNF levels in picograms/ml in matched recovered cases and controls. 
Baseline TNF levels were subtracted to derive the totals, and natural logarithms 
calculated. The analysis of these data is shown in table 3. 
LPS +IFN 
4955 
4670 
2470 
2105 
5735 
1395 
3525 
404 
6475 
4170 
1870 
3730 
405 
2340 
2390 
3380 
3030 
1336 
1300 
3770 
6020 
1986 
8350 
3280 
7920 
13260 
13760 
5500 
10400 
2430 
9553 
26563 
11913 
25320 
3403 
7896 
12870 
12100 
In (LPS+IFN) 
8.5082 
8.4489 
7.8120 
7.6521 
8.6543 
7.2406 
8.1676 
6.0014 
8.7757 
8.3357 
7.5337 
8.2242 
6.0039 
7.7579 
7.7790 
8.1256 
8.0163 
7.1974 
7.1701 
8.2348 
8.7028 
7.5939 
9.0300 
8.0956 
8.9771 
9.4925 
9.5295 
8.6125 
9.2496 
7.7956 
9.1646 
10.1873 
9.3854 
10.1393 
8.1324 
8.9741 
9.4627 
9.4010 
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1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1 1 
12 
13 
14 
15 
16 
17 
18 
1 9 
20 
21 
22 
23 
24 
25 
26 
27 
28 
Recovered cases Controls 
LPS In (LPS) LPS +IFN In (LPS+IFN) LPS In (LPS) 
2055 7.6280 1335 7.1967 483 6.1800 
1722 7.4512 1630 7.3963 376 5.9296 
1353 7.2101 1165 7.0605 248 5.5134 
253 5.5334 1070 6.9754 890 6.7912 
2503 7.8252 1590 7.3715 252 5.5294 
112 4.7185 182 5.2040 175 5.1648 
143 4.9628 362 5.8916 85 4.4427 
30 3.4012 62 4.1271 371 5.9162 
177 5.1761 362 5.8916 31 3.4340 
1152 7.0493 955 6.8617 313 5.7462 
1040 6.9470 863 6.7604 292 5.6768 
1040 6.9470 305 5.7203 4178 8.3376 
598 6.3936 520 6.2538 46 3.8286 
193 5.2627 215 5.3706 250 5.5215 
105 4.6540 123 4.8122 285 5.6525 
112 4.7185 198 5.2883 72 4.2767 
68 4.2195 130 4.8675 372 5.9189 
127 4.8442 167 5.1180 162 5.0876 
97 4.5747 148 4.9972 232 5.4467 
377 5.9322 440 6.0868 213 5.3613 
3768 8.2343 2802 7.9381 1180 7.0733 
102 4.6250 138 4.9273 63 4.1431 
58 4.0604 63 4.1431 927 6.8320 
5610 8.6323 6233 8.7376 1670 7.4206 
2065 7.6329 2813 7.9420 925 6.8298 
95 4.5539 
3143 8.0529 
6032 8.7048 
Appendix 4.2 
IL-l f3 levels in picograms/ml in matched recovered cases and controls. . 
Baseline IL-l f3 levels were subtracted to derive the totals, and naturalloganthms 
calculated. The analysis of these data is shown in table 3. 
LPS +IFN 
218 
460 
540 
308 
510 
255 
307 
712 
313 
658 
350 
4622 
57 
278 
293 
122 
645 
232 
195 
197 
607 
103 
837 
963 
410 
123 
2943 
4983 
In (LPS+IFN) 
5.3845 
6.1312 
6.2916 
5.7301 
6.2344 
5.5413 
5.7268 
6.5681 
5.7462 
6.4892 
5.8579 
8.4386 
4.0431 
5.6276 
5.6802 
4.8040 
6.4693 
5.4467 
5.2730 
5.2832 
6.4085 
4.6347 
6.7298 
6.8701 
6.0162 
4.8122 
7.9872 
8.5138 
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Recovered cases 
LPS In (LPS) LPS +IFN In (LPS+IFN) LPS 
1 1152 7.049 681 6.524 447 
2 866 6.764 519 6.252 146 
3 1293 7.165 488 6.190 821 
4 284 5.649 158 5.063 198 
5 965 6.872 216 5.375 170 
6 163 5.094 154 5.037 151 
7 516 6.246 280 5.635 233 
8 46 3.829 36 3.584 226 
9 142 4.956 133 4.890 256 
10 326 5.787 135 4.905 260 
1 1 391 5.969 166 5.112 260 
12 599 6.395 166 5.112 950 
13 394 5.976 132 4.883 69 
14 191 5.252 69 4.234 462 
15 85 4.443 46 3.829 64 
16 153 5.030 103 4.635 32 
17 74 4.304 30 3.401 317 
18 143 4.963 53 3.970 304 
19 130 4.868 100 4.605 104 
20 2087 7.643 1504 7.316 906 
21 152 5.024 83 4.419 96 
22 133 4.890 134 4.898 253 
23 66 4.190 65 4.174 374 
24 501 6.217 288 5.663 56 
25 336 5.817 257 5.549 239 
26 705 6.558 378 5.935 208 
27 141 4.949 75 4.317 378 
28 81 4.394 75 4.317 120 
29 639 6.460 407 6.009 222 
30 491 6.196 192 5.257 68 
31 275 5.617 87 4.466 74 
32 2494 7.822 1494 7.309 1765 
33 1071 6.976 228 5.429 1048 
34 1135 7.034 743 6.611 279 
35 262 5.568 152 5.024 111 
36 271 5.602 103 4.635 69 
37 153 5.030 85 4.443 186 
38 1114 7.016 706 6.560 189 
Appendix 4.3 
IL-IO levels in picograms/ml in matched recovered cases and controls. 
Baseline TNF levels were subtracted to derive the totals, and natural logarithms 
calculated. The analysis of these data is shown in table 3. 
Controls 
In (LPS) LPS +IFN In (LPS+IFN) 
6.103 560 6.328 
4.984 155 5.043 
6.711 597 6.392 
5.288 187 5.231 
5.136 164 5.100 
5.017 149 5.004 
5.451 104 4.644 
5.421 123 4.812 
5.545 52 3.951 
5.561 107 4.673 
5.561 761 6.635 
6.856 32 3.466 
4.234 137 4.920 
6.136 48 3.871 
4.159 30 3.401 
3.466 265 5.580 
5.759 110 4.700 
5.717 48 3.871 
4.644 403 5.999 
6.809 44 3.784 
4.564 219 5.389 
5.533 143 4.963 
5.924 51 3.932 
4.025 161 5.081 
5.476 180 5.193 
5.338 127 4.844 
5.935 61 4.111 
4.787 75 4.317 
5.403 51 3.932 
4.220 48 3.871 
4.304 264 5.576 
7.476 451 6.111 
6.955 270 5.598 
5.631 73 4.290 
4.710 56 4.025 
4.234 80 4.382 
5.226 78 4.357 
5.242 
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APPENDIX 5 MICRO SATELLITE GENES DATA AND INFLUENCE ON 
MICROBIAL INDUCED RESPONSES 
x2 is the symbol for chi square, D.F. represents degrees of freedom and p is the p value 
(conditional probability). There was no quantitative trait measurements for LAM induced 
responses for those with the genotype 2.1. p-valves were compared between four 
genotypes for each cytokine and stimulant. None of the alleles of the promoter repeat 
were shown to influence cytokine production. 
TABLE 5.1 IL-41 
Cytokines Stimulant X2 DF p-value 
TNF LAM 13.5 10 0.19 
IL-l~ 8.46 10 0.58 
11-10 8.2 10 0.6 
TNF LAM&IFN-y 13.9 10 0.17 
IL-l~ 15.8 10 0.10 
IL-I0 8.05 10 0.62 
TNF LPS 22.3 10 0.013 
IL-l~ 12.3 10 0.26 
12.7 10 0.24 IL-I0 
18.6 10 0.04 LPS&IFNy TNF 
16.7 10 0.08 IL-l~ 
26.9 10 0.002 IL-I0 
p valves as compared between eleven genotypes for each cytokine and stimulant. 
Alleles of IL-4Plmarker were shown to influence LPS induced TNF-a secretion (p = 
0.013). Priming with IFN-y though significantly different between alleles did not enhance 
this effect (p =0.04). 
29.t 
TABLE 5.2 IL-9 
Cytokines Stimulant X2 DF p-value 
TNF LAM 6.0 10 0.8 IL-IB 3.3 10 0.97 
11-10 3.85 10 0.95 
TNF LAM&IFN-y 9.57 10 0.47 
IL-IB 1.74 10 0.99 
IL-I0 5.9 10 0.82 
TNF LPS 9.22 10 0.51 
IL-IB 21.1 10 0.02 
IL-I0 6.9 10 0.73 
TNF LPS&IFNy 11.6 10 0.31 
IL-IB 11.0 10 0.35 
IL-I0 13.5 10 0.19 
p valves as compared between eleven genotypes for each cytokine and stimulant. 
IL-l B release after LPS stimulation differed significantly between IL-9 genotypes 
(p=0.02). 
TABLE 5.3 TNFa 
Cytokines Stimulant X2 DF p-value 
TNF LAM 26.6 17 0.06 
IL-IB 19 17 0.33 
II-I0 21.5 17 0.2 
TNF LAM&IFN-y 18.67 17 0.35 
IL-IB 15.6 17 0.55 
26.8 17 0.06 IL-I0 
TNF LPS 9.46 17 0.92 
IL-IB 13.l 17 0.73 
7.9 17 0.99 IL-I0 
8.3 17 0.96 TNF LPS&IFNy 17 0.88 10.4 IL-IB 
10.3 17 0.89 IL-I0 
I d between eighteen genotypes for each cytokine and stimulant. p va ves as compare 
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TABLE 5.4 IFNyRl 
Cytokines Stimulant X2 DF p-value 
TNF LAM 18.4 23 
IL-1B 
0.73 
16.3 23 0.84 
II-10 17.5 23 0.77 
TNF LAM&IFN-y 21.7 23 0.54 
IL-1B 19.6 23 0.66 
IL-10 20 23 0.64 
TNF LPS 22.1 23 0.51 
IL-1B 21.4 23 0.55 
IL-10 22.5 23 0.49 
TNF LPS&IFNy 20.4 23 0.62 
IL-1B 20.2 23 0.63 
IL-10 26.2 23 0.29 
p valves as compared between twenty four genotypes for each cytokine and stimulant. 
TABLE 5.5 NOS2A 
Cytokines Stimulant X2 DF p-value 
TNF LAM 27.5 20 0.2 
IL-1B 31.5 20 0.05 
II-10 24.2 20 0.23 
TNF LAM&IFN-y 20.9 20 0.39 
IL-1B 26.1 20 0.16 
IL-10 23 20 0.25 
TNF LPS 18.8 20 0.53 
IL-1B 20.5 20 0.43 
IL-10 20.5 20 0.43 
TNF LPS&IFNy 21.1 20 0.39 
IL-1B 22 20 0.34 
IL-10 25 20 
0.19 
p valves as compared between twenty one genotypes for each cytokine and stimulant. 
Whole blood secretion of IL-1 B after stimulation with LAM alone differed significantly 
between NOS2A genotypes (p=0.05). 
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TABLE 5.6 D17S250 
Cytokines Stimulant X2 DF p-value 
TNF LAM 21.8 24 0.59 
IL-l~ 15.1 24 0.92 
II-I0 14.75 24 0.93 
TNF LAM&IFN-y 23.6 24 0.48 
IL-l~ 21.2 24 0.6 
IL-I0 15.7 24 0.89 
TNF LPS 21.6 24 0.6 
IL-l~ 24.8 24 0.41 
IL-I0 16.8 24 0.86 
TNF LPS&IFNy 26.2 24 0.34 
IL-l~ 24.3 24 0.44 
IL-I0 19.6 24 0.72 
p valves as compared between twenty five genotypes for each cytokine and stimulant. 
Cytokine induced in response to LAM or LPS stimulation and cytokine induced in 
response to pre IFN -y and LAM stimulation. 
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